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Abstract
The ADAMTSs (a disintegrin and metalloproteinase with thrombospondin type 1-like 
motifs) are a group of peptidases with important roles in normal physiology and 
pathology. ADAMTS-9 is expressed in the central nervous system (CNS) and has been 
reported to cleave aggrecan and versican, which are chondroitin sulphate proteoglycans 
(CSPGs) with critical roles in the extracellular matrix (ECM) of the brain. CSPGs are 
structural components of the glial scar, which forms in response to destructive CNS 
inflammation, inhibiting axonal outgrowth but protecting neurones against 
inflammatory infiltrates. Therefore, ADAMTS-9 has the potential to be involved in 
normal processing of the brain ECM as well as contributing to or protecting against 
pathology. In this study the expression of ADAMTS-9 was analysed in CNS-derived 
cells in vitro under basal conditions and following treatment with factors pertinent to 
CNS inflammatory disorders. ADAMTS-9 expression was also analysed in rat brains 
following transient middle cerebral artery occlusion (tMCAo), a model of focal cerebral 
ischaemia.
Real-time RT-PCR data demonstrated that ADAMTS-9 mRNA was constitutively 
expressed by human astrocytic (U373-MG, U87-MG and B327-01), microglial 
(CHME3) and neuronal (SHSY-5Y) cell lines in vitro, under basal conditions. In U373- 
MG cells, ADAMTS-9 mRNA expression was increased 25 and 8-fold following 
treatment with 1 ng/mL interleukin-1 beta (IL-ip) and tumour necrosis factor (TNF) 
respectively. In B327-01 cells, IL-ip (100 ng/mL) modulated a 6-fold increase in 
ADAMTS-9 mRNA expression. In contrast, treatment with 1 ng/mL interferon-gamma 
(IFN-y) led to a decrease in ADAMTS-9 expression in B327-01 cells. The effect of 
IFN-y in CHME3 cells differed to that observed in B327-01 in that 10 ng/mL increased 
expression of ADAMTS-9 mRNA 2-fold in the astrocytic cells. The study also 
demonstrated that ADAMTS-9 mRNA expression was modulated by retinoic acid in 
SHSY-5Y cells. Immunocytochemical analysis of U373-MG cells indicated that 
ADAMTS-9 protein is localised in the nucleus under basal conditions.
Real-time RT-PCR analysis of ADAMTS-9 mRNA expression demonstrated it was up- 
regulated in tMCAo tissue compared to sham-operated at 6, 24 and 120 h post­
procedure. In addition ADAMTS-9 mRNA levels were higher in ipsilateral (occluded) 
hemispheres when compared to contralateral (non-occluded) hemispheres in tMCAo
brains. Western blotting indicated that the mature form of the ADAMTS-9 protein was 
only detected in brains subjected to tMCAo at 24 h. An ADAMTS-9-specific riboprobe 
was generated by subcloning and expression of a plasmid containing ADAMTS-9 
cDNA in the XL-1 blue strain of E. coli followed by in vitro transcription and labelling 
with digoxigenin (DIG). The probe was utilised to perform in situ hybridisation, which 
showed that neurones were the predominant cell-type expressing ADAMTS-9 mRNA in 
tMCAo tissue.
Preliminary bioinformatical analysis of the putative human and rat ADAMTS-9 
promoter regions demonstrated that consensus binding sites for transcription factors 
(nuclear factor kappa B [NFkB], activator protein 1 [AP-1], hypoxia inducible factor-1 
[HIF-1] and interferon regulatory factor 1 [IRF-1]) pertinent to CNS inflammation were 
present in the sequence. Such transcription factors are potentially involved in activating 
the expression of ADAMTS-9 expression. Consequently, this study confirms that 
ADAMTS-9 is expressed by endogenous CNS cells and its expression is modulated by 
CNS inflammatory conditions both in vitro and in vivo.
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1.1 The ADAMTSs
1.1.1 Overview of Peptidases
Peptidases are enzymes that hydrolyse peptide bonds. In the human genome, 1.6 % 
(over five-hundred) o f all genes encode for peptidases and their inhibitors (Rawlings et 
al, 2006). Exopeptidases are peptidases that hydrolyse a bond close (within three 
residues) to either the N-terminus or C-terminus (or both). Alternatively, the hydrolysis 
of internal (away from N-terminus or C-terminus) a-peptide bonds is the hallmark of 
endopeptidases, which includes oligopeptidases that act on substrates smaller than 
proteins (peptides) (Rawlings et al, 2004). Endopeptidases vary in the type of catalysis 
they perform and examples include the serine-, aspartic-, threonine- and metallo- 
proteinases.
The term given to a peptide bond which is hydrolysed by a peptidase is 'scissile bond'. 
Many peptidases have substrate specificity for certain amino acids that make up scissile
bonds as well as the location within the substrate. The active site of peptidases is
located in a structural groove along which a substrate can bind at different sites 
(subsites). A method o f representing the substrate specificity taking into account 
subsites as well as the location of the scissile bond within the substrate was originally 
described by Schechter & Berger (1967) and is shown below:
scissile
bond
1
Substrate: - P3 - P2 - PI + PI' - P2' - P3' -
Peptidase: - S3 - S2 - SI * SI' - S2' - S3' -
Where: + = scissile bond, * = catalytic site, S/Pn = subsite/peptide numbered from 
catalytic site/scissile bond to N-terminus, S/Pn' = subsite/peptide numbered from 
catalytic site/scissile bond to C-terminus.
The MEROPS database is a valuable resource, providing a hierarchical system of 
classification of about three-thousand peptidases and their inhibitors in many different 
organisms (Rawlings et al, 2006). MEROPS classifies into families; peptidases with
2
relationships in amino acid sequence in the part of the molecule termed the 'peptidase 
unit' (catalytic site). MEROPS also classifies peptidases into clans, which contain 
families with common ancestry. Sets of families in which all the peptidases have 
diverged from a single gene over time are grouped into clans, of which there are about 
forty.
1.1.2 The M12 Peptidase Family
The M l2 family contains peptidases with a metallopeptidase catalytic site: His-Glu- 
Xaa-Xaa-His-Xaa-Xaa-GIy-Xaa-Xaa-His (where His residues are ligands o f a zinc 
atom). Members of the M l2 family have been shown to be expressed in bacteria, 
protozoa, fungi and animals and include; ADAMs (a disintegrin and metalloproteinase) 
(also known as adamalysins), the snake venom metalloproteinases (reprolysins) and the 
ADAMTSs (a disintegrin and metalloproteinase with thrombospondin type 1-like 
motifs).
The M l2 family, along with a variety of other metallopeptidases is contained within 
clan MA. The families in clan MA all contain the motif Xaa-Xbb-Xcc-His-Glu-Xbb- 
Xbb-His-Xbb-Xdd (where Xaa is hydrophobic or Thr, Xbb is uncharged, Xcc is any 
amino acid except Pro, and Xdd is hydrophobic) (Jongeneel et al, 1989). Clan MA 
peptidases also possess a third zinc ligand towards the C-terminus, the nature o f which 
varies depending on the subclan to which the peptidase belongs. The M l2 family is 
categorised as being in subclan MA(M). The other subclan of clan MA is MA(E).
All secreted proteinases including those belonging to both MA(E) and MA(M) subclans 
are synthesised as proenzymes. The general difference between the two is that some 
MA(E) subclan peptidases are activated by removal of an N-terminal propeptide (e.g. by 
furin-cleavage) (Kessler & Safrin, 1994). Alternatively, peptidases in some families of 
the MA(M) subclan are secreted as latent proenzymes requiring activation by 
proteolytic cleavage of an amino terminal domain to expose the active catalytic site 
('cysteine-switch' mechanism) (Van Wart & Birkedal-Hansen, 1990). Virtually all the 
peptidases in the MA(M) subclan that lack the ‘cysteine switch’ contain a Tyr located 2 
residues beyond Met of the Met-tum (described in Section 1.1.4.2). Peptidases in 
subclan MA(M) are termed metzincins because of the presence of zinc-binding 
segments and a Met-tum in the catalytic domain.
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The M l2 family can be divided into two subfamilies. The M12A subfamily is also 
known as the Astacin family, so named after the crayfish metalloproteinase astacin. The 
M12B subfamily (Adamalysin) contains a total of thirty-two peptidases found in Homo 
sapiens including the ADAMs and ADAMTSs. Figure 1.1 shows the phylogenetic 
(evolutionary) tree of the human members of the M12B family. A phylogenetic tree 
displays the evolutionary relationship between the different peptidases by aligning the 
sequences and calculating the percentage difference.
1.1.3 Overview of ADAMTSs
In 1997, Kuno et al transplanted colon adenocarcinoma cells into mice and screened the 
resultant tumour for genes which were expressed in vivo to further understand cancer 
cachexia pathogenesis. One novel complementary DNA (cDNA) clone was identified 
which encoded a cysteine-rich protein related to the ADAMs in that it contained a 
prodomain, a metalloproteinase domain and a disintegrin-like domain. The protein 
possessed thrombospondin type 1-like motifs (TSP-1) absent in the ADAMs, hence the 
name ADAMTS-1 was given to the protein and ADAMTS was used subsequently to 
describe a new group of peptidases with sequence similarity to the reprolysins. 
ADAMTSs lack the transmembrane (TM) domain present in ADAMs and thus have 
generally been considered to be secreted as opposed to membrane-bound, until recently 
(Koo et al, 2007).
Since ADAMTS-1 was discovered, eighteen more ADAMTS genes and the proteins 
they encode have been identified in humans. It is now believed that all the human 
ADAMTSs have been discovered, mainly due to the work of Cal et al (2002) who 
cloned the final seven members following a bioinformatics screen of the human genome. 
The complete list and phylogenetic tree of the ADAMTSs is displayed in Figure 1.2. All 
ADAMTSs have the same basic domain organisation as the prototype ADAMTS-1 with 
the main differences between the peptidases existing at the C-terminus. In addition to 
the ADAMTSs, three ADAMTS-like genes have been identified which encode proteins 
called ADAMTSL-1 (punctin), ADAMTSL-2 and ADAMTSL-3, containing ancillary 
ADAMTS domains but lacking obvious metalloproteinase domains and a disintegrin- 
like module (Wang et al, 2007).
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Figure 1.1 Homo Sapiens Members o f the M12B Family: Phylogenetic Tree
Legend
Sequence Peptidase
1 ADAM-8
2 ADAM-19
3 ADAM-12
4 ADAM-33
5 ADAM-15
6 ADAM-28
7 ADAM-9
8 ADAM-1
9 ADAM-21
10 ADAM-20
11 ADAMTS-6
12 ADAMTS-10
13 ADAMTS-7
14 ADAMTS-12
15 ADAMTS-18
16 ADAMTS-16
17 ADAMTS-1
18 ADAMTS-15
19 ADAMTS-4
20 ADAMTS-8
21 ADAMTS-5
22 ADAMTS-9
23 ADAMTS-20
24 ADAMTS-19
25 ADAMTS-17
26 ADAMTS-2
27 ADAMTS-3
28 ADAMTS-14
29 ADAMTS-13
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Tree adapted from MEROPS Peptidase Database. % identity relates to how similar the 
primary sequences are following a multiple sequence alignment of peptidase units. The 
peptidase unit is defined as 'the part o f the protein sequence that is directly responsible 
for peptidase activity' i.e. aligns with the smallest mature peptidase molecule in the 
family (Rawlings et al, 2006). ADAMTS-9 represented by
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Documented roles of ADAMTSs include processing of procollagens (ADAMTS-2, -3 
and -14), von Willebrand factor (ADAMTS-13) and extracellular matrix (ECM) 
components such as chondroitin sulphate proteoglycans (CSPGs) (ADAMTS-1, -4, -5, - 
8 and -9) (reviewed by Flannery, 2006). ADAMTSs have also been demonstrated to 
mediate connective tissue organisation, coagulation, inflammation, arthritis, 
angiogenesis and cell migration (reviewed by Tang, 2001).
1.1.4 Basic Domain Structure/Function
ADAMTS peptidases have the same basic domain organisation as illustrated in Figure 
1.3, in that they all possess (from N-terminus to C-terminus) a signal peptide, 
prodomain, metalloproteinase domain, disintegrin-like domain, central TSP-1 motif, 
cysteine-rich domain (CRD), spacer region and C-terminal TSP-1 motifs. The 
‘proteinase domains’ (from signal peptide up to and including metalloproteinase domain) 
are highly conserved between ADAMTSs (except ADAMTS-13). The main structural 
difference between ADAMTSs occurs at the C-terminal ancillary domains, where the 
number of TSP-1 motifs varies. Many ADAMTSs also contain additional domains (e.g. 
a cubulin [CUB] motif) at the C-terminus which (as described in Section 1.1.4.3) 
potentially influences the function of the peptidase (Tao et al, 2005).
1.1.4.1 Signal Peptide and Prodomain
The amino-terminal signal peptide of ADAMTSs directs the post-translational transport 
of the peptidase into the secretory pathway via the endoplasmic reticulum (ER), 
involving a signal recognition particle. The size of the signal peptide varies in length 
between ADAMTSs (-5-30 amino acids) and is removed prior to the secretion of the 
protein from the cell (Dunn et al, 2006).
The prodomain displays a high level of sequence similarity between the ADAMTSs and 
is generally of a comparable length throughout (220-300 amino acids). The exception to 
this rule is ADAMTS-13, which has a significantly smaller prodomain (74 amino acids). 
In fact this is the only notable structural variability between all the ADAMTSs within 
the ‘proteinase domains’ (N-terminus). It has been widely reported that the prodomain 
of ADAMTSs contain highly conserved residues, which are of importance in the 
maturation, protein folding and secretion of these peptidases (Longpre and Leduc, 2004;
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Figure 1.3 Basic Domain Structure o f the ADAMTSs
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The ADAMTSs have the same general structure in that they all contain a signal peptide, 
prodomain, metalloproteinase domain, disintegrin-like domain, central TSP-1, CRD, 
spacer domain and variable numbers of C-terminal TSP-1 motifs. Additional domains 
are present at the C-terminus of specific ADAMTSs including PLAC, mucin-like, GON 
and CUB domains. Note: HEXGHXXGXXHD ('X' = any amino acid residue) 
represents the zinc-binding motif o f metalloproteinase domain (not the full sequence o f 
domain). Adapted from Porter et al (2005).
Cao et al, 2000). Most ADAMTSs contain three cysteine residues in the prodomain 
with the exception of ADAMTS-2, -3, -14 (which contain two) and -13 (one). The 
presence of a prodomain is generally considered to confer latency on ADAMTS 
enzymatic activity as it has been shown to do for other members of the MA clan (Hijova,
2005).
1.1.4.2 Metalloproteinase Domain
A 193-249 residue metalloproteinase domain as shown in Figure 1.4 enables 
ADAMTSs to function as peptidases. There is a high level of sequence similarity 
between the catalytic domains of the different ADAMTSs with an average sequence 
identity (ASI) of 43%. It is worth noting that the catalytic domain of ADAMTSs is also 
highly similar to that of the ADAMs with an ASI of 24% between the two types of 
peptidases (Andreini et al, 2005). The domain consists of a reprolysin-type zinc-binding 
motif (ZBM) containing three conserved His in the C-terminal region, 
HEXGHXXGXXHD ('X' = any amino acid residue). The conserved aspartic acid 
residue (D) distinguishes the ADAMTSs (and ADAMs) from other metalloproteinases 
(Porter et al, 2005).
In order for ADAMTSs to be catalytically active, it is essential for a zinc ion to be 
bound to the His residues within the ZBM. The zinc activates a water molecule by 
removal of a hydrogen, rendering it a reactive nucleophile with the ability to attack 
peptide carbonyl groups (Berg et al, 2002). The glutamate (E) has been shown to have 
an important role in this mechanism by polarising (deprotonation) the water molecule 
through hydrogen bonding (Andreini et al, 2005). Yiallouros et al (2000) performed site 
directed mutagenesis to substitute glutamate for alanine in astacin, the prototype 
member of the metzincin superfamily. The resultant mutant was unable to cleave known 
substrates of astacin, whereas the wild-type (WT) was.
In common with other members of subclan MA(M), ADAMTS metalloproteinase 
domains have a conserved methionine residue within the sequence V/IMA/S C-terminal 
to the ZBM (10-20 amino acids after 3rd His), which forms the ‘Met-turn’. The 
crystallographic structure of the Met-turn was characterised by Bode et al (1993) 
and it is known to provide a hydrophobic environment for the zinc ion and the three His 
residues in the catalytic site. It is thought that the presence of the Met-turn also
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Figure 1.4 Catalytic (Metalloproteinase) Domain of ADAMTSs
10-20 amino acid
Simplified interpretation o f the 'peptidase unit' o f ADAMTSs showing the binding of 
the zinc ion to the His residues. Note the importance o f the interaction of the glutamate 
with the H2O molecule in the catalytic mechanism. G, E, H, M, Y, D represent amino 
acids (single-letter code). X = any amino acid. Adapted from Bode et al (1993).
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contributes to the catalytic properties of the ADAMTSs because of the presence of a 
tyrosine residue. Using methods described above, Yiallouros et al (2000) showed that 
the presence of the Tyr residue increased astacin catalytic activity 40-fold. The group 
proposed that the Tyr stabilised the substrate binding to the zinc ion during hydrolysis.
1.1.4.3 Ancillary Domains
The domains C-terminal to the metalloproteinase domain are known as the ancillary 
domains. All ADAMTSs have a highly conserved 60-90 amino acid domain with 
primary sequence similarity to snake venom disintegrins (SVD), hence the name 
'disintegrin-like domain'. SVDs are low molecular mass (Mr), cysteine-rich peptides 
which bind to cell-surface adhesion molecules; the integrins (Huang, 1998). Some 
SVDs contain a characteristic arginine/glycine/aspartic acid (RGD) integrin-recognition 
sequence, although this is lacking from the disintegrin-like domain and there is no 
evidence to suggest ADAMTSs adhere to integrins. This differs from many ADAM 
enzymes where the corresponding region is involved in integrin-mediated adhesion e.g. 
the binding of ADAM-2 to a6$\ during sperm passage through oviducts (Kim et al,
2005).
C-terminal to the disintegrin-like domain is a highly conserved 48-54 amino acid central 
TSP-1, homologous to type I motifs seen in thrombospondins 1 and 2. The 
thrombospondins are glycoproteins proven to have a role in platelet function, wound 
healing, inflammation and angioinhibition (Bomstein, 2001). As well as having a single 
central TSP-1, ADAMTSs have additional TSP-ls at the C-terminus, ranging from zero 
(ADAMTS-4) to fourteen (ADAMTS-9, -20). The motifs of the C-terminal TSP-ls are 
far more variable than the highly conserved central TSP-1 and are usually arranged 
singly or in groups of two, three or four (except ADAMTS-9, -20 [both have TSP-ls in 
groups of four and seven] and -13 [a group of six]) separated by short linker peptides 
(reviewed by Jones & Riley, 2005).
Rather than have linker peptides between TSP-ls, ADAMTS-12 and -7 have a longer 
mucin-like domain between the third and fourth of their seven C-terminal TSP-ls, a 
region which is heavily O-glycosylated (Somerville et al, 2004). Similarities are drawn 
between mucin and the mucin-like domain because both are high in threonine, proline 
and serine residues (Porter et al, 2005). ADAMTS-7 has a glycosaminoglycan (GAG)
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attached to the mucin-like domain, hence it can be described as a 'proteoglycan', a fact 
that could have profound effects on the peptidase's localisation and function (Somerville 
et al, 2004).
Immediately adjacent to the central TSP-1 is a highly conserved CRD containing ten 
cysteine residues. The next domain downstream to the CRD is a cysteine-free spacer 
region of 127-221 amino acids containing a conserved N-terminal region of 
hydrophobic amino acids and a highly variable C-terminal region (Hurskainen et al, 
1999). Additional C-terminal domains are present in some ADAMTSs e.g. ADAMTS- 
13 contains two CUB domains, perhaps involved in binding to ligands such as an 
'unusually large' multimer of von Willebrand factor (UL-vWF) (Zheng et al, 2001; Tao 
et al, 2005). The C-termini of ADAMTS-2, -3, -10, 14, -17 and -19 terminate with a 
forty-residue PLAC (proteinase and lacunin) domain containing six cysteines, originally 
observed in lacunin. As yet the function of the PLAC domain in ADAMTSs is largely 
unknown, although lacunin is an important ECM protein in basal lamina formation in 
lepidopteron Manduca sexta wing morphogenesis (Nardi et al, 2001).
The ancillary domains are highly important in terms of ADAMTS function, activation, 
localisation and substrate specificity. Rodriguez-Manzaneque et al (2000) demonstrated 
this by deleting two TSP-ls from the C-terminus of ADAMTS-1. The resulting protein 
had a decreased ability to inhibit endothelial cell (EC) proliferation as well as reducing 
the enzyme’s affinity for sulphated GAG, heparin and EC cultures. Therefore it appears 
that the TSP-ls contribute to the angio-inhibitory properties displayed by recombinant 
full-length ADAMTS-1, reported in a study by Vazquez et al (1999). Further evidence 
implicating TSP-ls in the angio-inhibitory process came from the same study because 
thrombospondin-1 protein also inhibited vascular endothelial growth factor (VEGF)- 
mediated vascularisation. In fact thrombospondin-1 is now well known to be anti- 
angiogenic (Bocci et al, 2003).
1.1.4.4 Binding of ADAMTSs via the Ancillary Domains
It became apparent from early work on ADAMTSs that they sequester themselves into 
the ECM and that it is the ancillary domains that are responsible for this. The first 
observation of this property came from Kuno et al (1997) who demonstrated that the 
TSP-1 of ADAMTS-1 is functional for binding to heparin and almost certainly to the
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structurally related heparan sulphate. Both molecules are composed of repeating 
disaccharide units, the difference being that only heparan sulphate GAG-side chains 
connect to core proteins to form proteoglycans (HSPGs) such as in syndecans, perlecan 
and the glypicans (glycosylphosphatidylinositol [GPI]-anchored protein) (Capila & 
Linhardt, 2002).
There have been further studies characterising the binding of ADAMTSs to substrates 
via the ancillary domains. When compared to the zymogen, isoforms of ADAMTS-4 
(lacking cysteine-rich and/or spacer domains) (Flannery et al, 2002) and truncated 
ADAMTS-9 (lacking all domains C-terminus to the central TSP-1 motif) (Zeng et al,
2006) displayed a reduction in binding with heparin. Also full-length ADAMTS-4 and - 
5 bound to chondroitin sulphate with higher affinities than the autocatalytically 
produced isoforms. In contrast, the loss of these domains did not have an important 
effect on the heparin-binding affinity of ADAMTS-5 (Zeng et al 2006). It therefore 
appears that the binding properties of the ancillary domains vary between ADAMTSs 
and that removal of them alters the interactions of the peptidase with different ECM 
components.
It has become apparent that such binding of ADAMTSs to the ECM has a profound 
impact on catalytic activity. The fact that ADAMTSs can localise themselves to the 
ECM via GAGs is likely to be a contributing factor in their ability to cleave specific 
substrates e.g. proteoglycans containing GAG side-chains (lecticans). On the other hand 
the binding of ADAMTSs to ECM ligands may have an inhibitory effect on proteolytic 
activity by immobilising/sequestering the peptidase. For example, Hashimoto et al 
(2004) showed that the binding of ADAMTS-4 to the adhesion molecule fibronectin 
inhibited its cleavage of aggrecan.
1.1.5 Activation and Control of ADAMTSs
In contrast to the matrix metalloproteinases (MMPs), there is no conclusive evidence to 
suggest that ADAMTS activation occurs extracellularly via the 'cysteine-switch' 
mechanism. Despite an unpaired cysteine being present in the prodomain (XXCGVXD) 
of ADAMTSs, it has not been reported that it forms an inactivating bridge to the zinc 
atom forming the active site. Instead, ADAMTSs are synthesised as inactive ‘full- 
length’ zymogens prior to intracellular cleavage of the prodomain and subsequent
secretion as an active mature peptidase. It has been well documented that a ubiquitously 
expressed 794 amino acid proprotein convertase (PC) named furin is responsible for 
such activation in the secretory pathway. In fact all ADAMTSs (except ADAMTS-10, - 
12) have a furin cleavage consensus site (RXR/KR) located at the C-terminal end of the 
prodomain (reviewed by Porter et al, 2005).
Furin was the first PC to be identified (Bresnahan et al, 1990) and it has been shown to 
have important roles in many diseases as well as in protein trafficking (Thomas, 2002). 
It belongs to the subtilisin superfamily of serine peptidases which includes six other PCs 
(PC2, PC1/PC3, PC4, PACE4, PC5/PC6 and PC7). All the PCs contain a signal peptide, 
propeptide, subtilisin-like catalytic domain (SLCD), homo B domain and a CRD. In 
addition, furin, PC7 and an isoform of PC5/PC6 each contain a single TM domain 
(Nakayama, 1997). There is a level of amino acid sequence identity between all the PCs, 
the most similarity occurring in the SLCD (Thomas, 2002).
1.1.5.1 Evidence for Furin-Mediated Activation of ADAMTSs
The first report of furin-mediated activation of ADAMTSs was by Kuno et al (1999). 
The group transfected an ADAMTS-1 expression vector (X5) into a human colon 
carcinoma cell line (LoVo) which does not express functional fiirin. Western blotting 
showed that only the precursor (zymogen) form of ADAMTS-1 was detected in the 
culture supernatant. However, in a cell line expressing furin (COS-7), both the precursor 
and mature forms of ADAMTS-1 were detected. Furthermore, following the co­
transfection of LoVo with furin cDNA and X5, the precursor form of ADAMTS-1 was 
not detected but the mature form was. Following on from these data, evidence for furin- 
cleavage activation was obtained for other ADAMTSs, with particular emphasis on 
ADAMTS-4. Gao et al (2002) reported that proADAMTS-4 (100 kDa) in media from a 
cell line transfected with ADAMTS-4 was converted to a smaller form (75kDa) by 
digestion with recombinant fiirin.
Following on from these preliminary experiments, Wang et al (2004) conducted an in- 
depth analysis of the processing of intracellular ADAMTS-4 by furin. Initially, 
ADAMTS-4 transfected cells (HEK293 and SQ1253) were used to show that cleavage 
of the prodomain was blocked by chloromethylketone (CMK), an inhibitor o f furin. It 
was demonstrated that endogenous fiirin was responsible for the processing of
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ADAMTS-4 by using siRNA (short interfering RNA) to block furin expression within 
the cells. The result was an increase in the levels of proADAMTS-4 protein when 
compared to cells that were not subjected to siRNA. The group also characterised three 
potential furin recognition sites between the prodomain and catalytic site of ADAMTS- 
4 (206RPRR209, 209RAKR212, 211KR212) as well as performing important studies to 
ascertain the location within the cell where furin cleavage of ADAMTS-4 occurred. By 
conducting experiments to block protein trafficking, it was shown that the processing of 
pro-ADAMTS-4 occurred in the trans-Golgi network (TGN) and not the ER (where 
furin is synthesised) or cell surface (where furin is also localised). The group also 
demonstrated by confocal microscopy that ADAMTS-4 was colocalised with furin in 
the TGN.
It has been demonstrated that furin-cleavage can occur at locations other than the TGN. 
Activation of ADAMTS-7 appeared to involve a multi-step mechanism with partial 
processing in the TGN prior to further removal of the prodomain at the cell surface 
(extracellular) by membrane-bound furin (Somerville et al, 2004). Another study 
showed that ADAMTS-9 was processed exclusively extracellularly at the cell surface 
by furin (Koo et al, 2006). The authors extended their analysis of ADAMTS-9 to show 
that the peptidase has unique properties in terms of activation and secretion. 
Experiments in HEK293F cells suggested that a) ADAMTS-9 requires the presence of 
the propeptide to be secreted, b) the ADAMTS-9 propeptide must be A-linked 
glycosylated in order for ADAMTS-9 to be secreted and it remains highly-resistant to 
furin cleavage throughout the secretory pathway, c) propeptide fragments and the 
catalytic domain of ADAMTS-9 remain non-covalently associated following furin 
processing, and surprisingly d) ADAMTS-9 cleaved versican more efficiently when the 
propeptide was still attached as opposed to it being cleaved by furin (Koo et al, 2007). 
However, these data are subject to conjecture as many of the experiments were 
performed with transfected mutants o f ADAMTS-9 lacking many domains, which may 
influence peptidase maturation.
In a furin-deficient cell line (RPE.40), Wang et al (2004) showed that ADAMTS-4 was 
processed to a smaller form indicating that a furin-independent activation pathway 
exists for this peptidase. Following on from this evidence, Tortorella et al (2005) 
investigated five of the PCs, serine proteases (trypsin, chymotrypsin and plasmin) as 
well as twelve MMPs and ADAM-17 in respect to ADAMTS-4 activation. Out of this
15
comprehensive list of enzymes, it was shown that only PACE4, PC5/6B, furin (all by
9 1 9  9 i ' lcleavage at Arg -Phe ), MMP-9 and trypsin had the capacity to remove the 
prodomain. This work indicated that ADAMTS-4 activation occurs by a limited number 
of mechanisms and activators, a conclusion supported by the fact that MMP-9- 
processed ADAMTS-4 did not show aggrecanase activity.
1.1.5.2 Activation of ADAMTSs by C-Terminal Processing
It is clear that ADAMTSs are not solely cleaved at the N-terminus, but also at the C- 
terminus and that such processing has a significant effect on enzyme activity, substrate 
specificity and localisation. There are a number of mechanisms by which C-terminal 
processing of ADAMTSs is likely to occur including proteolysis by MMPs and 
autocatalysis.
There have been a number of studies that have implicated MMPs in ADAMTS C- 
terminal processing. Rodriguez-Manzaneque et al (2000) transfected kidney cells with 
the complete ADAMTS-1 cDNA prior to detecting only a 110 kDa unprocessed form in 
the cell layer. In contrast an 87 kDa and 65 kDa form was detected in the conditioned 
media. It was shown that the 87 kDa form was a result of prodomain cleavage by furin 
whereas the 65 kDa form was a result of additional processing events at the C-terminus 
(following initial furin-cleavage to produce p87). The group showed that MMP-2, 
MMP-8 and MMP-15 had the ability to cleave p87 to form p65. ADAMTS-4 has also 
been shown to be processed by MMPs (MMP-17) at the C-terminus (Gao et al, 2004).
Evidence that C-terminal processing has a direct effect on activation of ADAMTS 
catalytic activity Was shown by Gao et al (2002). Only isoforms of ADAMTS-4 
generated by C-terminal truncation (shown by domain-specific antisera) displayed 
aggrecanase and versicanase activity. Consistent with data by Rodriguez-Manzaneque et 
al (2000), C-terminal cleavage appeared to have occurred following initial prodomain 
removal by furin. Importantly, both studies identified the C-terminal cleavage site as 
being close to the same amino acid residue (744).
Another mechanism of ADAMTS C-terminal activation that has been described is 
autocatalysis. Flannery et al (2002) incubated purified recombinant full-length 
ADAMTS-4 at 37°C without the presence of any PCs or MMPs. The presence of
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ADAMTS-4 isoforms that displayed aggrecanase activity suggested that autocatalytic 
activation by C-terminal clipping (showed by sequencing) had taken place. 
Autocatalysis has also been described for ADAMTS-1 generating N- and C-terminal 
cleavage fragments (Liu et al, 2005). When compared to full length ADAMTS-1, these 
fragments inhibited pulmonary metastasis in carcinoma cells by inhibiting cell 
signalling pathways, proliferation, survival and angiogenesis. An important observation 
was that autocatalysis was inhibited by HSPGs, suggesting that the interaction of 
ADAMTSs with the ECM has a bearing on activation.
Further evidence that ADAMTS activation occurs by removal of ancillary domains 
came from Kashiwagi et al (2004) who constructed ADAMTS-4 C-terminal domain 
deletion mutants. The results showed that deleting each of the ancillary domains had a 
profound effect on ADAMTS-4 activity and specificity. These data appeared to suggest 
that the spacer domain acts as an ‘intramolecular suppressor’, deletion of which 
coincided with ADAMTS-4 being able to cleave different substrates including 
carboxymethylated transferrin, fibromodulin and decorin. Further deletions of C- 
terminal domains created mutants that varied in ability to cleave different bonds within 
the aggrecan molecule and with different efficiencies. For example the spacer domain 
deletion mutant cleaved the Glu373-Ala374 and Glu1480-Gly1481 inter-globular bonds more 
effectively than a mutant lacking just the CRD.
Another study utilising domain deletion mutants showed that the CRD and spacer 
region are required for ADAMTS-13 to cleave UL-vWF (Soejima et al, 2003). This is 
an important finding because a lack of ADAMTS-13 and thus insufficient UL-vWF 
breakdown causes thrombotic thrombocytopenic purpura (TTP) which is characterised 
by thrombus formation, renal failure and neurological dysfunction (Zheng et al, 2001). 
The spacer region has also proved crucial for ADAMTS-1 to cleave aggrecan as shown 
by domain deletion studies (Kuno et al, 2000). The potential processing o f ADAMTS-9 
by removal of the signal peptide, prodomain and C-terminal domains is summarised in 
Figure 1.5.
1.1.5.3 Alternative Splicing of ADAMTSs
Another potential mechanism of ADAMTS regulation is pre-transcriptional via the 
generation of multiple isoforms. This phenomenon is caused by alternative splicing,
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Figure 1.5 Potential Processing of ADAMTS-9
whereby pre-RNA exons are arranged in various ways to yield slightly different 
messenger RNA (mRNA) and hence proteins. Splice variants have been demonstrated 
for ADAMTS-6, -7, -9 and potentially -16 and -18 (reviewed by Jones & Riley, 2005). 
The generation of proteins with different C-terminal domain structures could be a 
mechanism of controlling the function of ADAMTSs.
1.1.6. Inhibitors of ADAMTSs
The ADAMTSs are important in many normal physiological roles such as angiogenesis, 
wound healing and development. It is important that ADAMTS activity is controlled to 
prevent the shift in balance from normal physiology to destructive pathological 
conditions. ADAMTSs are controlled at many levels including: transcriptional (e.g. 
cytokine modulation of transcription initiation), post-transcriptional (e.g. alternative 
splicing) and post-translational (e.g. prodomain or C-terminal cleavage) regulation. As 
is the case with all secreted eukaryotic proteinases, it is apparent that in order to 
counteract the destructive potential of ADAMTSs, endogenous inhibitors are present in 
the body as another form of regulation.
1.1.6.1 Tissue Inhibitors of Metalloproteinases (TIMPs)
Tissue inhibitors of metalloproteinases (TIMPs), of which there are four (TIMP-1, -2, -3 
and -4), are the major endogenous inhibitors of the MMPs. Recent studies indicate that 
TIMP-3 is the main inhibitor of ADAMTSs, although TIMP-1 and TIMP-2 also show 
slight inhibitory capacity when used in higher concentrations in vitro (Hashimoto et al, 
2001). Compared to ADAMTSs, TIMPs are relatively small proteins of between 21 and 
34 kDa, with twelve conserved cysteine residues. The proteins are folded into two 
domains, with all the TIMPs containing a conserved binding site for proteinases 
(VIRAK amino acid sequence), in the domain responsible for the inhibitory activity, the 
N-terminal domain (Lambert et al, 2004).
There have been a number of studies implicating TIMP-3 in the inhibition of 
ADAMTSs. Hashimoto et al (2001) showed that TIMP-3 blocked aggrecan cleavage 
by ADAMTS-4 at a significantly lower concentration than TIMP-1 and TIMP-2 
whereas TIMP-4 had no effect. Kashiwagi et al (2001) observed similar results with the 
N-terminal domain of TIMP-3 (N-TIMP-3), which blocked ADAMTS-4 and -5
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cleavage of aggrecan in vitro. In contrast, N-TIMP-1 and TIMP-2 had no effect on 
aggrecanase activity of both ADAMTSs whereas TIMP-4 showed 35% inhibition when 
added in higher concentrations to ADAMTS-4 but not to ADAMTS-5. These data 
obtained by Kashiwagi et al would perhaps have been more conclusive if the full length 
TIMP-3 protein was utilised as opposed to the truncated construct lacking the C- 
terminus, which is perhaps crucial in directing the inhibitory effect of TIMP-3 in vivo. 
In fact the C-terminus is thought to be involved in binding to proenzymes as opposed to 
active metalloproteinases (Lambert et al, 2004).
TIMP-3 was also shown to inhibit ADAMTS-1 although in contrast to its action on 
ADAMTS-4 (as described above) not all activity was blocked (Rodriguez-Manzaneque 
et al, 2002). Further evidence that ADAMTSs have varying inhibitor profiles came 
from the same study, with TIMP-2 having a similar effect on ADAMTS-1 activity as 
TIMP-3. The question o f where inhibition o f ADAMTSs is occurring is an important 
one. TIMP-3 is the only TIMP known to bind to the ECM (via GAGs) (Yu et al, 2000), 
suggesting it has the potential to inhibit ADAMTSs in matrix-rich tissue e.g. cartilage or 
brain. Inhibition of ADAMTSs may also be taking place in the circulatory system 
because a 2-macroglobulin which is present in the blood (~2-4 mg/mL) has been shown 
to inhibit ADAMTS-4 and -5 (Tortorella et al, 2004).
1.1.6.2 Inhibition of ADAMTSs as Potential Therapies
The field of 'ADAMTS inhibition' is important in that potential therapies could be 
developed based on such studies. One such treatment could involve the augmentation or 
activation of endogenous TIMP-3. Another potential approach could be to use 
molecules/drugs to inhibit ADAMTSs directly. Therefore, as well as studying the 
TIMPs, Rodriguez-Manzaneque et al (2002) performed a comprehensive analysis of the 
effects of a number of synthetic inhibitors on ADAMTS-1 activity. Partial or total 
inhibition was observed with monoclonal antibodies (raised against ADAMTS-1 
epitopes), metal (zinc) chelators such as ethylenediamine tetraacetic acid (EDTA), 1,10- 
phenanthroline and doxycycline, hydroxamates e.g. BB94, MMP inhibitor I and heparin. 
It has also been shown that catechin gallate esters, present in green tea inhibit 
ADAMTS-1, -4 and -5 (Vankemmelbeke et al, 2003).
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With such a variety of roles for the ADAMTS peptidases in normal turnover, it could 
prove difficult to achieve beneficial tissue-specific inhibition in vivo to treat diseases 
where ADAMTS-induced proteolysis is a factor. There is a complex balance in all 
systems between inhibitors and enzymes which is lost during pathological conditions. 
Further understanding of the inhibitory mechanism of endogenous TIMPs as well as the 
pathways by which ADAMTS expression is modulated prior to activation is required 
before any ADAMTS-related therapeutic interventions can be contemplated.
1.2 Glutamyl Endopeptidase ADAMTSs
1.2.1 Overview
The glutamyl endopeptidases (GEPs) are defined as enzymes that cleave proteins at the 
carboxyl end of glutamate residues. ADAMTSs which are GEPs are among the most 
extensively studied because of their ability to cleave aggrecan, the major CSPG of 
cartilage, thus implicating them in arthritic disorders including osteoarthritis (OA) and 
rheumatoid arthritis (RA). For this reason the ADAMTS GEPs are also known as the 
aggrecanases and include ADAMTS-1, -4, -5, -8, -9 and -15 (and possibly ADAMTS- 
20 due to similar domain structure to ADAMTS-9) (reviewed by Porter et al, 2005). OA 
is characterised by progressive degeneration of articular cartilage ECM by an increase 
in proteinase activity and insufficient synthesis of new matrix components (reviewed by 
Hedbom & Hauselmann, 2002). Rheumatoid arthritis (RA) is a systemic autoimmune 
inflammatory disorder, caused by autoreactive T cells, cytokines, chemokines and 
proteinases, resulting in joint destruction (reviewed by Lee & Weinblatt, 2001).
The GEPs do not have greatly similar domain structures or primary sequences that are 
as highly conserved as the pro-collagen convertases. This suggests that the breakdown 
of collagen requires stringent structural requirements whereas aggrecan breakdown can 
be achieved with structurally diverse ADAMTSs. GEPs are expressed in a large number 
of tissue-types within the body and degrade substrates other than aggrecan e.g. the 
lectican; versican and cartilage oligomeric matrix protein (COMP, processed by 
ADAMTS-4), thus they are likely to have roles other than in cartilage turnover 
(reviewed by Flannery, 2006).
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1.2.2 Chondroitin Sulphate Proteoglycans
The main substrates of ADAMTS GEPs are the proteoglycans, which are important 
components of the ECM, found in all tissue types including cartilage and the brain. 
Some of the functions of proteoglycans were summarised by Rhodes & Fawcett (2004) 
including; cellular adhesion and growth, binding to receptors, formation of barriers and 
interactions with other ECM constituents. Proteoglycans are comprised o f a core protein 
carrying covalently bound, negatively charged GAG chains of -20-200 residues in 
length. GAGs are unbranched chains of repeating disaccharide units usually consisting 
of an uronic acid and an amino sugar. The main types of proteoglycan known to be 
cleaved by GEPs all have chondroitin sulphate GAGs (CSPGs), although aggrecan also 
has keratan sulphate GAGs attached (Roughley, 2006).
The disaccharide unit of chondroitin sulphate GAGs is glucuronic acid which is linked 
to N-acetyl galactosamine via a P-glycosidic bond. Polymerisation into the long GAG 
chains is facilitated by human chondroitin synthase and chondroitin sulphate 
polymerising agent. The serine residues of proteoglycan core proteins are linked to 
GAGs by the sugar xylose (by xylosyltransferase). The position on the core protein 
where GAGs bind has a profound influence on the ability of the proteoglycan to bind to 
other molecules (Galtrey & Fawcett, 2007).
1.2.2.1 The Lecticans
A group of CSPGs that have been shown to be GEP substrates are the lecticans, which 
are structurally related in that they have similar N and C-terminal domains but vary in 
the size of core protein as well as the length and number of GAGs attached as shown in 
Figure 1.6. The lecticans are also known as the hyalecticans (or hyaladherins) because 
of their ability to bind non-covalently to hyaluronan, a GAG residing in the ECM and 
on cell-surfaces. This interaction is stabilised by a link protein, to which lecticans also 
bind. In mammals, there are four members of the lectican family, two of which are 
expressed throughout the body; aggrecan (cartilage, notochord, central nervous system 
[CNS]) and versican (virtually all connective tissue, blood vessels, mesenchyme, brain, 
kidney, cartilage) and two which are only found in the CNS; brevican and neurocan 
(reviewed by Viapiano & Matthews, 2006; Bandtlow & Zimmermann, 2000).
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Figure 1.6 The Structure of the Lecticans
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The figure demonstrates the similarities and differences between the lecticans. All 
lecticans contain G1 and G3 domains whereas the size of the core protein is variable as 
well as the number o f GAGs, which are attached. Note aggrecan has both chondroitin 
sulphate and keratan sulphate GAGs attached to the core protein. Adapted from 
Roughley (2006).
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The core protein of aggrecan consists of three globular domains; G l, G2 and G3 with an 
interglobular domain (IGD) between G l and G2 and a GAG-attachment region between 
G2 and G3. Aggrecan exists in the ECM as aggregates, forming structural complexes 
with hyaluronan and link proteins and it is the Gl domain at the N-terminal end of the 
protein which is important for such interactions (Knudson & Knudson, 2001). The 
function of G2 has yet to be deciphered but no interactions with hyaluronan have been 
observed. At the C-terminus of aggrecan is G3, which can be alternatively spliced, 
producing aggrecan variants, the implications of which are as yet unknown (Roughley,
2006).
The GAG-binding region of aggrecan can be divided into three domains, one binding 
keratan sulphates (next to G2) and two binding chondroitin sulphates. The GAG- 
attachment domain is considerably larger in aggrecan than the other lecticans with -100 
chondroitin sulphates attached compared with -20  in versican, -3-7  in neurocan and ~1- 
3 in brevican (Viapiano & Matthews, 2006). It is this large GAG-attachment region 
which gives aggrecan a high anionic charge density, rendering the protein with crucial 
osmotic properties required for cartilage function (Roughley, 2006). Aggrecan prevents 
compression of cartilage by hydrating and swelling against the type II collagen scaffold. 
Proteolytic liberation of the GAG-attachment region may initiate a series o f cellular 
responses that cumulate in the loss of load-bearing properties (reviewed by Amer, 2002).
Brevican, versican and neurocan lack the G2 domain but contain highly similar G l and 
G3 domains to aggrecan. As a result of alternative splicing four different isoforms of 
versican have been identified; V0, V I, V2 (major species in adult brain) and V3. The 
four isoforms vary in terms of GAG-binding domains, with V0 having two (GAG-a and 
GAG-P), VI (GAG- P) and V2 (GAG-a) having one and V3 lacking both (just the 
globular domains).
1.2.3 ADAMTS Proteoglycanase Activity
Sandy et al (1991) discovered a novel aggrecan cleavage-site which was not a target for 
MMPs, thus triggering an eight-year search for the unknown aggrecanases. The bond 
was Glu373-Ala374 and similarly to the characteristic-cleavage site of MMPs (Asn341- 
Phe342) was located in the IGD, cleavage of which liberated the G2, GAG-binding and 
G3 domains of aggrecan from hyaluronan (G l still attached). A group at DuPont
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Pharmaceuticals (USA) were the first to show that ADAMTS-4 (aggrecanase-1) and 
ADAMTS-5 (aggrecanase-2) cleaved at the Glu373-Ala374 bond and as a result 
aggrecanases have become the focus of intensive research (Tortorella et al, 2000; 
Abbaszade et al, 1999).
The same group further characterised ADAMTS-4 cleavage of aggrecan by identifying 
two more cleavage-sites, both within the GAG-binding domain. Purified ADAMTS-4 
was incubated with bovine aggrecan (the cleavage-sites of which are highly similar to 
human aggrecan) over a period of time and antibodies were used to detect breakdown 
products. It was demonstrated that the preferred cleavage-site for ADAMTS-4 was the 
Glu1667-Gly1668 bond followed by Glu1480-Gly1481 bond with Glu373-Ala374 bond the least 
preferred. However, these data did not answer the question of whether G luI667-Gly1668 is 
the first to be targeted or whether it is the bond which is just cleaved the fastest (i.e. all 
sites are initially targeted at the same time). Problems with varying antibody reactivity 
for different breakdown products were also cited by the authors (Tortorella et al, 2000). 
Since this study it is understood that ADAMTS-4 and ADAMTS-5 generally cleave at 
the same sites and further bonds have been characterised or proposed as targets for these 
aggrecanases (GluI545-Gly1546, Glu1819-Ala1820 and Glu1919-Leu1920) (reviewed by 
Flannery, 2006).
0 * 7 0  *7*7 AADAMTS-1 has also been demonstrated to cleave aggrecan at the Glu -Ala site 
(Kuno et al, 2000) as well as all the bonds cleaved by ADAMTS-4 and -5, as shown by 
N-terminal sequencing of fragments, a more objective approach than using antibodies 
(Vankemmelbeke et al, 2003). Other aggrecanases, which cleave aggrecan far less 
efficiently than ADAMTS-1, -4 and -5 include ADAMTS-8, major cleavage site at 
Glu -Ala , which is expressed in human articular cartilage (Collins-Racie et al, 
2004), ADAMTS-15, major cleavage site at Glu373-Ala374 (Yamaji et al, 2004) and 
ADAMTS-9 at Glu441-Ala442 (Somerville et al, 2003).
1.2.3.1 Aggrecanase ADAMTSs in Arthritis
In arthritic disorders, ADAMTS-4 and -5 are considered to be the most important. 
ADAMTS-1'7' mice challenged with methylated bovine serum albumin (mBSA), which 
induced arthritis-like pathology, displayed no protection against 'accelerated 
aggrecanolysis' when compared to WT animals (Little et al, 2005). A recent study
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utilising siRNA techniques to knockdown ADAMTS-1, -4 and -5 genes in human 
cartilage explants showed further the redundancy of ADAMTS-1 in arthritis. A marked 
reduction in aggrecan degradation was observed in ADAMTS-4 and -5-suppressed 
explants. However no reduction in aggrecan catabolism was observed in explants 
transfected with ADAMTS-1 siRNA (Song et al, 2007). These findings backed up 
earlier data which demonstrated that ADAMTS-4 and -5 were the predominant 
aggrecanases in OA cartilage, based on the detection of aggrecan-neoepitopes cleaved at 
target sites for these enzymes (Malfait et al, 2002).
An in-depth in vivo analysis of aggrecan processing in human knee cartilage and 
synovial fluid was conducted by Sandy & Verscharen (2001). These data showed an 
important role for both ADAMTSs and MMPs. In normal, injured and late stage OA 
knee joint cartilage, five (>50% of total aggrecan present) of the seven major aggrecan 
breakdown products resulted from MMP processing and not ADAMTS activity. The 
major product detected that was a result o f ADAMTS proteolysis was formed by 
cleavage at the Glu373-Ala374 site. In contrast to the results obtained in cartilage tissue, 
aggrecan breakdown products in the normal synovial fluid and fluid-obtained from 
injured knee joints are a result of cleavage by ADAMTSs as opposed to MMPs (Sandy 
& Verscharen, 2001).
Recently the question of which aggrecanase is the most important in arthritis has been 
addressed by studies in ADAMTS-4 and ADAMTS-5 knock-out (KO) mice. There is 
substantial evidence demonstrating that ADAMTS-5 (not ADAMTS-4) is the crucial 
aggrecanase mediating OA and RA-like pathology in mice. Glasson et al (2004) 
originally showed that ADAMTS-4 KO mice showed no difference in progression or 
severity of OA-like pathology (induced surgically by transecting the meniscotibial 
ligament) compared to WT. Following on from this study, Glasson et al (2005) deleted 
the catalytic domain of ADAMTS-4 and -5 prior to inducing the same joint instability. 
In contrast to the ADAMTS-4 data, ADAMTS-5'7' mice displayed a reduction in 
aggrecan-cleavage product production compared to WT in vivo (showed by 
immunostaining technique). Furthermore, cartilage obtained from ADAMTS-5’7' mice 
and cultured in the presence of interleukin-ip (IL-ip) and Ret A in vitro showed 
minimal release of proteoglycan fragments. This was in contrast to tissue from WT and 
ADAMTS-4'7' tissue.
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Similar methods were adopted to ascertain the key aggrecanase in a RA mouse model, 
whereby ADAMTS-4 and -5 KO mice knee joints were injected with mBSA. In a 
similar pattern to the study undertaken by Glasson et al (2005), ADAMTS-5'7’ cartilage 
tissue explants displayed no release of aggrecan in vitro following inflammatory 
stimulus when compared to ADAMTS-4'7' and WT. Furthermore, in vivo studies 
showed that ADAMTS-5’7' mice had less aggrecan loss and cartilage erosion as showed 
by toluidine blue staining (Stanton et al, 2005).
1.2.3.2 Versican and Brevican Processing by Glutamyl Endopeptidase ADAMTSs
Aggrecanases have the potential to cleave lecticans other than aggrecan, although many 
have still to be tested. When incubated with brevican in vitro, ADAMTS-4 generated 
two major fragments thus demonstrating that only one cleavage site was targeted 
(Glu395-Ser396) (Nakamura et al, 2000). This same result was obtained by another group 
who conducted similar incubations following the observation that a glioma cell line 
synthesised and cleaved brevican at the same site (Matthews et al, 2000). Furthermore, 
Nakada et al (2005) showed that glioblastoma cells transfected with ADAMTS-4 and -5 
produced brevican cleavage products, whereas ADAMTS-1 and un-transfected cells 
displayed no cleavage.
ADAMTS-1 and ADAMTS-4 have been shown to cleave VI versican in the GAG-p 
binding domain at Glu441-Ala442 in a study which demonstrated that the resultant 
fragment (70 kDa) was detected in human aorta (Sandy et al, 2001). Additionally 
ADAMTS-4 has been shown to process V2 versican at the Glu405-Gln406 site within the 
GAG-a binding domain (Westling et al, 2004). ADAMTS-9 has also been described as 
having the ability to cleave versican (Somerville et al, 2003).
1.2.4 ADAMTS-9
ADAMTS-9 was originally cloned by Clark et al (2000), who localised the gene to 
chromosome 3pl4.2-pl4.3. The aggrecanase was characterised as having one central 
TSP-1 motif and three TSP-ls at the C-terminus. However, Somerville et al (2003) 
described a much longer form that is considered to be the full-length product of the 
ADAMTS-9 gene (Adamts9), containing fourteen TSP-ls at the C-terminus.
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ADAMTS-9 has an identical domain organisation and exon structure to ADAMTS-20 
(Somerville et al, 2003; Llamazares et al, 2003). In addition, both enzymes have similar 
primary sequences with ADAMTS-9 (1935) containing twenty-five amino acids more 
than ADAMTS-20 (1911). An important difference between the two enzymes is that 
they do not have identical zinc-binding catalytic site motifs. The catalytic site of 
ADAMTS-9 is identical to ADAMTS-1 and -15 in that a proline residue precedes the 
third zinc-binding histidine. In contrast, the catalytic site of ADAMTS-20 is not 
identical to that of any other ADAMTS but most closely resembles that of ADAMTS-7 
and ADAMTS-12 (8/12 matched amino acids) (Somerville et al, 2003). ADAMTS-20 
has been shown to be sparingly expressed in all tissues studied, when compared to 
ADAMTS-9 (except in leukocytes where ADAMTS-20 levels are higher than 
ADAMTS-9) (Somerville et al, 2003). Hence ADAMTS-9 has been far more 
extensively studied, especially in the field of development and embryogenesis.
1.2.4.1 ADAMTS-9 in Embryogenesis and Development
It is not surprising that the ADAMTSs have been implicated in development 
considering the need for remodelling of the ECM to allow for growth. Somerville et al 
(2003) and Llamazares et al (2003) demonstrated that human ADAMTS-9 and -20 have 
comparable domain organisations and primary sequences to GON-1, a proteinase 
required for gonadal morphogenesis in Caenorhabditis elegans nematode, by migration 
of distal tip cells. In fact ADAMTS-9, ADAMTS-20 and GON-1 have a unique 200 
residue GON domain containing several conserved cysteine residues at the C-terminus, 
which defines these enzymes as being in their own subgroup. Furthermore, either 
human ADAMTS-9 or -4 can substitute for GON-1 in GON-1 KO mice (Hesselson et al,
2004). Preliminary evidence implicating ADAMTS-9 in such processes came from 
reverse transcriptase polymerase chain reaction (RT-PCR) data showing that the 
peptidase was expressed in all foetal tissue tested (brain, heart, kidney, liver, lung, 
skeletal muscle, spleen and thymus) by Clark et al (2000). Somerville et al (2003) also 
detected Adamts9 in the same tissues as well as detecting it in foetal cartilage. Adamts9 
is also widely expressed during mouse embryo development (Jungers et al, 2005).
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1.2.4.2 Novel Activation Mechanisms of ADAMTS-9
ADAMTS-9 has recently attracted much interest because it appears to be retained at the 
cell-surface as opposed to being secreted into the ECM (Somerville et al, 2003; Koo et 
al, 2006; Koo et al, 2007), which is unusual for ADAMTSs because they lack a TM 
domain. In addition, novel mechanisms exist for ADAMTS-9 secretion and activation 
(described in Section 1.1.5.1), which the authors postulate; 'ensures that ADAMTS-9 
activity is maximal at the cell-surface', perhaps implicating the enzyme in cell migration 
and growth by clearing a path through the ECM.
1.2.4.3 ADAMTS-9 Expression and Substrate Profile
In addition to being expressed in foetal tissue, Adamts9 is widely expressed throughout 
the adult body including brain, heart, placenta, lung, liver, skeletal muscle, kidney, 
pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and skin 
fibroblasts (Somerville et al, 2003). The role(s) of ADAMTS-9 in such tissues can be 
speculated to some extent based on a very limited amount of substrate specificity data.
ADAMTS-9 is considered to be an aggrecanase and is categorised in this way in a 
number of reviews based on data by Somerville et al, 2003. However, there is some 
doubt as to whether ADAMTS-9 does in fact function as an active aggrecanase. COS-1 
cells were transfected with ADAMTS-9 or ADAMTS-4 (positive control) expression 
plasmids and incubated overnight with aggrecan or versican. Antisera and antibodies 
raised against aggrecan or versican catabolites generated by cleavage at known sites 
were utilised for western blotting. A VI versican neoepitope of approximately 75 kDa 
was detected with sera raised against the C-terminus resulting from cleavage at Glu441- 
Ala442 generated by ADAMTS-9-transfected cells. The same band was detected with 
ADAMTS-4-transfected cells whereas no band was observed with cells expressing the 
plasmid but lacking the insert (negative control). Therefore, from these findings 
ADAMTS-9 can be considered a versicanase.
The amount of aggrecan (20 pg) that was incubated with the transfected cells was four­
fold greater than the amount of versican utilised. Intense immunoreactivity (band at 100
1771kDa) to antisera raised against an aggrecan neoepitope generated by cleavage at Glu
29
1 779Ala bond was observed following incubation with ADAMTS-4-transfected cells. 
However, a very faint band is observed with ADAMTS-9-transfected cells.
The conclusion that can be drawn from these data is that ADAMTS-9 cleaves aggrecan 
less effectively than it cleaves versican in vitro. However, the investigators do not report 
that they tested antibodies or antisera raised against other neoepitopes, consequently 
there is no evidence to suggest that ADAMTS-9 does not cleave aggrecan at sites other 
than those tested, such as at the Glu373-Ala374 bond. Another limitation with the work 
was that only the signal peptide, prodomain and catalytic domain of ADAMTS-9 was 
expressed and not the full-length protein. The ancillary domains of many ADAMTSs 
are crucial for activity/substrate specificity, therefore the fourteen C-terminal TSP-ls 
(and other domains) of ADAMTS-9 may contribute to a more efficient cleavage of 
aggrecan. A direct comparison between ADAMTS-9 and ADAMTS-4 activity cannot 
be drawn because of variations in transfection efficiencies, expression levels and 
secretion levels (Somerville et al, 2003). It is likely that ADAMTS-9 has substrates 
other than aggrecan and VI versican, such as other isoforms of the latter and the 
structurally similar brevican.
1.2.4.4 ADAMTS-9 in Arthritis and Inflammation
In light of this study demonstrating that ADAMTS-9 has the potential to cleave 
cartilage proteoglycans, arthritis is an area of research in which it has been investigated. 
Expression of Adamts9 was shown to be synergistically induced by IL-ip and tumour 
necrosis factor (TNF) in OUMS-27 chondrosarcoma cells and in human chondrocytes. 
In the same study, Demircan et al (2005) showed that p38 and p44.42 mitogen activated 
protein kinases (MAPKs) played a role in regulating some responses of Adamts9 to IL- 
ip. These data indicate that ADAMTS-9 is potentially involved in physiology and/or 
pathology as a result of cytokine-induced inflammation. ADAMTS-9 may not be as 
critical in OA, in which inflammation is a less significant aspect when compared to RA. 
Adamts9 levels were shown to be decreased in hip joints and synovium from patients 
with OA when compared to samples from the same region displaying normal 
physiology (Davidson et al, 2006).
Further evidence that ADAMTS-9 is involved in inflammation came from a study 
utilising a retinal pigment epithelium (RPE) derived cell line ARPE-19. The RPE is a
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cell layer that plays an important role in the regulation and development of the 
photoreceptors in the vertebrate retina. It lies adjacent to Bruch's membrane, a region of 
ECM containing numerous CSPG species. Treatment of ARPE-19 with TNF resulted in 
an up-regulation of Adamts9 expression (as well as Adamtsl and Adamts6) (Bevitt et al, 
2003).
Analysis o f Adamts9 expression levels in response to an anti-inflammatory stimulus 
shed further light on its role in inflammation. Cross et al (2005a) showed that 
transforming growth factor-pl (TGF-pi) initiated a down-regulation (~3-fold decrease 
compared to control) o f Adamts9 (as well as other ADAMTSs) in prostatic stromal cells. 
Treatment with TGF-pl also initiated a ~7-fold increase in the expression of versican. 
The authors speculated that the increased levels of versican observed in benign prostatic 
hyperplasia (BPH) is a result of both decreased ADAMTS expression and increased 
versican expression modulated by TG F-pl.
1.2.4.5 ADAMTS-9 in other Pathologies
Recent work has identified Adamts9 as a potential tumour suppressor gene in 
oesophageal cancer. The group used microcell-mediated chromosome transfer to 
introduce chromosome 3 into an oesophageal cell line prior to identifying the 
ADAMTS-9 gene within the tumour suppressive critical region. Furthermore, levels of 
ADAMTS-9 were lower in 94% of oesophageal cell lines tested as well as in over 40% 
of primary tumours in high-risk regions (Far East) (Lo et al, 2007). In another study, 
Keating et al (2006) demonstrated by gene-silencing approaches that ADAMTS-9 could 
be involved in the pathogenesis of lung fibrosis. Despite ADAMTS-9 mRNA being 
abundantly expressed within the adult and developing brain, as of yet no studies have 
focussed on ADAMTS-9 within the CNS from a functional or pathological view point.
1.3 Central Nervous System
1.3.1 Organisation/Structure
The CNS consists of the brain and spinal cord which are made up of a complex 
meshwork of a variety of cell-types, structural proteins, vasculature and circuits that 
relay electrical signals; triggering neural functions such as memory, cognition, emotion
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and movement. The human brain weighs -1-1.5 kg and can be divided into regions, 
each with generally specific functions and structures (Purves et al, 2001).
The cerebrum is concerned with conscious thoughts such as memory and emotions and 
can be separated into two hemispheres; right (controls left side of body) and left 
(controls right). Each cerebrum hemisphere consists of four lobes; frontal, parietal, 
temporal and occipital. The cerebellum is located at the back of the brain and is 
important for balance and coordination. The cerebral cortex (grey matter) is a thin layer 
of tissue that forms the outer surface of the cerebrum and cerebellum and has long been 
considered responsible for perception/cognition. Two hippocampuses are located in 
medial temporal lobes, located on either side of the brain and are involved in memory 
and spatial recognition. The brain stem is at the bottom of the brain, connecting it to the 
spinal cord and ultimately the rest of the body and is crucial for sustaining important 
processes such as blood pressure, heart beat and breathing (Purves et al, 2001).
The brain receives blood from four arteries; two vertebral arteries (which join to form 
the basilar artery) and two internal carotid arteries. The vasculature within the brain is 
arranged around the circle of Willis from which the main arteries branch off including 
posterior cerebral artery (serves the midbrain and superior cistern), internal carotid 
artery (delivers to the optic chiasm), middle cerebral artery (MCA, feeds lateral sulcus 
and entire lateral surface of cerebral hemisphere and temporal pole) and anterior 
cerebral artery (leads to the optic nerve). In general it has been established that arteries 
dictate cerebral blood pressure and the much smaller more branched capillaries control 
CNS nutrition and waste removal (Farkas & Luiten, 2001).
A number o f problems exist when studying the human brain including: a) samples are 
difficult to obtain from the tissue (because of the skull), b) volunteers are reluctant to be 
involved in studies, c) its 3-D structure is easily distorted during handling (due to its 
high state of hydration and loose connections), d) post-mortem tissue is often not stored 
(frozen) quickly enough, leading to tissue degradation and e) there is a lack of post­
mortem tissue (few donors). Consequently, the brain is perhaps the least understood 
organ in the human body and animal-models are relied upon for experimental analysis.
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1.3.2 N eu ro n es
The role of neurones (nerve/neuronal cell) as the information processors/transmitters of 
the body is well established. The basic mechanism by which 'messages' are passed from 
neurone to neurone and ultimately to other regions of the brain/target-tissues can be 
termed 'synaptic transmission'. The process involves the generation of an action 
potential in an electrically excited axon prior to the influx of Ca2+ ions and the passage 
of neurotransmitter molecules across the synaptic cleft (Siegel et al, 1999).
1.3.2.1 Neuronal Structure
All neurones have the same basic structure consisting of a soma (perikaryon), an axon 
and dendrites. The neuronal soma (cell body) contains organelles common to most cells 
of the body including the nucleus, smooth ER, Golgi apparatus and lysosomes. The 
axon can extend a great distance from the soma and can be divided into four 
morphologically distinct regions: 1) the ribosome-abundant 'axon hillock', 2) the 'initial 
segment', containing axolemma, responsible for action potential generation, 3) the 'axon 
proper' (also contains axolemma), which is surrounded by insulating myelin sheath, 
aiding in smooth nerve-impulse propagation and 4) the 'axon terminal', which interacts 
with other neurones by extending out from the axon proper and releasing 
neurotransmitters. Dendrites are arranged around the neuronal soma in many branches, 
hence the term 'dendritic tree'; they are responsible for the nerve impulse entering the 
cell prior to transmittance down the axon (Siegel et al, 1999).
1.3.2.2 Types of Neurones
Within the CNS different types of neurones exist with subtle structural variations and 
functions. Some neurones are widespread throughout the brain whereas others are 
specific to a particular region. The most abundant neuronal cell type in the CNS is the 
granular neurone (granule cells), present in the cerebellum (granular layer), cerebral 
cortex, dentate gyrus of hippocampus and the olfactory bulb (forebrain). Granular 
neurones are the smallest neurones in the CNS and are characterised by a round soma 
(Yamasaki et al, 2001).
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Another neuronal-type is the pyramidal neurone, which is characterised by a conical 
(triangular) soma, one large apical dendrite and numerous, distinctly large basal 
dendrites, which extend over vast regions of the cerebral cortex and the hippocampus 
(Tsiola, 2003). Elston (2003) proposed that the evolution of the specialised structure of 
pyramidal neurones within the cerebral cortex is a major factor in how humans have 
developed such a complex level of cognition. Furthermore, there is evidence to suggest 
that pyramidal neurones in the hippocampus play a key role in environmental and 
spatial responses by becoming active and changing their orientation (O'Keefe, 1999).
The presence of Purkinje cells is a characteristic morphological feature of the 
cerebellum. Purkinje cells have multiple postsynaptic dendritic spines which change 
morphology in different experimental conditions e.g. mushroom-shaped spines are more 
dynamic and have different signalling mechanisms than branched spines (Lee et al,
2005). Another morphological feature o f Purkinje cells is an extremely large soma 
(Purves et al, 2001). Other types of neurones include Renshaw cells, medium spiny 
neurones and Basket cells.
1.3.3 Glial Cells
Spindle-shaped glial cells are the most abundant (-90%  of all cells) cell-type in the 
CNS, consisting of astrocytes, microglia and oligodendrocytes, which are all smaller 
than neurones. Glia possess no synaptic contacts and were originally considered to play 
supporting roles for neurones with no real functions, other than structural hence they 
were named after the Greek word for 'glue' (He & Sun, 2007). However, it has become 
apparent that glial cells perform essential roles in neuronal function and maintenance as 
well as in response to injury (Siegel et al, 1999).
Astrocytes are the most abundant cell-type in the brain, providing physical support, 
chemicals and nourishment to neurones. These star-shaped cells form a matrix which 
keeps neurones in place and isolates synapses, thus aiding in transmission of neural 
messages (Bear et al, 2001). Other functions of astrocytes in normal CNS physiology 
include; glycogen storage and export of metabolites, uptake of unutilised 
neurotransmitters (glutamate), neurotrophic factor (NTF) and cytokine 
production/secretion, synapse genesis and maintenance (Flynn et al, 2003; Farina et al,
2007).
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Microglia, the smallest of the glial cells, are the resident immune cells of the CNS, 
whose roles include immune surveillance and phagocytosing debris from damaged 
nerves. They belong to the same phagocytic lineage as other tissue macrophages e.g. 
Kupffer cells, a liver-specific macrophage population. Morphologically, microglia are 
similar to dendritic cells in that they have many 'spiky' outgrowths from the cell body, 
however an amoeboid shape is adopted in response to injury (Vilhardt, 2005). In the 
healthy brain, microglia are supportive cells but are also extremely motile suggesting 
they are 'busy and vigilant housekeepers' (Nimmerjahn et al, 2005). There is evidence to 
suggest microglia are kept in a quiescent state in the healthy brain by signalling from 
neurones. The mechanism is thought to involve the interaction of the neuronally 
expressed CD200 membrane glycoprotein with the CD200 receptor, present on 
microglia (Hoek et al, 2000). Noted functions of microglia in normal physiology 
include stimulating migration of neuronal precursor cells by releasing soluble factors 
including chemokines (Aarum et al, 2003), axonal growth (via the release of NTFs) 
(Batchelor et al, 2002) and synthesis of ECM components (Vilhardt, 2005).
The cells responsible for manufacturing myelin sheaths around axons are 
oligodendrocytes (Schwann cells are principle myelinating cells in the peripheral 
nervous system [PNS]) as first described by Hortega & del Rio (1921). The process of 
myelination initially involves the migration of the oligodendrocyte precursors to the 
axons where adherence takes place. Next, the cells proceed to differentiate and spiral 
their processes around the axon via a poorly understood mechanism. One theory is that 
the timing of oligodendrocyte differentiation and thus myelination is controlled by the 
developmentally regulated decrease in the expression of Jagged 1 in axons (Stangel & 
Hartung, 2002). Jagged 1 is thought to inhibit oligodendrocyte differentiation by 
interacting with the Notchl receptor; therefore the down-regulation of Jaggedl 
potentially increases oligodendrocyte maturation and thus myelination (Wang et al, 
1998).
Glial precursor cells have become the focus of extensive study in recent years because 
of their ability to differentiate into various cell-types. During embryogenesis, radial glial 
cells can differentiate into neuronal, oligodendrocyte and astrocyte precursor cells. 
Furthermore, astrocyte precursor cells can also differentiate into neuronal and 
oligodendrocyte precursor cells as well as astrocytes in the perinatal period. It has been 
described that MAPK1/2 and extracellular signal-regulated kinase 1/2 (ERK1/2) are
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important signalling pathways within radial glial cells, which contribute to the 
proliferation of these cells (Vaccarino et al, 2007).
1.3.4 CNS Extracellular Matrix
The ECM is a complex structure which surrounds and supports cells in all tissue-types 
in the body. It is made up of diverse proteins and proteoglycans which are secreted into 
the extracellular space by numerous cell-types. The composition and form of ECM 
varies greatly between tissue types and has a large impact on its different functions. 
CNS ECM lacks fibrillar collagen, fibronectin and laminin, giving the brain a soft 
consistency when compared to other proteoglycan-rich tissues (e.g. cartilage). The 
matrix has a critical role in a wide variety of physiological brain processes such as 
development (migration of precursor cells), repair, proliferation and cell signalling (via 
integrins) (Bellail et al, 2004).
A significant percentage (-20%) of the normal brain volume is occupied by the ECM, 
forming both general 'loosely-defined' matrices as well as perineuronal nets (PNN) 
which surround and support neurones in a tightly packed, condensed manner. PNNs 
have been shown to stabilise/limit synaptic plasticity (cellular adaptation to the 
environment) and support ion homeostasis of neurones (Galtrey & Fawcett, 2007). It is 
known that neurones and glial cells contribute to the secretion of PNN components; 
principally hyaluronan, proteoglycans, tenascin-C (adhesive molecule related to laminin 
and fibronectin) and thrombospondins (Yamaguchi, 2000; He & Sun, 2007).
The GAG hyaluronan is a major component of the cerebral ECM. It is comprised of 
long chains of up to 25,000 repeating non-sulphated disaccharide units (made of 
glucuronic acid and N-acetylglucosamine) forming molecules of up to 106 Da in size 
(Galtrey & Fawcett, 2007). It is highly anionic, electrostatically attracting Na+ and 
inducing an osmotic influx of H2O into the extracellular space (Bellail et al, 2004). 
Many ECM components are attached non-covalently to hyaluronan, which acts as the 
'back-bone' to form complex ECM structures with lecticans, tenascins, link proteins and 
carbohydrates.
The lecticans have been described as 'organisers o f the brain ECM' and 'molecular 
bridges' because they bind to two key ligands; hyaluronan via the N-terminus and to
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tenascin-C/-R via the C-terminus (Yamaguchi, 2000) as shown in Figure 1.7. Lecticans 
are the most abundant CSPGs in the brain and are important because they a) provide 
structural support to the hyaluronan scaffold and b) influence matrix function by 
interacting with cell-surface molecules of other ECM components. Link proteins are 
small glycoproteins thought to secure the interactions of lecticans with hyaluronan. 
Bral2/Hapln4 is a link protein which is colocalised with brevican in PNNs, whereas 
Bral2/Hapln2 is colocalised with V2 versican (Aono & Oohira, 2006).
Examples of lectican molecular interactions in the CNS ECM include neurocan with 
members o f the cell adhesion molecule superfamily (CAM), brevican with sulphated 
glycolipids and aggrecan/versican with fibulin family members. In addition all lecticans 
have the potential via their G AG-side chains to interact with NTFs, cytokines and cell- 
surface signalling receptors (e.g. tyrosine kinases, CD44) (Viapiano & Matthews, 2006).
The ECM of the CNS contains proteoglycans other than the lecticans; including 
phosphacan, which interacts with tenascin-R but is unable to bind to hyaluronan 
(Galtrey & Fawcett, 2007). Another PNN component is thrombospondin-1, which binds 
to HSPGs via its C-terminus and promotes platelet aggregation and cell adhesion (De 
Fraipont et al, 2001).
In normal physiological conditions the ECM of the brain is a dynamic structure which 
undergoes constant remodelling. In brevican'7' mice, neurocan expression was found to 
be up-regulated because there were more binding sites for it within the matrix 
(Brakebusch et al, 2002). Furthermore, mice lacking neurocan, brevican, tenascin-C and 
-R were healthy and fertile because aggrecan and versican compensated for the absent 
molecules. Also, fibulin-1 and -2 increased in expression to neutralise the loss of 
tenascin-C and -R (Rauch et al, 2005).
1.4 CNS Inflammation
1.4.1 Immunology of the CNS
Inflammation is the body's innate response to injury or microbial infection involving 
white blood cells (leukocytes) and plasma enzyme systems, which generate 
inflammatory mediators. If it is localised correctly with limited severity and duration it
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Figure 1.7 Structure of the CNS Extracellular Matrix
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Simplified interpretation of the ECM of the CNS showing how lecticans act as anchors 
between the hyaluronan scaffold (via the N-terminus) and tenascins (via the C-terminus). 
Note how neurocan does not bind with tenascins yet can anchor to the CAM family on 
the cell surface. Adapted from Galtrey & Fawcett (2007); Viapiano & Matthews (2006).
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can be effective at returning the host to a state of normality by eliminating pathogens, 
repairing damaged tissue and preventing further destruction (Allan & Rothwell, 2003). 
A complex series of pro-inflammatory pathways promote inflammation in the body. 
However if  it is not controlled effectively or is triggered inappropriately, devastating 
damage can occur. To counteract detrimental inflammation, the body has a cohort of 
anti-inflammatory responses/mediators.
It was not long ago that the brain was considered an 'immunologically privileged' 
environment, which did not respond to inflammatory stimuli. It is true to a certain 
extent that the brain guards against self-damage by having a scaled down immune 
system. However, the brain still possesses many features which facilitate an immune 
response including oedema, immune cell invasion, endogenous glial cell (especially 
microglia) activation, complement activation, acute phase proteins and cytokines (Allan 
& Rothwell, 2003; Aktas et al, 2007). It is when the balance of inflammatory mediators, 
inhibitors, receptors and immune cells becomes disturbed that destructive CNS 
inflammation can lead to neuronal damage characteristic o f CNS inflammatory 
disorders.
1.4.1.1 The BIood-Brain Barrier
The blood-brain barrier (BBB) protects the fragile ECM of the neuronal parenchyma 
from chemicals and variations in blood composition. A simplified interpretation of the 
BBB structure is displayed in Figure 1.8. The BBB is comprised of three main 
structures; capillary ECs, astrocytic end-feet and pericytes. Tight junctions and adherens 
junctions are present between the ECs allowing selective permeability of 
molecules/nutrients, which are -0.5 kDa or less (e.g. glucose, amino acids, insulin and 
leptin), into the brain (Petty et al, 2002; Ballabh et al, 2004). Capillary ECs of the BBB 
are phenotypically different from those found on non-cerebral capillaries and contain a 
greater amount of mitochondria required for the mechanisms involved in transporting 
larger molecules across the BBB (Rubin & Staddon, 1999). The astrocytic end-feet are 
in close proximity to the ECs and are thought to provide support to the structure as well 
as intercellular signals (Ballabh et al, 2004).
The blood vessel endothelium is surrounded by a 30-40 nm thick matrix known as the 
basement membrane (BM/basal lamina). The ECM components of the BM are thought
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Figure 1.8 Structure of the Blood-Brain Barrier (BBB)
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The barrier that prevents the passage of inflammatory cells into the CNS from the blood. 
In health, the barrier is effective. However, in many CNS inflammatory disorders the 
integrity o f the BBB is compromised. BM = basement membrane, TJ = tight junction, 
AJ = adherens junction. Adapted from Ballabh et al (2004).
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to be produced by capillary cell-types (Farkas & Luiten, 2001). It is arranged into a 
trilaminar structure, the layer in closest proximity to the ECs being the 'lamina rara 
interna' which is made up o f HSPGs (especially perlecan), laminin and collagen type IV 
(both comprise the BM 'scaffold'). A layer of similar structure, the 'lamina rara externa' 
is in contact with astrocytic end-feet, thus linking the BM to the rest of the BBB. A 
collagen type IV layer (lamina densa) separates the two lamina rara layers. The BM has 
many functions such as support of microvessels, providing a route for cell migration, 
selective permeability o f molecules, modulation of EC function, adhesion and general 
protection of neurones from inflammatory cells (Farkas & Luiten, 2001).
Pericytes are embedded into the BM and have been shown to have a role in regulating a) 
CNS vascular diameter and capillary blood flow (by their ability to contract), b) BBB 
EC differentiation/proliferation and c) phagocytosis (Rucker et al, 2000). It has been 
demonstrated that pericytes synthesise HSPGs, which have a high level of hydration and 
therefore fill the gaps in the BM. HSPGs have also been implicated as 'molecular sieves' 
within the BBB, blocking leukocyte extravasation as well as having a role in binding 
growth factors (GFs) and cytokines (Parish, 2006).
In normal physiological conditions, the BBB limits the entry o f monocytes, 
lymphocytes and other cells of the immune system preventing cellular damage caused 
by autoimmunity and destructive inflammatory responses. However, disruption of the 
BBB in pathological conditions such as multiple sclerosis (MS) and stroke allows the 
entry of activated, inflammation-inducing leukocytes which initiate CNS damage.
1.4.2 CNS Inflammatory Disorders - Overview
CNS inflammatory disorders can be characterised into two main types; acute and 
chronic. The aetiology of chronic CNS inflammatory disorders are far less understood 
than acute disorders but they generally present and worsen with age and are likely to 
involve environmental factors triggered in a genetically susceptible host. Multiple 
sclerosis (MS) presents at an earlier age than most chronic CNS diseases, with most 
sufferers, of which there are -85,000 in the UK, first experiencing symptoms between 
the ages o f twenty and forty (Burridge et al, 2007). Symptoms of MS include; weakness, 
lack of coordination and impaired vision/speech because autoimmune responses destroy 
myelin (demyelination) resulting in axonal damage and ultimately death. MS is
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characterised by inflammatory cascades thought to be triggered by the immune system 
mistakenly recognising myelin antigen as 'foreign', although this theory has not yet been 
proven (reviewed by Hafler, 2004).
MS pathogenesis is complex and not fully understood although it is considered to be 
initiated in the periphery by the presentation of myelin derivative-like antigens on 
antigen presenting cells (e.g. macrophages) by major histocompatibility complex class 
II (MHC II) molecules (Compston, 2004) to CD4+ T lymphocytes (T helper cells), 
which are thus activated (Sospedra & Martin, 2005). The activated lymphocytes pass 
through the BBB via expression of adhesion molecules and chemokines (chemo- 
attractant cytokines) (Bar-Or et al, 1999). It has been reported that the release of MMP- 
2 and -9 facilitates the infiltration of activated cells through the BBB (Sospedra & 
Martin, 2005). Following migration into the CNS, T cells re-encounter myelin antigen, 
and initiate delayed-type hypersensitivity reactions, resulting in the release of 
inflammatory-mediators leading to the activation of microglia/macrophages and 
cytotoxic T cells. The resultant auto-pathogenic responses target critical myelin- 
components, which are broken down by oxygen/nitrogen free radicals and proteinases, 
mediated by pro-inflammatory cytokines (Markovic-Plese et al, 2004).
Chronic inflammatory disorders of the aged population are areas of intense research 
activity due to the increased life expectancy. Alzheimer's disease (AD) is characterised 
by neuronal cell death in the hippocampus and frontal cortex leading to poor memory 
and disorientation. The pathogenesis of AD involves the abnormal processing of 
amyloid p protein (AP), leading to the production of insoluble forms, resulting in senile 
plaques. Parkinson's disease (PD) is a chronic inflammatory disease characterised by 
loss of neurones from substantia nigra causing shaking and sporadic muscle contraction. 
Other long-term inflammatory CNS disorders include the motor neurone disease; 
amyotrophic lateral sclerosis (ALS) and the prion disease Creutzfeldt-Jakob disease 
(CJD) (reviewed by Aktas et al, 2007).
Acute CNS inflammation is triggered by trauma such as a blow to the head, seizure 
caused by discharging neurones (epilepsy) or blocking of the blood supply to the brain 
(stroke). The resultant loss of nerve cells can have a significant impact on brain function 
either permanently or temporarily. Acute traumatic brain injury (TBI) according to the 
International Brain Injury Association (IBIA) (2007) accounts for one million hospital
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admissions per year in the European Union. The inflammatory response following head 
trauma can be delayed and may have varying degrees of severity or symptoms. There is 
evidence to suggest that pro-inflammatory cytokines, COX-2 and complement 
components have a role in the ensuing inflammation (Lucas et al, 2006).
Cerebral ischaemia (stroke) is triggered when a blood vessel carrying O2 and nutrients 
to the brain is either blocked by a clot or bursts. The ischaemia usually arises from clots 
in cerebral arteries (thrombotic) but can also be embolic (an embolus elsewhere in 
circulation, which moves to the brain) causing symptoms such as speech-loss and 
impaired mobility. In 2005, cerebrovascular disease accounted for 12.9% of all female 
and 7.9% of all male deaths in the UK according to the government-issued national 
statistics (http://www.statistics.gov.uk/pdfdir/hsq0506.pdf). The damage caused to 
neurones post-stroke involves a highly complex pathway of inflammatory events and 
counter-events.
1.4.3 Inflammatory Response to Cerebral Ischaemia
The role of inflammation in stroke is a complex one and our understanding is limited 
because of the lack of data obtained within the early stages of stroke onset. Also, it has 
proved difficult differentiating between inflammation stimulated by cerebral infarction 
and that o f pre-existing infective processes (Emsley et al, 2003). However, it is clear 
that stroke inflammatory responses are unique when compared to many other CNS 
disorders in that necrosis is a key stimulatory event (Esiri, 2007).
Necrosis is caused by the depletion of cerebral blood flow to the CNS, which starves the 
tissue of O2 and glucose and thus causes a breakdown in the energetics required to 
sustain ionic gradients. This results in a disruption in the regular neuronal uptake and 
release of Ca2+, Na+, Cf, K+, amino acids and H2O, causing oedema and excitotoxicity 
(nerve damage by excess glutamate). As well as necrosis, cell death can also occur by 
apoptosis, particularly in the ischaemic penumbra, an intermediate region which 
surrounds cells that have permanently lost their membrane potential (the ischaemic core) 
(Dimagl et al, 1999; Esiri, 2007). A number of mechanisms stemming from such events 
have been speculated to trigger the inflammatory response to stroke. In a review on 
stroke pathobiology, Dimagl et al (1999) highlighted key events that trigger the 
transcription of pro-inflammatory genes including Ca2+ activation of intracellular
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secondary messenger systems contributing to tissue damage by proteolysis and free 
radical generation.
In addition, hypoxia itself can also induce synthesis of transcription factors including 
nuclear factor-icB (NF-kB), interferon regulatory factor 1 (IRF-1) and signal transducer 
and activator o f transcription 3 (STAT3). However, perhaps the most important 
transcription factor in stroke is hypoxia inducible factor 1 (HIF-1) because a) many 
studies have shown it is only expressed in hypoxic conditions (unlike the above 
mentioned factors) (Hirota, 2002), b) it has been shown to be up-regulated in animal 
models of cerebral ischaemia (Ke & Costa, 2006) and c) many o f the characterised HIF- 
1-target genes are involved in the body's response to O2 depletion i.e. they encode for 
pro-erythropoiesis and pro-angiogenic proteins (Bracken et al, 2003). HIF-1 exists as a 
heterodimer comprising of a H IFla and a HIFlp (aryl hydrocarbon nuclear translocater 
[ARNT]) subunits, which bind to the consensus sequence 5'-R(A/G)CGTG-3' (Semenza 
et al, 1996; Bracken et al, 2003; Choi et al, 2004) in the promoter regions of target 
genes to trigger transcription.
Transcription can be triggered in this manner in endogenous cells such as glial cells and 
neurones as well as inflammatory cells, which migrate to the site of the infarct 
(damaged tissue). Inflammation is not considered to be an event which occurs directly 
following ischaemia due to a 4-6 h delay in leukocyte migration through the BBB via 
adhesion molecules, selectins and integrins (Wang et al, 2007). In the minutes following 
ischaemia, excitotoxicity and neurone depolarisation are the main causes o f necrosis. 
The inflammatory cells postulated to be involved in such secondary damage of 
potentially salvageable tissue are polymorphonuclear leukocytes, monocytes, 
neutrophils and macrophages with little evidence for lymphocyte involvement (Huang 
et al, 2006). Many pro-inflammatory mediators are released by such cell-types 
including cytokines.
It has been documented that proteinases are implicated in stroke pathogenesis but as yet 
their role is poorly understood. There is strong experimental evidence that cytokine- 
induced MMPs (mainly MMP-2 and -9) have an important role in post-stroke damage, 
potentially by compromising the integrity o f the BBB (Wang et al, 2007). Microglia 
have been shown to a) produce MMPs following ischaemia and b) stimulate astrocytes 
to secrete MMPs (del Zoppo et al, 2007). Furthermore, following ischaemia, neurones
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and brain ECs express MMPs (Rosenberg et al, 2001). The role of MMPs in the early 
stages following ischaemia seems to be a harmful one because MMP inhibitors have 
been shown to reduce infarct size, oedema and haemorrhage (Pfefferkom & Rosenberg, 
2003) whilst MMP-9'/_ mice also displayed smaller infarcts when compared to WT 
(Asahi et al, 2000). However, MMPs may be mediators of repair in the latter stages of 
stroke recovery by inducing angiogenesis and hence increased blood supply to necrotic 
regions (Wang et al, 2007).
1.4.4 Glial Cells in CNS Inflammation
In the CNS, microglia are the 'protectors' of neurones from pathogens and damage from 
trauma, their processes rapidly extend to sites of injury (Nimmerjahn et al, 2005). In the 
healthy brain, microglia function as resident macrophages carrying out classical innate 
immune functions seen in other organs such as phagocytosis of apoptotic cells and 
forming the first line o f defence against microbes. They also have the ability to 
contribute to an inflammatory, antibody-mediated response which can be beneficial if 
localised and controlled. However, these protecting cells can also 'betray' neurones and 
contribute to inflammation characteristic of autoimmune disorders and CNS 
inflammatory diseases (Kim & de Vellis, 2005; Block & Hong, 2005).
When microglia become activated they can present antigen to lymphocytes as well as 
express a range of pro-inflammatory mediators such as the cytokines TNF and IL-ip, 
chemokines, proteinases, reactive oxygen species and nitrogen intermediates (Vilhardt, 
2005). The role of microglia in pathology is complex because they have also been 
shown to secrete anti-inflammatory products such as IL-10 and TGF-p. In fact it is very 
difficult to say whether activated microglia are neuroprotective or neurotoxic.
In MS, it has been shown that microglial cells take part in the removal of myelin debris 
due to cytokine/chemokine interactions (Ayers et al, 2004) as well as associating with 
damaged axons (Werner et al, 2001). Furthermore, Cipriani et al (2003) showed that in 
guinea pigs sensitised for experimental autoimmune encephalomyelitis (EAE), a model 
of MS, the majority o f cells migrating to lesions were microglia. Zhang et al (1997) 
showed in a rat model of focal cerebral ischaemia; transient MCA occlusion (tMCAo), 
microglial morphological changes (from resting to active) correlated with injury 
severity. A number of reviews have further highlighted the importance of microglia in 
CNS inflammatory disorders (Wang et al, 2007; Kim & de Vellis, 2005).
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As components of the BBB, astrocytes are the first glial cell-type to be confronted by 
inflammatory infiltrates but similarly to microglia, their role in CNS inflammation is a 
complex one because they too release anti- as well as pro-inflammatory mediators such 
as chemokines (e.g. CCL3) (Ambrosini et al, 2005). During cerebral ischaemia there is 
evidence to suggest that astrocytes contribute to ionic concentration changes which 
trigger inflammatory pathways (Dronne et al, 2007).
1.4.4.1 Astrogliosis
In response to CNS tissue damage, reactive astrocytes partake in the formation of glial 
scars (reactive gliosis, astrogliosis), which protects the injured area from inflammatory 
cells but also forms an inhibitory barrier to neuronal regeneration and prevents plasticity 
(reviewed by Rhodes & Fawcett, 2004; Silver & Miller, 2004; Galtrey & Fawcett, 2007; 
Viapiano & Matthews, 2006). Many reports suggest that the main mediators of the 
inhibitory effect of astrogliosis are GAGs of CSPGs, which are tightly-packed within 
the glial scar (reviewed by Properzi et al, 2003). Treatment with chondroitinase ABC, 
which specifically cleaves chondroitin sulphate side chains from CSPGs, promoted 
functional recovery in the CNS following injury (Barritt et al, 2006).
Alternatively, there is evidence to suggest that glial scars may have a protective role in 
CNS inflammatory disorders by sealing off the damaged region and thus preventing 
secondary damage from pro-inflammatory mediators (Silver & Miller, 2004). Glial 
scars could serve as a 'bandage' around the damaged blood-brain barrier (BBB) 
preventing more inflammatory infiltrates from entering the CNS as indicated by the 
findings of Bush et al (1999) who ablated reactive astrocytes in mice and observed an 
increase of infiltrating CD-45-positive leukocytes, poor BBB repair and substantial 
neuronal degeneration. The blood clotting proteinase, thrombin, has been proposed to 
stimulate astroglial scar formation following extravasation through the compromised 
BBB by promoting astrocyte proliferation via MAPK signalling (Wang et al, 2002). 
Following a stroke, glial scars are usually formed after a few days as opposed to 
occurring in the early stages post-ischaemia (Trendelenburg & Dimagl, 2005).
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1.4.5 CNS Inflammatory Mediators
In the normal CNS, inflammation is not a phenomenon that spontaneously occurs. It 
requires a stimulus (e.g. infection or trauma) triggering pathways involving intercellular 
communication via pro-inflammatory mediators. One such family o f mediators is the 
cytokines, which are secreted by many cell-types and bind to specific cytokine receptors 
(on target cells) triggering intracellular signalling pathways which modulate 
transcription of specific genes (reviewed by Wang & Shuaib, 2002). Consequently, 
much attention has focused on unravelling the role of cytokines in the innate and 
adaptive immune response in CNS inflammatory disorders. This has proven challenging 
because a complex balance exists between pro- and anti-inflammatory cytokines.
1.4.5.1 Interleukin-1 (IL-1) Family
Perhaps the most extensively studied cytokines in CNS inflammation is the IL-1 family 
of which IL-1 a and IL-1 p are members (both 17 kDa). IL-1 binds to IL-1 receptor I (IL- 
1RI) through which signal transduction is initiated within the cell. Another IL-1 
receptor, IL-1RII acts as a molecular trap, inactivating IL-1 by binding it to the cell- 
surface with no effect on the cell because of the absence of a cell signalling domain 
(decoy receptor) (Lopez-Castlejon et al, 2007). A third member of the IL-1 family is IL- 
1 receptor antagonist (IL-lra), the only function of which seems to be the blocking of 
IL-1 action by competitively binding to IL-1 receptors without initiating a signalling 
cascade (Gibson et al, 2004).
IL-1 a and IL-1 P are expressed at low levels in the healthy brain with levels rising in 
response to local injury and minor infections. In contrast, a rapid up-regulation of 
mRNA and protein following clinical or experimental ischaemia, injury, neurotoxicity 
or inflammatory stimuli has been observed (Gibson et al, 2004). The mature form of IL- 
ip  is secreted whereas IL-1 a  largely remains intracellular (although it can be released 
via calpain-mediated activation pathways), thus IL-1 p is widely considered to be more 
important in mediating CNS inflammation (Gosselin & Rivest, 2007). IL -lra has proven 
to be a useful experimental tool to study the effects of IL-1. The antagonist reduced the 
damage caused by focal or global ischaemia by 50% following administration into the 
cerebral ventricles o f rodents. These early results indicated that IL-1 present in the brain
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contributes to CNS insults and that IL-lra could prove to be useful for therapeutic 
intervention (Relton & Rothwell, 1992).
Toulmond & Rothwell (1995) utilised tMCAo in the rat to show that IL-lra is effective 
when given 3 h post-operation. Importantly, the results were not as positive after 8-12 
hours suggesting a critical time-window for therapeutic intervention post-stroke. 
Another study showed that damage caused by tMCAo in mice lacking either IL-1 a or 
IL-1 p was similar in severity suggesting the two types of IL-1 were implicated. This 
seems likely because brain damage is reduced by 80% when both IL-1 a and IL-1 p are 
deleted (Boutin et al, 2001). IL-1 P is elevated in the cerebrospinal fluid (CSF) of MS 
patients as well as being localised in the plaque region. The expression of the cytokine 
was also noted to be increased in the CSF of EAE animals (Wang & Shuaib, 2002). In 
addition to acute CNS injury, IL-1 has been implicated in chronic inflammatory 
diseases such as PD, AD and CJD (Lucas et al, 2006).
1.4.5.2 Tumour Necrosis Factor (TNF)
Another pro-inflammatory cytokine heavily implicated in CNS pathology is TNF. It is a 
17 kDa polypeptide, which initiates intracellular signalling by binding to two TNF 
receptors (TNFRI [p55] and TNFRII [p75]). Binding to the p55 form has been 
demonstrated to induce cytotoxicity and arachidonic acid release whereas binding to 
p75 induces cell proliferation (Viviani et al, 2004). With the exception of red blood 
cells, virtually all cells in the body express TNF receptors (Wang & Shuaib, 2002). 
Furthermore, most cells within the CNS express and secrete TNF in pathological 
conditions. Studies in mice subjected to tMCAo showed that astrocytes as well as 
neurones produced TNF in the brain (Wang & Shuaib, 2002), whereas, in situ 
hybridisation (/&H) illustrated that TNF mRNA was localised to microglial cells in mice 
post-ischaemia (Gregersen et al, 2000). In chronic and active MS lesions, TNF was 
expressed by macrophages, astrocytes, microglia and ECs (Wang & Shuaib, 2002).
In a mouse model of global ischaemic CNS injury, TNF-protein was shown to be 
increased in the brain 1 h post-injury (Uno et al, 1997). Importantly, the protein 
expression levels went down before increasing again after 3 days, a result which was 
replicated in gerbils (Saito et al, 1996). In ischaemic rats, TNF neutralising antibodies 
significantly reduced infarct volume and MMP-9 expression, suggesting that TNF- 
induced expression of MMP-9 plays a role in post-stroke CNS damage (Hosoini et al,
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2005). Studies in MS patients demonstrated that elevation in TNF levels correlated with 
disease severity. Additionally, at the peak of EAE symptoms, TNF levels were 
demonstrated to be elevated in serum and the CSF (Munoz-Femandez & Fresno, 1998).
1.4.5.3 Interferon-Gamma (IFN-y)
Interferon-gamma (IFN-y) is not normally produced in the healthy CNS but is expressed 
by T and NK cells during CNS inflammation making it a noteworthy cytokine to study 
(Owens et al, 2004). Transgenic CNS expression of IFN-y has been shown to increase 
expression of TNF, further demonstrating the complex interactions o f many mediators 
in pro-inflammatory pathways (Jensen et al, 2000). There is evidence that IFN-y may 
induce and control chemokine responses. Studies in IFN-y KO mice induced with EAE 
have shown that IFN-y has a profound effect on the chemokine profile in the disease 
model. Expression of chemokines CCL5 and CXCL10 were down-regulated whereas 
CXCL2 was up-regulated. Furthermore, the usual T cell and macrophage infiltration 
observed in WT mice was replaced by neutrophil infiltration (Tran et al, 2000).
1.4.5.4 Anti-Inflammatory Mediators
To counteract such powerful and prolific pro-inflammatory instigators, cells in the CNS 
synthesise a host of anti-inflammatory cytokines such as TGF-P and IL-10. TGF-P has 
traditionally been known as a suppressor of the immune system. However recent 
evidence suggests it may also attract inflammatory cells (Wahl, 2007). Three 25 kDa 
isoforms of TGF-P exist in humans: TGF-pi, -P2 and -P3, which bind as dimers to type 
II membrane receptors on cells. Following binding, a type I receptor is recruited, which 
undergoes phosphorylation triggering Smad-protein signal pathways. This can trigger 
apoptosis in a variety of cell-types (Chen et al, 1998).
1.4.5.5 Neurotrophic Factors
An important family of neuronal protective proteins are the NTFs, of which there are 
four members: nerve growth factor (NGF), brain-derived NTF (BDNTF), neurotrophin 
3 (NT-3) and NT-4. NTFs bind to cell signalling receptors; tyrosine kinase TrKA and 
pan-neurotrophin receptor p75, promoting differentiation and proliferation of neurones 
by stimulating outgrowth and preventing degeneration (Boyd & Gordon, 2003; Allen &
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Dawbarn, 2006). NGF is considered the prototype NTF and its critical role in neuronal 
development, adult cholinergic system protection, response to neurotoxic injury, 
prevention of neuronal loss, synaptic plasticity and beneficial effects in the aged brain 
are well established (Connor & Dragunow, 1998; Williams et al, 2006; Allen & 
Dawbarn, 2006).
1.5 ADAMTSs in the CNS
1.5.1 Studies of ADAMTSs in the CNS
Proteinases such as tissue plasminogen activator (tPA) and MMPs are up-regulated in a 
host of CNS inflammatory disorders suggesting that proteolysis is a key event in such 
pathologies (reviewed by Galtrey & Fawcett, 2007). To date, a limited number of 
reports have indicated that not only are ADAMTS proteinases expressed in the CNS but 
they also have potentially important roles within the tissue. The most extensively 
studied of the ADAMTSs within the brain are the GEPs because they have been shown 
to cleave CSPGs, which are key components of the CNS ECM. The expression levels of 
the GEP ADAMTSs have been studied in specific disorders of the CNS, producing 
some potentially important findings.
A previous study by our laboratory suggested that ADAMTSs may have a role in 
cerebral ischaemia by showing that ADAMTS-1 and -4 (mRNA and protein) were up- 
regulated following tMCAo in rats (Cross et al, 2006). Importantly, TIMP-3 levels 
remained constant between sham-operated and tMCAo brains, suggesting ADAMTS 
activity was not sufficiently inhibited. In the same study, TNF modulated an increase in 
ADAMTS-4 expression (mRNA and protein) in B327-01 human astrocytes in vitro 
indicating that inflammation is a trigger for the ADAMTSs in the CNS.
Studies in our laboratory with human and EAE tissue have demonstrated a potential role 
for GEP ADAMTSs in MS. In post-mortem MS brain tissue, ADAMTS-1, ADAMTS-5 
and TIMP-3 mRNA was decreased compared to control tissue. In addition, ADAMTS-4 
protein expression was raised in MS tissue when compared to healthy brain 
(demonstrated by western blotting) and was associated with astrocytes (shown by 
immunohistochemistry [IHC]) (Haddock et al, 2006). In EAE, our group detected 
differential expression of ADAMTS-1, -4, -5 and TIMP-3 at various stages of disease
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progression (Cross et al, 2005b). It has also been demonstrated that there is a genetic 
association between polymorphisms in the ADAMTS-14 gene and MS; however the 
functional reasons for this are unclear (Goertsches et al, 2005).
There have been a limited number of reports in other CNS disorders focussing on 
ADAMTS involvement. Following hypoglossal nerve (in lower brain stem [medulla 
oblongata]) injury in rats, ADAMTS-1 mRNA was shown to be up-regulated (Sasaki et 
al, 2001). ADAMTS-1 (but not ADAMTS-5) expression was also shown to be raised in 
Down syndrome (genetic, congenital mental illness), AD and Pick's disease 
(degeneration of frontal and temporal lobes) tissue (Miguel et al, 2005).
1.5.2 Why Study ADAMTS-9 in the CNS?
The first preliminary indication of ADAMTS-9 expression in the CNS came from Clark 
et al (2000) who cloned a splice variant of the enzyme from a p amyloid-treated rat 
astrocyte cDNA library. There is evidence that the group cloned ADAMTS-9 from 
partially processed pre-RNA (Somerville et al, 2003) and therefore it is highly likely 
that the authentic mRNA encoding for full-length ADAMTS-9 was also present in the 
CNS-derived library that was screened. Any doubt that the authentic product of the 
ADAMTS-9 gene was expressed in the human brain (foetal and adult) was removed by 
RT-PCR analysis (Somerville et al, 2003). Further evidence of ADAMTS-9 CNS 
expression came from ISH studies of mouse brain embryo development. Adamts9 was 
detected in the floorplate of the diencephalon, cerebral cortex, dorsal root ganglia, 
choroid plexus and neuroepithelium (Jungers et al, 2005).
Despite the fact ADAMTS-9 is clearly abundantly expressed in the CNS, no studies 
have focussed specifically on the peptidase in the brain. Clearly ADAMTS-9 has the 
potential to contribute to a host of physiological and pathological processes in the CNS 
because it has been shown to cleave aggrecan (albeit with limited efficiency) and 
versican, which are major structural components of the CNS ECM (Somerville et al, 
2003). ADAMTS-9 may also degrade other proteins including other CNS ECM CSPGs 
brevican and neurocan, on which the peptidase has yet to be tested. Therefore, 
ADAMTS-9 may be involved in normal ECM turnover e.g. clearing a path for the 
migration of endogenous cells.
As well as having a role in normal physiology, studies in non-CNS tissue point towards 
ADAMTS-9 expression being modulated by mediators, important in CNS inflammatory 
disorders. It has been demonstrated that ADAMTS-9 is up-regulated in response to pro- 
inflammatory cytokines, in particular IL-1 p, TNF and oncostatin M (Demircan et al, 
2005; Hui et al, 2005). Whereas, anti-inflammatory mediators such as TGF-01 have 
been shown to down-regulate ADAMTS-9 expression (Cross et al, 2005a). Such data 
indicate that the proteinase could be part o f inflammatory pathways in which control of 
expression is a key regulatory event.
In CNS pathology, ADAMTS-9 could mediate the opening of the BBB following 
binding to BM HSPGs because the peptidase has a BBXB (where B = a basic amino 
acid [Lys or Arg], X = any amino acid) consensus site for binding to heparin 
(Somerville et al, 2003). If the metalloproteinase domain is accessible to substrates 
following binding, ADAMTS-9 could have a similar role to MMP-2 and -9, which have 
been shown to compromise the integrity of the BBB (Sospedra & Martin, 2005). 
Following astrogliosis which accompanies neuronal injury, ADAMTS-9 has the 
potential to be bound to HSPGs present in glial scars (Trendelenburg & Dimagl, 2005). 
CSPGs, which are substrates of ADAMTS-9, are the main inhibitory component of glial 
scars (reviewed in Properzi et al, 2003) thus the peptidase could have a profound impact 
on post-neuronal damage responses.
ADAMTS-9-mediated degradation of the glial scar could be either protective or 
detrimental to the damaged CNS. It could enable the migration of neuronal precursor 
cells to damaged regions and allow for neurite outgrowth thus restoring neuronal 
function. In contrast, CSPG-processing may allow for the passage of inflammatory cells, 
activated microglia and pro-inflammatory mediators e.g. cytokines to access susceptible 
neurones and mediate further damage. As well as cleavage o f CSPGs within the glial 
scar, ADAMTS-9 may also compromise the structure of more general ECM regions 
away from injured sites thus aiding in the migration of infiltrating inflammatory cells 
from the BBB to areas of damage.
The BBXB motif is also a consensus site for binding to sulphatide, a sulphated 
glycosphingolipid, which is a membrane protein predominantly expressed in the CNS 
on oligodendrocytes and neurones. Sulphatide is also found in myelin and is a target for 
autoimmune responses in MS (Haider et al, 2006). Thus binding of ADAMTS-9 to
52
sulphatide may have implications in MS by either aiding or inhibiting myelin 
breakdown. Alternatively, sulphatide may be another binding site for ADAMTS-9 
within the CNS. With such a wealth of potential roles for ADAMTS-9 in the normal 
and inflamed CNS, this study of the expression profile and modulation of ADAMTS-9 
in the brain is both timely and relevant.
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1.6 Aims and Objectives of the Study
Despite having the potential to be involved in CNS inflammatory disorders and normal 
brain physiological processes, a study of ADAMTS-9 in this field has not been reported.
Hypothesis: ADAMTS-9 is an important enzyme in the normal and inflamed CNS.
Overall Aim: To establish the expression profile of ADAMTS-9 in CNS-derived cells 
and a model of CNS inflammation, to provide preliminary evidence that the peptidase is 
modulated by inflammatory conditions in the brain.
Objectives:
1. To develop, optimise and validate methods (real-time RT-PCR, ISR, western 
blotting) to test ADAMTS-9 mRNA and protein expression by cells of the CNS 
in vivo and in vitro.
2. To analyse the modulation of ADAMTS-9 expression by factors (e.g. cytokines) 
pertinent to CNS inflammation in astrocytic, microglial and neuronal cells in 
vitro.
3. To establish the expression profile and cellular origin of ADAMTS-9 in tMCAo, 
a rat model of focal cerebral ischaemia.
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Chapter 2
Materials and Methods
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All procedures were performed at ambient temperature (~20°C) and atmospheric 
pressure (-0.1 MPa) unless otherwise stated.
2.1 Cell Culture
The isolation of a particular CNS-derived cell-type in culture allows the analysis of 
target protein/mRNA (e.g. ADAMTS-9) expression levels under a) basal conditions and 
b) experimental conditions, which mimic a particular physiological or pathological state. 
By controlling or modifying the culture medium, the effect on the cell of one variable or 
molecule from a complex disease process can be analysed e.g. a cytokine. There are two 
main types of cell culture: primary and secondary (cell lines). Primary human cells are 
separated and purified from the body tissues and cultured directly with limited 
modifications and are utilised over a small number of passages. Cell lines are often 
immortalised but still have density inhibition and anchorage-dependant growth. 
Alternatively, cell lines can be obtained from tumours which are already immortalised.
Human CNS-derived cells were obtained in accordance with international ethical 
requirements, guidelines and legislation. The cell-types, origins, where they were 
obtained and the media in which they were cultured are listed in Table 2.1. Foetal calf 
serum (FCS) was heat-inactivated prior to addition to the media by incubation at 56°C 
for 30 min to destroy complement components and prevent cell lysis by antibody 
binding. All cells were incubated at 37°C in a humidified atmosphere of 5% (v/v) CO2 
(in air) in a Hera Cell incubator (Heraeus Instruments, Kandro Laboratories Products, 
Germany). All plasticware (flasks, tubes) was purchased from BD Falcon Biosciences 
(Oxford, UK).
Cells were passaged when they became confluent by disposal o f the medium and the 
addition of 0.05% trypsin/0.53 mM EDTA (Gibco, Invitrogen Co, Paisley, UK). Once 
cells dissociated from the flask, they were centrifuged in a Sorvall RT7 Plus centrifuge 
(Kendro Laboratory Products, Newtown, USA), which was used throughout the cell 
culture work, at 200 x g  and the pellet was re-suspended in fresh media. Cells were 
either divided into new flasks or counted on a haemocytometer for plating in 
experiments. Alternatively, the pellet was resuspended in freezing medium consisting of 
10% cryopreservative dimethyl sulfoxide (DMSO, Sigma Aldrich, Poole, UK), 90% 
(v/v) growth media prior to depositing 1 x 106 cells in cryovials, which were placed in a
56
Ta
ble
 2
.1 
Hu
ma
n 
Ce
ll 
Lin
es 
use
d 
in 
this
 S
tud
y 
and
 th
e 
Co
mp
osi
tio
n 
of 
Me
dia
C/5Ux
^  B03 5
£  CD bO vs
2  1 3
C/3
CL
S ’
O '
CD>3
CXCD
2  " o
£ -3_  CD
3  ^
X
/ - n bO 
=  =L 
b a g
^  C  Z33 -M £S  3  £
  <D
.2  3
- 5  >3  3CD S~
c / j
C / 3  -
-  J=D  J —
£  S '  
I  £
’£  £  ■p o
3 34—» <D
bO J
e g
CN — '
<D “p £ 
O  3c -5S ' s
£  £
Xcd£cd-i—iJ 3
o
bO_p’£
’ cd
Po
cd
^  cdQ  ow  o£ =£ 1:10 
■ a  x
p 'bbs  £C / 3
“(D O  Om ■3"-apcd
S'P
bOcdx
cd h  (D £
I G  3  ”5 3n2
X  c/5■gO Q .  ^  o  p  O
CD
-T-*V gP  oo° ^  c 2\0 p
od£b p
C/3
bJ3
^  Xffi ^  ^S  > CO' sO p
O  o '  ~  »—‘ »—1 (N
£-ar-
nd
CD
bOcd
cdCX
CX3-aa>
X  o
IX, X
CD
CoN‘5bp
3  C/5
so  so
O '  o 'O Oc n  cr>
X
DocnCN
CD
n  C/3
£  U  P  f c£ X
x  ^ - sr“V > 
>  >
s °  ' Po x  o x
' PoxO
< j  J d
3  O  CD Ucxo1—I
3X
<DI—,3
3
3 1
u  J d  
3  oCD Ucx
os-
3X
(D
X  u  r£ U U  h
CDCX s X
H 5
<D O£ V  <
r- ^g g
^  >s0  <D
CD ^
H  !
S '  2  ^
CD 2  D
1 £
c*: 3  . »_M  CD . >
Q  * 2
D
■S « 
p  e3  O 
C  3 2  cd bi3
(D■ ocdi -bi3-i—>CcdG
c3 CD > ,  cd
^  £
\ o
3cdc R 
. 2  .S Pc« - 3cd ^CD P  3  C  cd "d- o  c
T 3  ^"P ° 10 "O '1 gg &
■X nT
5  2
bD
PCD b p  
’-P  P03
H
3  0 0  
P  >- 
b 0_S 22 O .CD'3 >  S  5/33 JS
a5 - P  
c R  ^
c n
ONON
JO03pcd
cd <D £ OcR 2  
3  V.2 -£1/33  3CD ^  3  " 3
P  PO  . CD
cdcx
O
>-• ^  1-4cd 3  cdU  -J2 3C / 2* 3  cd
cd cdO p  >2 ^ 
3 -
-sCD ^
2  ^  
3  ' £ -_ 3  3  C *-> 3  o  ^  cx p£ oP
ooo
(N
3P
o
3
£  CD^  3  3  
rA 2 «
3
O  |  CD
§  ® .£I ^  —
g  =a s  P  «
P  ’M W^  C/33
<D
3 O
fO  
X
I f lu  «
3
X £>  o w 
«  3  
> .  3  =C/5 43 —W o  a>x  CD C/5 3
CDS
C/51—( QJ
= ?  S ,
t -  WpfO J3pa «3
4
57
All
 re
age
nts
 p
urc
has
ed 
from
 
Gib
co,
 In
vit
rog
en 
Co
. u
nle
ss 
oth
erw
ise
 s
tat
ed.
Cryo 1°C (temperature decreases -l°C/min) freezing container (Nalgene, Rochester, 
USA) containing isopropanol in -80°C freezer. Once cells were at -80°C, cryovials 
were transferred to liquid N2 storage. Cells were thawed by placing cryovials in a 37°C 
incubator before depositing cells in 10 mL of growth media prior to centrifugation at 
200 x g  to remove DMSO. Pellets were resuspended in fresh growth medium prior to 
depositing in a cell culture flask.
Through binding to RetA receptors (RetARa, RetARp and RetARy), RetA regulates the 
expression of hundreds o f genes in the CNS (Clagett-Dame et al, 2005). Treatment with 
physiological concentrations (10'5M) of RetA has been shown to decrease proliferation 
of SHSY-5Y cells and promote extension of neuritic processes resulting in a 
morphologically neuronal population of cells (Encinas et al, 2000). Therefore, to 
differentiate the SHSY-5Y neuroblastoma cells to a phenotype comparable to in vivo
• 9 •neurones, the cells were treated with RetA (vitamin A). A 10' M RetA stock solution 
was prepared in 100% molecular grade ethanol. Cells were cultured in 10'5 M RetA 
diluted in culture media for one week prior to either passaging or plating for 
experiments. For comparative studies, SHSY-5Y cells were additionally cultured in 
parallel without RetA. Neuronal morphology of the SHSY-5Y cells was confirmed by 
visualisation under a light microscope (Leica Microsystems, Wetzlar, Germany) prior to 
image capture and analysis with the USB 2.0 camera/XLi-Cap software (XL Imaging 
Ltd. Swansea, UK).
2.2 Treatment of Cells with Cytokines/Growth Factors
Cells were seeded into 24-well plates at a density of lx l0 5 cells/well in 1 mL of 
medium and left for 24 h to adhere. IL-ip, IFN-y, TNF (all Tebu-Bio Laboratories, 
Peterborough, UK), TGF-pi and NGF (both PeproTech) were diluted in serum-free 
media at concentrations of 0.2 ng/mL (4 x 10'8 M), 0.4 ng/mL (8 x 10'8 M), 0.8 ng/mL 
(1.6 x 10'7 M), 1 ng/mL (2 x 10'7 M), 10 ng/mL (2 x 10'6 M) or lOOng/mL (2 x 10'5 M). 
Medium was removed prior to the addition of 1 mL of each cytokine/GF in triplicate 
wells. Combinations of these concentrations were prepared for IL-ip and TNF prior to 
analysis of the synergistic effect of both cytokines added together. Cells were incubated 
with cytokines/GFs for 24 h after which the media was removed ahd replaced with 333 
pL of TRI Reagent (Sigma) per well (1 mL per treatment). All experiments were 
repeated a minimum of three times independently.
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2.3 Transient Middle Cerebral Artery Occlusion (tMCAo) 
Rat Model of Focal Cerebral Ischaemia
All animal procedures were carried out at The University of Manchester by Dr. Stuart 
Allan and Dr. Chris Stock. Male Sprague-Dawley rats (290-320 g, Charles River, UK) 
were subjected to halothane anaesthesia (Fluorothane, Zeneca, UK, 1-2% in a mixture 
of oxygen and nitrous oxide [1:2 ratio]). Body temperature was maintained at 37.0 ± 
0.5°C throughout anaesthesia by means of a homoeothermic blanket (Harvard 
Apparatus, UK). All surgical procedures were carried out in accordance with the 
'Guidance on the Operation of Animals (Scientific Procedures) Act' (1986).
Transient focal cerebral ischaemia was induced in rats by luminal thread occlusion of 
the MCA, as described previously (Longa et al, 1989; Mulcahy et al, 2003) and 
illustrated in Figure 2.1. The thread was withdrawn to allow reperfusion at 90 min post­
occlusion. Sham-operated animals were exposed to the same surgical procedure, with 
the exception that the thread was inserted only briefly and not to its full extent. Six, 24 
and 120 h after tMCAo or sham-operation, the animals were sacrificed by exposure to a 
rising concentration of CO2 and the brains removed and frozen on dry ice. Brains were 
dissected into ipsilateral (occluded in tMCAo) and contralateral (non-occluded in 
tMCAo) hemispheres prior to each hemisphere being cut in half again coronally (all 
dissecting performed on dry ice). Frozen sections of each quarter o f each brain (10 pm 
thickness) were cut on a cryostat (Leica) and collected on polylysine slides (VWR 
International, Belgium) for ISR  and IHC analysis. For extraction of protein and RNA, 5 
x 30 pm sections of each quarter of each brain were cut and deposited into Eppendorf 
tubes prior to the addition of 1 mL TRI reagent. Table 2.2 shows the number of animals 
included in the study.
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Figure 2.1 Procedure of Inducing tMCAo in the Rat
F r o n t
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The diagram shows the route of luminal thread insertion and resultant occlusion o f the 
middle cerebral artery (MCA). Thread is inserted via the external carotid artery (ECA) 
and internal carotid artery (ICA) prior to reperfusion after 90 min. ACA = anterior 
cerebral artery, SCA = superior cerebral artery, BA = basilar artery, PCA = posterior 
cerebral artery, VA = vertebral artery. Crossed-out arrows indicate blocked blood-flow. 
Image courtesy of Dr. Peter Thornton (Manchester, UK).
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Table 2.2 Numbers of Animals Utilised in the tMCAo Study
H ours Post-Operation Procedure N um ber of Animals
6 sham 2
6 tMCAo 5
24 sham 4
24 tMCAo 4
120 sham 3
120 tMCAo 3
2.4 RNA/Protein Extraction
RNA and protein were extracted from cells and tMCAo tissue using TRI Reagent in 
accordance with the manufacturer's protocol. TRI Reagent is a mixture of guanidine 
thiocyanate and phenol in a mono-phase solution. Briefly, TRI Reagent was added to 
cells and tissue prior to homogenisation (pippeting up and down). Upon addition of 
chloroform and centrifugation the mixture separated into three phases: 1) an aqueous 
RNA phase, 2) an interphase containing DNA and 3) an organic protein phase. RNA 
was isolated by a series of washes in molecular grade isopropanol and ethanol with 
intervening centrifugation steps. Protein was isolated by a series of washes in molecular 
grade ethanol and 0.3 M guanidine hydrochloride, 95% (v/v) ethanol with intervening 
centrifugation steps.
2.5 Bicinchonic Acid (BCA) Protein Assay
Protein concentration was determined by bicinchonic acid (BCA) protein assay, in 
which protein reduces Cu2+ to Cu+ in an alkaline medium (Biuret reaction). The binding 
of Cu+ to BCA yielded a purple-coloured product, the intensity of which was 
proportional to the amount of protein present. Protein concentration was subsequently 
calculated by plotting a standard curve of known protein concentrations. Protein 
samples (20 pL) were added to 96-well plates in duplicate as well as 20 pL bovine 
serum albumin (BSA) standards (0-20 mg/mL) in triplicate. To each well, 200 pL of 
working BCA reagent (50:1 BCA : 4% [w/v] copper [II] sulphate) was added and the 
plate incubated for 30 min prior to analysing the absorbance by spectrophotometry (570
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nm) on a Wallac Victor2 1420 Multilabel Counter (PerkinElmer, Turku, Finland). The 
protein assay allowed the calculation of the correct volume of protein to load for SDS- 
PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis).
2.6 cDNA Synthesis
Extracted mRNA cannot serve as a template for real-time PCR and therefore it is used 
to synthesise cDNA with the enzyme reverse transcriptase (RT). The synthesis of the 
first strand of cDNA requires a primer in order for the RT to extend. The cDNA copy is 
produced by the addition of deoxynucleotide triphosphates (dNTPs) to the 3’ end of the 
extending primer. There are three main priming approaches to perform the cDNA 
synthesis reaction, yielding different products depending on the purpose of the 
experiment. The primers can either be: 1) oligo (dT) primers, which prime all mRNAs 
simultaneously, yielding complete cDNA, 2) sequence specific primers, which target 
one mRNA sequence or 3) random hexanucleotides (hexamers), which are short (~8 
nucleotides long) single stranded DNA (ssDNA) of every combination of bases that 
copy mRNA scattered from all over the sequence. In this study, random hexamers were 
utilised because the synthesised cDNAs are shorter thus there is an increased probability 
that the 5’ ends of the mRNA are copied because RT is rarely able to extend the full 
length of the mRNA molecule (Turner et al, 2001).
The cDNA synthesis was performed with RNAse/DNAse free tips, tubes and gloves 
following the de-contamination of surfaces with alcohol wipes. The total reaction 
volume for each RNA sample was 19 pL including: Superscript II RT (1 pL), 5x 1st 
strand buffer (4 pL), preservative dithiothreitol (DTT) (2 pL), RNAseOut ribonuclease 
inhibitor (0.5 pL), random hexamers (0.5 pL) (all Invitrogen) and 1 pL dNTPs mix 
containing 12.5% dATP, 12.5% dCTP, 12.5% dGTP and 12.5% dTTP in 50% H20  (all 
v/v) (Bioline, London, UK), RNA sample (1 pL) and molecular grade H20  (10 pL). The 
reaction was performed at 42°C for 2 h in a heat block. The reaction was stopped by 
incubating the samples at 95°C for 5 min in a heat block, to inactivate the enzyme. For 
each cDNA synthesis preparation two samples were included as negative controls, one 
lacking RT and the other RNA (replaced by water). The resulting cDNA was used as a 
template for real-time RT-PCR.
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2.7 Agarose Gel Electrophoresis
Throughout this thesis, agarose gel electrophoresis (AGE) was routinely performed to 
visualise nucleic acids e.g. to assess the quality of an RNA sample prior to cDNA 
synthesis. AGE works on the principle that nucleic acids are negatively charged and 
thus migrate to the positive pole in an electric field. The size of the molecule dictates 
the speed at which it migrates through the pores in the agarose gel resulting in a 
separation of different sized nucleic acid chains. Within the agarose is ethidium bromide 
(EtBr), which intercalates between the base pairs (bps) of DNA/RNA and fluoresces 
under UV light. DNA ladders were loaded in order to ascertain the size of the nucleic 
acid.
Agarose (2% or 4%) was dissolved in Tris-boric acid-EDTA (TBE) buffer (89 mM Tris, 
89 mM boric acid, 2 mM EDTA, pH 8.3) prior to addition of 5 mg/mL EtBr. Nucleic 
acids were mixed 1:1 (3 pL:3 pL) with 2x loading buffer (50% glycerol, 0.1% 
bromophenol blue, lx  TBE) prior to loading in agarose wells with a DNA ladder (10, 
100 or 500 bp) (Promega, Madison, USA). Electrophoresis was performed at 100 V for 
approximately 1 h prior to visualisation under a UV light in a BioChemi system (UVP 
Bioimaging System, USA) and subsequent analysis with LabWorks Image Acquisition 
and Analysis Software (UVP, USA).
2.8 Real-Time RT-PCR
2.8.1 Real-Time RT-PCR Theory
Real-time RT-PCR is a powerful tool for quantifying relative differences in amounts of 
mRNA of the same gene between different samples e.g. control versus treated. 
Conventional PCR analysis occurs at the end o f the reaction process, the amount of 
product and starting material theoretically being proportional at any cycle number. 
However, replicate reactions yield different amounts of PCR products (due to 
undetected deviations from normal amplification) and therefore results cannot be 
considered quantitative, merely qualitative. Real-time RT-PCR was developed by 
Higuchi et al (1992) as a technique which allows the measurement of the reaction whilst 
the amplification is taking place as opposed to the end-point.
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Classical PCR can amplify minute amounts of DNA using a pair of oligonucleotide 
primers each complementary to one end of the DNA target sequence. Primers are 
extended towards each other by a thermostable polymerase in a reaction cycle of 
denaturation (~95°C), primer annealing (~55°C) and polymerisation (~72°C). Real-time 
RT-PCR adheres to these basic principles but the monitoring of accumulating amplicon 
has been made possible by utilising fluorescent molecules to label primers, oligoprobes 
or the amplicon itself. The change in signal which occurs when these labels directly 
interact or hybridise to the amplicon is proportional to the amount of amplicon present 
during each cycle (Wong & Medrano, 2005).
Data obtained from a real-time RT-PCR run yields a sigmoidal curve when fluorescence 
intensity is plotted against cycle number as shown in Figure 2.2A. The initial 
amplification is not taken into account because the signal does not significantly rise 
above background noise. The rate of amplification occurs in three phases; a log-linear 
phase (LP) where exponential progress is observed, a transitional phase (TP) where 
reagents become limiting (e.g. primers and enzyme) and finally a plateau phase (PP) 
where no further product is formed (Mackay, 2004). The point where the fluorescence is 
clearly higher than the background is known as the cycle threshold (Cj), which is 
reached at a lower cycle number if a higher level of target template is present in the 
reaction, thus the curve is shifted to the left.
There are a number of different detection chemistries currently available which can be 
categorised as ‘specific’ or ‘non-specific’ for the amplicon target sequence. All 
chemistries are based on fluorogenic detection and have generally the same level of 
sensitivity. SYBR green is a non-specific double stranded DNA (dsDNA)-binding 
fluorogenic molecule which was utilised in this project. The unbound dye exhibits 
negligible fluorescence in solution but during LP it intercalates to the minor groove of 
dsDNA and an increasing signal is observed upon light excitation and amplicon 
amplification. Measurements are taken at the end of the elongation step o f every cycle 
to monitor the increasing amount of the amplicon (Bustin, 2000).
The main advantage o f using SYBR green over fluorogenic oligoprobes is that the dye 
can be utilised for different genes assays and only specific primers are required. Also 
SYBR green offers a lower cost detection system than oligoprobes. Unfortunately, 
SYBR green binds to any dsDNA which may form, thus fluorescing because of non-
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Real-Time PCR amplification plot (A) with GAPDH and ADAMTS-9 primers showing 
log-linear phase (LP), transitional phase (TP) and plateau phase (PP). Cycle-threshold 
(Ci) is represented by the red line. ARn = fluorescence signal - residual background 
fluorescence (fluorescence intensity). Note that ADAMTS-9 ( C t  values ~23-28) 
expression levels vary under different experimental conditions, in contrast to the stable 
expression of GAPDH (Cy values -16-17). GAPDH expression > ADAMTS-9 
expression, hence GAPDH plots are shifted to the left.
Figure B represents a typical melt curve analysis showing specific melt curves with 
ADAMTS-9 and GAPDH primers. Derivative ’-dF/dT' = fluorescence as a function of 
temperature against time. Note the lack of smaller peaks, which represent primer dimer 
formation (non-specific amplification).
65
Figure 2.2 Representative Real-Time PCR Amplification and Melt Curves
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specific products (i.e. primer-dimer) and generating inaccurate data. To counteract this 
problem a short additional step is included after the extension step whereby the 
temperature is increased and non-specific products are denatured prior to detection of 
fluorescence (Mackay et al, 2002).
To verify that no non-specific products are contributing to the signal, melt curve 
analysis must be performed. Each amplicon product has its own specific nucleotide 
composition and thus a specific melting temperature (7m). Melt curve analysis involves 
increasing the temperature above the 7m of the amplicon and utilising software (ABI 
Prism 7900 HT Sequence Detection System, Applied Biosystems, Warrington, UK) to 
plot fluorescence as a function of temperature against time to produce a melt curve as 
shown in Figure 2.2B. The small primer-dimer and amplification artefacts melt at a 
much lower temperature than the amplicon and when analysing are easily 
distinguishable from the characteristic melt curves of the amplicon product (Mackay et 
al, 2 0 0 2 ).
There are two main types of applications for real-time RT-PCR, the first one being 
'absolute quantification' whereby a standard curve is constructed from known standards, 
which is used to determine the concentration (copy number) of the starting template 
(Bustin, 2000). In this study a standard curve was not required because 'relative 
quantification' compares the amount of template between samples using a mathematical 
formula (e.g. 2 'AACt) to calculate relative fold increases/decreases in expression.
In parallel to detecting the target gene, it is critical to analyse the expression levels o f at 
least one housekeeping gene in all samples tested. This compensates for introducing 
varying amounts of total mRNA into the RT reaction and thus producing different 
concentrations of starting template cDNA between samples. Housekeeping genes are 
consistently expressed at moderately abundant levels and their products are crucial for 
preserving cellular function and completing the cell-cycle (Butte et al, 2001). In any 
real-time RT-PCR analysis, it is critical that the expression of the normalising 
housekeeping gene is not altered by the experimental conditions being tested.
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2.8.2 Primer Design and General Real-Time RT-PCR Protocol
The real-time RT-PCR primers were designed to span intron/exon boundaries in order 
to preclude the amplification of contaminating genomic DNA, which can lead to false 
positives. This eradicated the need for treating RNA samples with DNase prior to 
cDNA synthesis (Bustin, 2002). Primers had a G/C content of 20-75% and had an 
optimal length of 15-20 bp (long enough for high-specificity, short enough for high 
annealing-efficiency). Primers generated a product which did not exceed 150 bp (for 
optimal amplification efficiency) (Gunson et al, 2006). A key property was that the 7fn 
of the primer pairs were similar (within 1-2°C), in the range of 58-60°C.
The primers utilised in this study were designed using Primer Express (Applied 
Biosystems), which is a powerful tool that generates primers based on the above 
requirements (Bustin, 2000). Synthesis of primers was performed by MWG-Biotech AG 
(Ebersberg, Germany). Table 2.3 lists the details of all fully optimised and validated 
primers utilised in this study. Human and rat GAPDH as well as human ADAMTS-1, -4, 
-5 and -9 primers were validated and optimised previously (by Dr. Alison Cross). In this 
study it was necessary to design and validate rat ADAMTS-9 primers as well as human 
YWHAZ primers (housekeeping gene used with B327-01 and SHSY-5Y cells). All 
real-time RT-PCR products were visualised by 4% AGE to confirm the correct size 
prior to sending for sequencing (Core Genetics Service, The University of Sheffield, 
UK) to confirm that primers were specific to the correct target gene. In preparation for 
sequencing, PCR-clean-up was carried out on the product with QIAquick kit (Qiagen) 
in accordance with the manufacturer’s protocol. The clean-up removed components of 
the PCR reaction (primers, nucleotides and polymerase enzyme) by a series o f binding, 
washing and eluting steps from a silica membrane column. The reverse complement of 
the sequence obtained with the reverse primer was obtained by utilising The Sequence 
Manipulation Suite (http://www.bioinformatics.org/sms/) and was subjected along with 
the sequence obtained with the forward primer to a nucleotide-nucleotide BLASTn 
search (basic local alignment search tool) (http://www.ncbi.nlm.nih.gov/BLAST/). All 
RT-PCR product sequences were a 100% match with the sequence from which the 
primers were designed.
All real-time RT-PCR experiments were performed using the ABI Prism 7900 sequence 
detection system (Applied Biosystems). Real-time RT-PCR was carried out with 10 pL
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Table 2.3 Primers Utilised in Real-Time RT-PCR Experiments for Analysis of ADAMTS mRNA Expression Levels
P roduct 
Size (bp)
on
101
ONOO
©00
csON
Onr-'
124
Location
Forward: 7 
Reverse: 86
Forward: 1092 
Reverse: 1193
Forward: 945 
Reverse: 1034
Forward: 1641 
Reverse: 1721
Forward: 1340 
Reverse: 1432
Forward: 7 
Reverse: 86
Forward: 171 
Reverse: 295
Reverse Sequence 
(Concentration used at)
5' TCGGATGGGAGACACGATTT 3' 
(3.3 pmol/pL)
5' AGAAGGCCGGGCAGTTG 3' 
(3.3 pmol/pL)
5' AAGCATGGTTTCCACATAGCG 3' 
(0.5 pmol/pL)
5' GGAAAGTCACAGGCAGATGCA 3' 
(10 pmol/pL)
5' CGCTTATCTTCTGTGGAACCAAA 3' 
(3.3 pmol/pL)
5' ACCTCCCCCATGGTGTCTGA 3’ 
(3.3 pmol/pL)
5' AGCATCACCCCATTTGATGT 3' 
(3.3 pmol/pL)
Forward Sequence 
(Concentration used at)
5' GCACCCGAGGCAAGTGAA 3' 
(3.3 pmol/pL)
5' G AAGT AC AT C ACCG AGTT CTT AG AC ACT 3' 
(10 pmol/pL)
5' GCACTGCAAGGCGTAGGAC 3' 
(3.3 pmol/pL)
5' TCACTGACTTCCTGGACAATGG 3' 
(0.5 pmol/pL)
5' CACTGTGGCTCACGAAATCG 3' 
(0.5 pmol/pL)
5' GCTCCTCCTGTTCGACAGTCA 3' 
(10 pmol/pL)
5' TGATTCTACCCACGGCAAGT 3’ 
(3.3 pmol/pL)
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reactions in duplicate and each experiment was repeated three times. The reaction 
consisted of 5 pL 2x SYBR green master-mix (containing SYBR green dye, AmpliTaq 
Gold DNA polymerase, dNTPs and dUTPs) (Applied Biosystems), 2 pL H2O, 1 pL 
each of forward and reverse primers (made up to optimised concentrations, see Tables
2.3 and 2.4) and 1 pL cDNA sample.
2.8.3 Comparative Cj Method of Data Analysis
Relative fold increases/decreases in mRNA expression levels of test samples (treated) 
compared to control samples (untreated) were calculated using the comparative C j (2 " 
AACt) method using the formula and calculation below (Livak & Schmittgen, 2001). 
Levels of target gene mRNA expression in untreated samples are expressed as ‘1’. The 
fold differences in treated samples are expressed as values relative to the untreated 
samples.
2 - a a c t
Calculation:
Step 1 : ACt = C j of target gene - C t of housekeeping gene 
Step 2 : A A C t= ACt of test sample - ACt control sample 
Step 3: 2'AACr = relative fold increase
For the 2"AACr method to be valid, the amplification efficiencies o f the target gene and 
housekeeping gene must be approximately equal (Livak & Schmittgen, 2001). In order 
to ascertain that the ADAMTS-9 human and rat primers had similar efficiencies to the 
housekeeping genes, a primer efficiency comparison test was conducted. Real-time RT- 
PCR was performed on serially diluted cDNA (1:2, 1:3, 1:4, 1:5, 1:10, 1:100, 1:1000, 
1:10,000) prior to plotting the ACt value of each sample against logio(cDNA 
concentration) (Ginzinger, 2002). A slope close to zero (0±0.1) indicated that the target 
gene and housekeeping gene primer efficiencies were approximately equal (Wong & 
Medrano, 2005).
In this study, relative levels of ADAMTS-9 expression were also analysed between test 
samples i.e. comparison of target gene expression between different cell-types under
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basal conditions. In order for this approach to be valid, the efficiencies of the target 
gene and housekeeping gene primers must also be close to 100% (and -equal). To 
compare the expression levels of test samples (as opposed to comparing treated with 
control) the following formula was utilised:
2 _ACt
Note: 2'ACt values represent the relative levels of target gene expression between 
samples in a particular experimental system, normalised to a housekeeping gene. Hence 
2'ACt values have no units. Values can only be compared across experiments if the same 
housekeeping gene is utilised and the experimental procedure was comparable (i.e. cells 
cultured in the same manner).
2.8.4 Real-Time RT-PCR Primer Concentration and Efficiency Tests
If the concentration of real-time RT-PCR primers is too high, mis-priming is a more 
likely occurrence, leading to the amplification o f non-specific regions of DNA (Bustin, 
2000). To ascertain the optimal concentration of forward and reverse rat ADAMTS-9 
primers, a primer concentration test was performed. Three concentrations of the forward 
and reverse primers were prepared (0.5, 3.3 and 10 pmol/pL) yielding nine different 
combinations (10F/0.5R, 10F/3.3R, 10F/1 OR, 3.3F/0.5R, 3.3F/3.3R, 3.3F/10R, 
0.5F/10R, 0.5F/3.3R, 0.5F/0.5R). Each primer pair combination was used to amplify the 
same amount of rat tMCAo cDNA sample and a negative sample (no cDNA) prior to 
analysis of melt-curve, ARn (amplification efficiency) and Ct value.
Wong & Medrano (2005) stated the importance of having high amplification efficiency 
in real-time RT-PCR reactions. The efficiency of the rat ADAMTS-9 and GAPDH 
primers was determined by performing a primer efficiency test. Real-time RT-PCR was 
performed on serially diluted cDNA (as in Section 2.8.3) and Ct value was plotted 
against logio(cDNA concentration). Efficient primers (-100%) would expect to yield a 
gradient close to -3.2 on a graph of Ct value against logio(cDNA concentration) because
3.2 is the number of cycles it would take for 1 unit of DNA to be amplified to 10 units.
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It is possible that primers can appear 'too efficient' i.e. >100% (slopes steeper than -3.2) 
as caused by too much template, which is inhibitory to PCR (Ginzinger, 2002) or too 
little template (i.e. 1:10,000 dilutions) being present in the reaction. Thus acceptable 
primer efficiencies range from 85-115% (Hamatani et al, 2004; Sohn et al, 2006; 
Germann et al, 2006; Aidinis et al, 2005). Primer efficiencies were calculated using the 
formula below:
% Efficiency = l0-'/slope -1
2.8.5 Housekeeping Gene Validation
Real-time RT-PCR is far more sensitive than conventional PCR, which has led to the 
observation that some widely used housekeeping genes do change their expression 
levels in certain experimental conditions and therefore it is crucial to validate the choice 
of housekeeping gene for each experimental condition tested in a study (Bustin, 2002). 
The fact that one housekeeping gene is suitable for one cell-type does not mean it is 
suitable for another. Also, a housekeeping gene which is stably expressed in cell-lines 
treated with factors in vitro may be up- or down-regulated in vivo (e.g. animal models), 
where many other factors are present, which potentially influence expression.
Housekeeping genes for use with U373-MG, U87-MG, CHME3 cells and the tMCAo 
models were optimised and validated previously by Dr. Alison Cross. For the B327-01 
and SHSY-5Y cells, the following seven genes were analysed for suitability as 
normalisers for real-time RT-PCR; hypoxanthine phosphoribosyl-transferase I (HRPT1), 
P-actin, ribosomal protein L I3a (RPL13A), tyrosine 3-monooxygenase activation 
protein, zeta polypeptide (YWHAZ), ubiquitin C (UBC), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and succinate dehydrogenase complex, subunit A (SDHA), 
details of which are in Table 2.4.
SHSY-5Y and B327-01 cells were subjected to each experimental condition studied 
prior to RNA being extracted and quantified accurately with the Experion automated 
electrophoresis system (BioRad, Richmond, USA). RNA (1 pg) was reverse transcribed 
and the resulting cDNA was used as a template for real-time RT-PCR. For each sample,
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Table 2.4 Primer Pairs Utilised for Real-Time RT-PCR Analysis of Suitable Housekeeping Genes for use with SHSY-5Y and B327-01 Cells
Reverse Sequence 
(Concentration used at)
5' A A G G G A C T T C C T G T A A C A A T G C A  3 ’ 
(0.5 p m o l/p L )
5' G G C A T G G A C T G T G G T C A T G A G  3' 
(3.3 p m o l/p L )
5' G G T C C T T T T C A C C A G C A A G C T  3 ’ 
(3.3 p m o l/p L )
5' T T G A G G G A C C T C T G T G T A T T T G T C A A  3' 
(3.3 p m o l/p L )
5' C C A C C A C T G C A T C A A A T T C A T G  3' 
(3.3 p m o l/p L )
5' T G C C T T G A C A T T C T C G A T G G T  3 ’ 
(3.3 p m o l/p L )
5' CCGCC AGG AC A A ACC AGT AT 3' 
(3.3 p m o l/p L )
Forward Sequence 
(Concentration used at)
5' C T G G A C G G T G A A G G T G A C A  3' 
(3.3 p m o l/p L )
5' T G C A C C A C C A A C T G C T T A G C  3' 
(10 p m o l/p L )
5' T G A C A C T G G C A A A A C A A T G C A  3' 
(10 p m o l/p L )
5' C C T G G A G G A G A A G A G G G A A A G A G A  
3 ’
(3.3 p m o l/p L )
5' T G G G A A C A A G A G G G C A T C T G  3' 
(3.3 p m o l/p L )
5' A T T T G G G T C G C G G T T C T T G  3' 
(3.3 p m o l/p L )
5' A C T T T T C C T A C A T T G T G G C T T C A A  3' 
(10 p m o l/p L )
Function
C y to sk e le ta l
p ro te in
G lyco lysis  and  
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Purine s y n th e s is
C om ponent o f  
large 6 0 S  
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were confirmed by geNorm. YWHAZ was the most suitable housekeeping gene for use with the B327-01 and SHSY-5Y cells under all 
experimental conditions tested. All primers yielded products which were <150 bp.
2ACt values were calculated and analysed using Microsoft Excel based GeNorm 
software (http://medgen.ugent.be/~jvdesomp/genorm/). Since its development in 2002, 
geNorm has been cited in 590 papers and has proven to be an accurate and reliable tool 
for determining the best housekeeping genes in many sets of tissues (Vandesompele et 
al, 2002). Note: GAPDH was used as the housekeeping gene for the original 
preliminary study of ADAMTS-1, -4, -5 and -9 mRNA expression in SHSY-5Y cells 
under basal conditions. The same cDNA samples were tested for expression of these 
aggrecanases without being subjected to differing experimental conditions.
2.8.6 Statistical Analysis of Real-Time RT-PCR Data
The statistical significance of relative fold increases/decreases (2'AACt) in ADAMTS-9 
mRNA expression between untreated cells and cells treated with cytokines/GFs was 
determined by performing a single-factor ANOVA followed by a Dunnett's test 
(Wallenstein et al, 1980). Initially, ANOVA analysed the variance between the full data 
set from all concentrations of a particular cytokine/GF. If the ANOVA test showed that 
variance existed within these data set (null hypothesis rejected) then a Dunnett's test was 
performed, which allowed for the analysis of each particular treatment relative to the 
control sample to ascertain whether the values were statistically significant. If the 
ANOVA test showed no variance between a data set then Dunnett's was not conducted 
and treatment with the particular cytokine/GF was considered to have a null effect on 
ADAMTS-9 expression. Both ANOVA and Dunnett's test were performed using 
GraphPad Prism Software Inc. (San Diego, USA).
To ascertain whether the difference in relative ADAMTS-9 mRNA expression levels 
between RetA differentiated and undifferentiated SHSY-5Y cells were statistically 
significant an unpaired, 2-tailed T-test was performed. In the tMCAo study, a 2 sample 
T-test assuming unequal variance, was performed to ascertain whether differences in 
relative ADAMTS-9 mRNA expression levels between CHs/IHs from tMCAo/sham 
brains were statistically significant. T-tests were performed using Microsoft Excel 
software.
Statistically significant differences are represented in figures by *** = p< 0.001, ** = 
p<0.01, * = p<0.05.
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2.9 SDS-PAGE and Western Blotting
Proteins in a sample (i.e. cell lysates) can be separated by SDS-PAGE on the basis of Mj 
by migrating through a polyacrylamide gel in the presence of a current via electrostatic 
attraction of the negative charge (caused by SDS binding) to the anode. Smaller proteins 
are resolved further along the gel than larger proteins and a sample with known Mr 
markers is run in parallel to determine the Mj o f the test sample.
Following SDS-PAGE, the presence of a particular protein within a sample can be 
confirmed by western blotting with a specific primary antibody raised against the target 
antigen. Enzyme-labelled secondary antibodies are used to bind to the resulting antigen- 
primary antibody complex prior to detection by chemiluminescence or coloured- 
precipitate formation. Western blotting offers the advantage over real-time RT-PCR in 
that different species of a protein can be detected. Bands can represent mature or 
processed enzyme/protein as opposed to detecting the mRNA which codes for the 
zymogen. Furthermore, mRNA is not always translated to protein.
In order to achieve reproducible separation by SDS-PAGE, protein extracted from 
tMCAo tissue and CNS-cell lysates were denatured to their primary structures by 
dilution in 4x NuPAGE lithium dodecyl sulphate (LDS) (cf SDS) sample buffer (pH 8.4) 
and 5x reducing agent (DTT) (both Invitrogen). The denaturation process involves the 
breaking of S-S bonds by DTT and the amino acids gaining negative charges (from 
LDS) which repel against each other forcing all proteins into a comparable extended 
linear structure. The process occurs most efficiently at high temperature; therefore 
samples were heated to 100°C for 5 min.
SDS-PAGE was performed in Novex Minicell tanks (Invitrogen) with 10% NuPAGE 
Novex Bis-Tris gels (pH 7.0) in the presence of NuPAGE lx  3-(N- 
Morpholino)propanesulfonic acid (MOPS) SDS running buffer (pH 7.7) or Novex 4% 
Tris-Glycine gels (pH 8 .6 ) in the presence of Novex Tris-Glycine SDS running buffer 
(pH 8.3) (all Invitrogen) with 6  pg of protein/well (as loaded previously by our 
laboratory: Cross et al, 2005b, Cross et al, 2006, Haddock et al, 2006, Plumb et al, 2005) 
for approximately 1.5 h at 150 V (300 mA). Determination of protein Mj was achieved 
by running 8  pL SeeBlue Plus2 pre-stained Mj markers (Invitrogen). SDS-PAGE 4%
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gels were only utilised for preliminary testing of commercial anti-ADAMTS-9 
antibodies.
Protein was transferred to Hybond-C nitrocellulose membrane (Amersham Biosciences, 
Amersham, UK) at 150 V (300 mA) for 1 h in the presence of lx  NuPAGE transfer 
buffer (Invitrogen) (with 10% methanol). All western blot incubations were performed 
with agitation to allow solutions to wash over the surface of the nitrocellulose. Details 
of the primary and secondary antibodies utilised in this study are displayed in Table 2.5. 
The anti-ADAMTS-9 (raised against the linker 2 domain) antibody (ADAMTS-9L2 
antibody) was a kind gift from Dr. Suneel Apte (Cleveland, USA) and its generation 
and characterisation was reported previously (Demircan et al, 2005). Membranes were 
blocked in 5% (w/v) Marvel low-fat skimmed milk powder (Premier Brands, Spalding, 
UK) in Tris-buffered saline (20 mM Tris, 0.9% [w/v] NaCl, pH 7.4) (TBS) (Sigma) 
with 0.05% Tween 20 (Sigma) (TBST) for 1.5 h prior to 3 x 10 min washes with TBST 
and incubation of primary antibody for 18 h at 4°C. Unbound antibody was washed with 
TBST ( 3 x 1 0  min) prior to incubation with horseradish peroxidase (HRP)-conjugated 
secondary antibody for 1.5 h. A further 3 x 1 0  min wash in TBST was followed by 2 x 5 
min washes in TBS to remove excess Tween 20 prior to detection with the ECL Plus 
Western Blotting Detection Reagent (Amersham Biosciences) in accordance with the 
manufacturer's protocol. The HRP catalyses a photon-generating chemical reaction 
involving the generation of acridinium ester intermediates, which react with peroxide 
under slight alkaline conditions to result in intense light emission (chemiluminescence) 
(Kricka, 1991). Intensity of bands was quantified by densitometry in a Biochemi system, 
measuring the integrated optical density (IOD) using LabWorks software. An identical 
procedure was performed in parallel but with primary antibodies omitted to serve as 
negative controls.
To confirm that equal concentrations o f protein (as calculated by BCA assay) were 
loaded between samples, western blotting with an anti-p-actin antibody (see Table 2.5) 
was routinely performed. P-actin is a ubiquitously expressed cytoskeletal protein, the 
levels of which remain relatively stable in most experimental conditions and thus the 
signal generated between protein extracts of the same concentration should be highly 
comparable. Our laboratory has previously validated the use of p-actin as a protein 
loading control in the tMCAo model (Cross et al, 2006). The antibody has been 
extensively characterised and the protocols for its use have been well established.
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Therefore p-actin was chosen as the normalising control for western blotting with the 
tMCAo study as opposed to GAPDH (housekeeping gene for real-time RT-PCR).
Peptide blocking of anti-ADAMTS-9 antibodies was performed to determine antibody 
specificity. In theory a specific antibody should have its reactivity blocked by binding to 
the 'immunising' peptide. Any bands observed with an antibody following peptide 
blocking are considered to be non-specific. Peptides were only available for Triple Point 
RP4 antibody (sequence undisclosed) and anti-ADAMTS-9L2 antibody (H- 
CQHPFQNEDYRPRSASPSRTH-OH, synthesised by Invitrogen). Antibodies (15 mL) 
were incubated with peptides (30 pg for ADAMTS-9L2, 100 pg for RP4) for 30 min 
prior to western blotting.
2.10 Immunocytochemistry and Immunohistochemistry
Immunocytochemistry (ICC) relies on antibody specificity to locate the distribution of a 
cellular antigen in the cell. The antigen-antibody complex can be detected by either 
direct or indirect methods. Direct methods of staining involve the use of primary 
antibodies that have fluorescent molecules or dyes attached. Indirect methods utilise 
secondary antibodies, which bind to the primary antibody and fluoresce or have 
enzymatic activity to form a coloured product when a substrate is added (Strachan & 
Read, 1999). Fixatives are utilised prior to antibody incubation to preserve and stabilise 
samples, thus protecting them from the rigours of the staining and washing techniques.
Cells were seeded into Nunc 8 -well chamber slides (Lab-Tek, Wiesbaden, Germany) at 
a density of 5 x 104 cells/500 pL media/well and left to adhere for 24 h. The media were 
discarded and the excess washed off with phosphate-buffered saline (0.138 M NaCl, 
0.0027 M KC1, pH 7.4) (PBS) prior to fixation with 4% (w/v) paraformaldehyde (PFA), 
0.2 M sodium phosphate pH 7.2 (100 pL/chamber) for 10 min. The fixative was 
prepared by dissolving PFA powder in 0.2 M sodium phosphate by heating to 60°C in a 
fume cupboard. Drops o f 1 M NaOH were added until the PFA went into solution. The 
solution was filtered using a funnel and filter paper (Whatman, Maidstone, UK) prior to 
adjusting the pH to 7.2 with 1 M HC1. PFA forms cross-links between proteins, creating 
a 'gel' which retains the cellular constituents in their in vivo relationship to each other by 
rendering proteins insoluble via fixation to structural proteins. The resultant structure is 
high in mechanical strength, enabling it to withstand the ICC procedure.
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After 2 x 5  min washes in PBS, cells were blocked in the normal serum (10%) of the 
animal in which the secondary antibody (goat) (Sigma) was produced for 30 min to 
prevent non-specific binding of the secondary antibody. Primary antibody (diluted in 
PBS) incubation was performed for 18 h at 4°C in a humidified chamber before washing 
slides for 3 x 10 min in PBS. Secondary antibody (diluted in PBS) was applied for 1 h at 
37°C before being washed 3 x 1 0  min in PBS. Samples were mounted with Vectashield 
mounting media (Vector Laboratories, Inc, Burlingame, USA), containing 4-6- 
Diamidino-2-phenylindole (DAPI), which forms fluorescent complexes with dsDNA, 
enabling nuclei visualisation. This serves as a control to confirm that cells have 
remained on the chamber slide during the process and also allows for comparison of cell 
number between chambers. Furthermore, it enables the visualisation of proteins 
distributed around the nucleus. Images were taken on a Zeiss 510 CSLM confocal 
scanning laser microscope and/or an Olympus BX60 fluorescent microscope with Cool 
Snap Pro colour digital camera (Media Cybernetics, Silver Spring, USA). Confocal 
images were analysed with the Zeiss LSM5 software whereas fluorescent microscope 
images were analysed with LabWorks Image Acquisition and Analysis Software.
In this study ICC was utilised to characterise cultured astrocytes prior to performing 
further experiments. ICC staining for astrocytic marker glial fibrillary protein (GFAP) 
was performed on U373-MG and B327-01 cells (U87-MG characterisation was 
performed previously by our laboratory) with rabbit anti-GFAP polyclonal primary 
antibody (see Table 2.5) at 1:100 dilution, which was detected by Alexa Fluor 488- 
conjugated goat anti-rabbit IgG (H+L) (Molecular Probes, Eugene, USA) at 1:500 
dilution. Detection of astrocytic marker S-100P was performed by ICC with mouse anti- 
S-100p-subunit IgG l monoclonal primary antibody (Sigma, cat no. S-2532) at a dilution 
of 1:50 prior to incubation with FITC-conjugated rabbit anti-mouse immunoglobulins 
(Ig) secondary antibody (DakoCytomation, Glostrup, Denmark) at a dilution of 1:200. 
ICC detection of ADAMTS-9 protein was performed with ADAMTS-9L2 antibody at a 
dilution of 1:50 followed by incubation with Alexa Fluor 488-conjugated goat anti­
rabbit IgG (H+L) (Molecular Probes) at 1:500 dilution.
IHC adheres to the same basic principles as ICC except that it allows for the detection 
and visualisation of a protein within tissue sections as opposed to in cultured cells. To 
analyse the localisation of ADAMTS-9, tMCAo tissue sections were subjected to IHC 
for the detection of well characterised CNS-cell-specific markers for comparison with
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ISR  ADAMTS-9 images. Details of primary and corresponding secondary antibodies 
used in IHC of tMCAo are in Table 2.6. Sections were warmed to ambient temperature 
for 30 min after removal from the -80°C freezer. Tissue was fixed for 10 min with 4% 
PFA prior to 2 x 5 min washes in PBS and was blocked in 1% BSA for 30 min before 
an 18 h incubation with primary antibody (100 pL) at 4°C. Unbound antibody was 
washed off with PBS/0.05% Tween 20 for 3 x 5 min prior to incubation with secondary 
antibody (100 pL) for 1.5 h. Unbound secondary antibody was removed with 
PBS/0.05% Tween 20 for 3 x 5 min. Sections were mounted, imaged and analysed 
using the same protocol as described for ICC.
2.11 In Situ Hybridisation
2.11.1 In Situ Hybridisation Theory
ISR  relies on antisense probes designed to bind to unique sequences of target mRNA in 
tissue sections, thus giving a clearer indication as to the cellular origin of a protein of 
interest as well as to whether it is being expressed at any point in time. In comparison to 
IHC, ISR  can confirm which cells actually synthesise a protein which is particularly 
useful if the protein is secreted or sequestered into the ECM. Also, protein detected by 
IHC could be mistaken as being synthesised by the cell when in fact it has been 
phagocytosed or adsorbed onto it.
The choice of probe-type is a crucial aspect of ISR  experimental design and there are a 
number of options available including oligonucleotide probes, ssDNA probes, dsDNA 
probes and riboprobes (cRNA, ssRNA). Oligonucleotide probes are highly resistant to 
RNAses as well as being small (40-50 bp) so can easily penetrate into a cell to access 
the target sequence. Another advantage is that they can be produced commercially by 
well established methods by automated chemical synthesis utilising deoxynucleotides. 
The problem with oligonucleotide probes is that they are more likely to bind non- 
specifically because they are composed of a small number of bases (Luehrsen et al, 
2000). However, riboprobes, ssDNA and dsDNA probes offer the advantage over 
oligonucleotide probes in that they are far longer (200-500 bp) and hence more specific 
(Goldsmith et al, 2007).
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The preparation of ssDNA probes usually involves PCR amplification of a DNA 
fragment (followed by a second round of PCR, with only one set of primers to produce 
DNA that is single stranded) or reverse transcription of RNA. The lesser used dsDNA 
probes can be mass-produced in bacteria or alternatively by PCR. However, dsDNA 
probes have low sensitivity because they have to be denatured prior to hybridisation and 
both strands can have a tendency to rehybridise together. Both ssDNA and dsDNA 
probes are highly specific but have the disadvantage that DNA-RNA hybrids are not as 
thermostable as RNA-RNA hybrids, the main advantage of riboprobes (McNicol & 
Farquharson, 1997; Hicks et al, 2004). Hence, it is possible to reduce non-specific 
binding by treating sections that have been hybridised with riboprobes with RNase to 
eliminate false-positive signals obtained with any non-specifically bound probe. The 
main disadvantage of riboprobes and dsDNA probes is that generation involves 
subcloning in bacteria and a number of molecular biological techniques. Also, 
riboprobes are relatively unstable so have to be utilised promptly or new batches 
prepared regularly (Hicks et al, 2004).
There are a number of ways in which 7SH probes can be labelled and detected. 
Traditionally, probes have been radiolabeled (i.e. 35S) and detected with photographic 
film or emulsion. This method is widely used in laboratories in which the containment 
and waste disposal procedures are already well established. A non-radioactive approach 
is to use digoxigenin (DIG), offering the advantage of no signal decay (35S has a half- 
life of 80 days) and quicker experimental procedure. DIG is a steroid only found in the 
digitalis plant (foxglove) (LeWinn, 1984) so anti-DIG antibodies can be used to detect 
bound probe without non-specific binding to an endogenous signal. A spacer arm of 11 
carbon atoms links DIG and the uridine nucleotides of the probe. DIG-labelled 
oligonucleotide probes and riboprobes have been shown in many experiments to 
generate less background signal and higher resolution than corresponding 35S-labelled 
probes (Komminoth et al, 1992) but are less conducive to quantitation.
RNA is highly susceptible to degradation by RNAses and limiting this is an important 
aspect of any ISH experiment. Steps to prevent RNAse degradation include freezing of 
freshly cut sections (-80°C), baking of glassware, use of RNAse free buffers (by 
treatment with 0.001% diethyl pyrocarbonate [DEPC]), gloves, tubes and tips. A 
method of ascertaining the quality o f RNA in a tissue sample is to use a poly(dT) (p[dT]) 
positive control probe, which binds to the poly A tails of all mRNA in the tissue. A poor
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signal with this probe indicates that the tissue is of a low quality and RNA degradation 
has occurred.
To ascertain whether probes are binding specifically to the target mRNA, hybridisation 
is performed not only with the antisense probe but also the sense strand. The signal 
obtained with the sense strand should be nothing more than background noise caused by 
the chemical properties of the probe. Consequently, if the signal obtained with the 
antisense probe rises above the background noise of that obtained with the sense probe, 
it is likely to be due to sequence-specific binding to mRNA and not other constituents of 
the tissue (Strachan & Read, 1999).
2.11.2 Oligonucleotide Probe Method
2.11.2.1 ADAMTS-9 Oligonucleotide Probe Details
The ADAMTS-9 antisense oligonucleotide probe was designed and synthesised to be 
specific to a unique sequence located in rat ADAMTS-9 sequence NM_001107877 
(confirmed by BLAST and FastA) by GeneDetect.com (Auckland, NZ). The probe was 
complementary to nucleotides 6375-6422 with a 7m of 104.1°C. The sense probe was 
also synthesised to serve as a negative control. A 48mer p(dT) probe was used as a 
positive control (Gene.Detect.com). All probes were labelled with DIG, added to the 3’ 
end.
Below is the 48mer antisense DIG-labelled probe sequence (the sense negative control 
probe was the reverse complement of this sequence):
6422 TGGCCACAGGACACAGAGCACTGACTCCATGCGCGAGCCTTCCATCGG 6375
2.11.2.2 In Situ Hybridisation Protocol with Oligonucleotide Probes
All reagents were purchased from Novagen (Madison, USA) unless otherwise stated.
Pre-hybridisation steps were performed with buffers and baked-glassware treated with
0.001% (v/v) DEPC in H2O. Tissue sections (tMCAo) were taken out o f the -80°C
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freezer and allowed to warm to ambient temperature for 30 min prior to treatment with 
chloroform (Sigma) for 10 min. The tissue was fixed with 4% PFA for 10 min prior to 
washing for 3 x 5 min with PBS. PFA was used because it prevents loss of material but 
is mild enough to allow the probe to penetrate into the cell (Nilsson et al, 1996). 
Sections were treated with 100 pL proteinase K (PK) (2 pg/mL in dP^O) for 10 min. 
PK is used to digest cross-linked proteins, thus allowing access of the probe to the target 
mRNA (Rheinhardt & Finkbeiner, 2001). A further PBS wash ( 3 x 5  min) was followed 
by a post-fixation step with 4% PFA prior to rinsing the sections in H2O. The tissue was 
dehydrated with an alcohol series of 70, 80, 95 and 100% molecular grade ethanol 
(Sigma) for 2 min each prior to air drying.
Slides were incubated at 39°C in pre-hybridisation buffer (Biochain, Hayward, USA) 
for 1 h in a humidified chamber. Probes were diluted (attempted 1:25, 1:50, 1:100 and 
1:500) in hybridisation buffer (Ambion, Applied Biosystems). The same concentration 
of antisense and sense probes was used. Probes were denatured at 70°C for 10 min prior 
to cooling on ice and incubation of 100 pL/slide in a humidified chamber for 18 h at 
39°C as calculated by the following formula (http://www.genedetect.com/Merchant2/01 
igoHandling.pdf):
H ybridisation temp. (°C) = 24.21 + 0.41(%GC) - 500/n
W here:
n = probe length, %GC = % of probe that is composed of G or C bases.
The positive control p(dT) probe was used at 1:50 at ambient temperature (inc. pre­
hybridisation buffer incubation). Unbound probe was removed by incubating slides in 
the following wash solutions for 30 min at 60°C for antisense/sense probes and 34°C for 
p(dT) unless otherwise stated:
1. 20x NaCl-sodium citrate in distilled H2O (SSC, 15 mM sodium citrate, 150 mM 
NaCl, pH 7.0), 0.01 M P-mercaptoethanol.
2. 20x SSC, 0.01 M P-mercaptoethanol, 10 mg/mL RNAse A at 37°C.
3. 20x SSC, 50% (v/v) deionised formamide, 0.01 M P-mercaptoethanol.
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4. 20x SSC, 1% (v/v) sodium pyrophosphate, 0.014 M P-mercaptoethanol.
5. Repeated Step 4.
Slides were air-dried for 10 min prior to washing in 100 mM Tris-HCl, 150 mM NaCl 
(pH 7.5) (Buffer 1) for 1 min prior to incubation in 100 pL 10% (v/v) normal sheep 
serum (NSS) (Sigma Immuno Chemicals)/PBS. Sheep anti-DIG-alkaline phosphatase 
(AP) antibody (Roche Diagnostics, Mannheim, Germany) was diluted 1:100 in 5% (v/v) 
NSS/PBS and 100 pL was applied to each slide prior to incubation for 18 h at 4°C in a 
humidified chamber. Slides were washed in buffer 1/0.05% (v/v) Tween 20 for 10 min 
before being washed in 100 mM Tris-HCl, 100 mM NaCl (pH 9.5) for 10 min. One 
tablet of SIGMA FAST BCIP/NBT (5-bromo-4-chloro-3'-indolyphosphate p-toluidine 
salt/nitro blue tetrazolium chloride) (Sigma) was dissolved in 10 mL H2O prior to 
incubation on slides until a purple precipitate was formed where hybridisation had 
occurred (~ 2-3 h). AP cleaves the phosphate from the BCIP, resulting in the formation 
of an indole (C8H7N), which undergoes a redox reaction with NBT to produce the 
coloured product. The reaction was stopped by incubation in 10 mM Tris-HCl, 1 mM 
EDTA (pH 8.0) (Buffer 2). EDTA chelates Zn2+/Mg2+ (required in the active site) 
making it unavailable to the AP. Sections were mounted with 50% PBS/50% glycerol 
(v/v) and visualised/captured with an Olympus BX60 microscope in bright-field mode 
prior to subsequent analysis with LabWorks Image Acquisition and Analysis Software.
2.11.3 Riboprobe Method
2.11.3.1 Riboprobe Generation Strategy
A second ZSH approach, which was adopted, was to generate a riboprobe from 
ADAMTS-9 plasmid DNA. ADAMTS-9 cDNA (715 bp) encoding for the CRD, spacer 
region and TSP-ls 2-4 was previously cloned into a pBluescript KS+ plasmid, as 
illustrated in Figure 2.3, and was a kind gift from Dr. Suneel Apte (Cleveland, USA). 
The cDNA clone was generated by the Apte laboratory during attempts to clone full- 
length mouse ADAMTS-9 as described previously (Jungers, et al, 2005). Cloning of 
cDNA allows the production, isolation and utilisation of DNA that encodes for the 
mRNA of a protein of interest. Incorporation of cDNA into a multiple cloning site 
(MCS) of a vector involves a number of steps, which would have been performed 
previously by the Apte laboratory. The ADAMTS-9 cDNA was engineered so that it
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contained unique restriction sites (Xbal and PstI) at each end (Fig. 2.3). Synthetic 
oligonucleotides are usually ligated to ends of the cDNA to act as 'linkers' in the correct 
alignment for specific restriction enzymes to target. Further modifications of the cDNA 
are necessary in order to make it accessible to the vector including generation of 
overhangs which are complementary to overhangs within the vector. Such modifications 
resulted in the insert and contents increasing in size to 960 bp.
Generation of the riboprobe from the plasmid involved a number of cloning steps, 
which were performed as part of this study. Transformation in E. coli was possible 
because pBluescript KS+ vector contained an origin of replication for propagation in E. 
coli (pUC ori). The plasmid was expressed in the host on ampicillin plates because of an 
ampicillin resistance gene in the vector (APr). Plasmid DNA was isolated from the host 
cell suspension by miniprep. Next, plasmid DNA was linearised prior to performing in 
vitro transcription (/FT) with suitable RNA polymerases to generate RNA antisense and 
sense strands. A DIG-labelling mix was utilised so that the RNA strands were labelled 
during the transcription reaction, thus generating riboprobes.
2.11.3.2 Transform ation of ADAMTS-9 Plasmid DNA
The uptake of foreign DNA (usually plasmids) by an organism (e.g. bacteria), is termed 
‘transformation’. E. coli can be rendered ‘competent’ (having the ability to take up 
plasmid DNA) by treatment with Ca2+ or by increasing the temperature (heat-shock). 
Transformation of the plasmid was carried out utilising aseptic technique. ADAMTS-9 
plasmid DNA (10 pL) was added to 200 pL XL-1 blue strain of E.coli (which was 
thawed on ice) prior to incubation on ice for 30 min. Cells were made competent by 
'heat shocking' in a 42°C water bath for 45 sec prior to returning the cells to ice for 2 
min. Next, 800 pL of SOC media (20 g tryptone, 5 g yeast extract, 0.5 g/L NaCl, 1% 
glucose, 20 mM MgCl2, pH 7.5) was added to the competent cells prior to 30 min 
incubation at 37°C. Cells were plated at a range of densities (50 pL, 100 pL, 200 pL, 
and 500 pL/plate) onto LB (Luria-Bertani) agar/ampicillin plates (0.5% yeast extract, 
0.5% NaCl, 1% tryptone, 1.5% agar, 50 pg/mL ampicillin) with a sterile spreader. 
Plates were incubated at 37°C for 24 h. Single colonies were picked and added to 5 mL 
of LB and 1 pg/mL ampicillin prior to shaking at 37°C for 18 h to grow a bacterial cell 
suspension.
2.11.3.3 Preparation of Plasmid DNA
A miniprep is a technique for preparing plasmid DNA from a bacterial cell suspension 
on the basis that plasmid DNA is far smaller than bacterial chromosomal DNA. The 
QIAprep Spin Miniprep Kit (Qiagen) was used to perform the miniprep in this study. 
Exact buffer compositions were undisclosed by the manufacturer and all centrifugation 
steps were performed in a microfuge. The overnight-cultured XL-1 blue cell suspension 
(3 mL) was centrifuged (1.5 mL in 2 Eppendorf tubes) at 8000 x g  for 1 min and the 
supernatant was discarded prior to resuspension in 250 pL Buffer PI (containing 
RNAse A). Buffer P2 (contains NaOH) (250 pL) was added to the solution and the tube 
was inverted 4-6 times prior to the addition of 350 pL Buffer N3 (contains guanidine 
hydrochloride, acetic acid). The tube was inverted 4-6 times prior to centrifugation at
11.000 x g  for 10 min. Next, the supernatant (~ 800 pL) was deposited (by pipetting) in 
a QIAprep spin column prior to centrifugation at 11,000 x g  for 1 min. The flow­
through was discarded and the column was washed by addition of 500 pL Buffer PB 
(contains guanidine hydrochloride, isopropanol) and centrifugation at 1 1 , 0 0 0  x g  for 1 
min prior to discarding the flow-through. The column was additionally washed in 750 
pL Buffer PE by centrifugation at 11,000 x g  for 1 min and the flow-through was 
discarded prior to an additional centrifugation step at 1 1 , 0 0 0  x g  for 1 min to remove the 
residual wash buffer. The column was placed in a fresh Eppendorf tube and Buffer EB 
(10 mM Tris-Cl, pH 8.5) (50 pL) was added to the centre of the column and left to stand 
for 1 min. Finally, the plasmid DNA was eluted from the column by centrifugation at
11.000 x g  for 1 min and was stored at -20°C.
A diagnostic restriction digest was performed with PstI and Xbal to confirm that the 
correct ADAMTS-9 insert was inserted in the pBluescript KS+ vector. The restriction 
digestion reaction consisted of 5 pL minipreped plasmid DNA, 1 pL PstI (20 U), 1 pL 
Xbal (20 U), 2 pL NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM 
DTT, [pH 7.9]), 11 pL ddH20  in an Eppendorf tube. Efficient digestion was achieved 
without the supplementation of NEBuffer 3 with BSA. Digestion was performed at 
37°C for 2 h prior to visualisation of insert by 2% AGE. All restriction enzymes and 
restriction enzyme buffers used in the generation of riboprobes were purchased from 
New England Biolabs, Ltd (Beverly, USA).
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2.11.3.4 Linearisation of Plasmid DNA and In Vitro Transcription
Digestion of the plasmid DNA with either Xbal or EcoRI downstream of the RNA 
polymerase promoter region (at the opposite end of the insert to the promoter region) 
resulted in 5’ overhangs and thus terminated the T7 or T3 polymerase reaction. Despite 
there being an EcoRI site 5' to the cDNA fragment within the MCS, it was the EcoRI 
site within the insert where T7 RNA polymerase termination occurred as shown in 
Figure 2.4. Fresh batches of riboprobes were generated regularly from a stock of 
linearised plasmid DNA. This was because cRNA is highly susceptible to degradation 
from RNAses whereas plasmid DNA is relatively stable.
Plasmid DNA (including ADAMTS-9 insert) was linearised by restriction digestion 
with Xbal (for sense probe) or EcoRI (for antisense probe) restriction enzymes. The 
reaction consisted of 10 pL lOx NEBuffer 2 (10 mM Tris-HCl [pH 7.9], 10 mM MgCl2, 
50 mM NaCl, 1 mM DTT), 10 pg minipreped plasmid DNA, 100 U Xbal or EcoRI (5 
pL), 75 pL sterile dH20. The digestion was performed at 37°C for 3 h prior to 
visualisation by 2% AGE. Uncut plasmids typically contain two forms of DNA 
(supercoiled and nicked circles), which migrate more rapidly by AGE (displaying two 
bands relatively close together). Linear plasmid DNA was concentrated by ethanol 
precipitation. Brifely, 100 pL DNA was added to 300 pL 95% (v/v) ethanol/0.12 M 
sodium acetate (pH 5.0) prior to mixing by inversion and incubation on ice for 10 min. 
The sample was centrifuged in a microfuge at 9000 x g  for 15 min at 4°C prior to 
discarding of the supernatant and addition of 80% ethanol (200 pL). After 10 min, the 
sample was centrifuged at 9000 x g  for 15 min at 4°C and the supernatant discarded 
before the sample was air dried in a vacuum concentrator 5301 (Eppendorf, Hamburg, 
Germany) for 10 min at 4°C. The pellet was dissolved in 10 mM Tris-HCl (pH 7.6-8),
0.1 mM EDTA.
DIG-labelled antisense and sense probes were generated by IVY  with T7 and T3 RNA 
polymerases respectively as demonstrated by the schematic in Figure 2.4. All reagents 
were purchased from Roche Diagnostics unless otherwise stated. The following was 
added to a tube on ice: 1 pg linear plasmid DNA (cut with either EcoRI or Xbal) (1 pL), 
lOx DIG labelling mix (10 mM ATP, 10 mM CTP, 10 mM.GTP, 6.5 mM UTP, 3.5 mM 
DIG-11-UTP, pH 7.5) (2 pL), lOx transcription buffer (400 mM Tris-HCl, pH 8.0, 60 
mM MgCl2, 100 mM DTT (2 pL), RNase Out (Invitrogen) (1 pL), 20 U RNA
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Figure 2.4 Schematic Representation of Linearisation of ADAMTS-9 Plasmid DNA and In Vitro Transcription
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depict RNA polymerase activity.
polymerase (T7 or T3) (2 pL), sterile H2O (12 pL). The reaction components were 
mixed prior to incubation at 37°C for 2 h. Template DNA was removed by incubation 
with DNAse I (2 pL) (Sigma) for 15 min at 37°C. The reaction was stopped by addition 
of 0.2 M EDTA (pH 8.0) (2 pL) prior to removal of unincorporated DIG with 
MEGAclear purification kit (Ambion) in accordance with the manufacturer's protocol. 
Briefly, ssRNA (riboprobe) was bound to a glass fibre filter membrane prior to removal 
of contaminants and elution in a low salt buffer by centrifugation. Riboprobe purity and 
yield was assessed by 2% AGE.
2.11.3.5 Dot Blot and Calculation of Riboprobe Dilution
Merely deducing the concentration of the riboprobes (by spectrophotometry) is not 
sufficient because it does not take into account DIG-labelling efficiency i.e. antisense 
and sense probes with the same cRNA concentration may vary in the amount of bound 
DIG. Therefore, the probes were subjected to dot blotting with an anti-DIG antibody 
prior to measuring the IOD by densitometry. By using the ratio of antisense:sense IODs, 
the required dilution of riboprobes was calculated to give the same concentration of 
DIG for each probe. The optimal dilution of the riboprobes where non-specific binding 
was at a minimum and the antisense probe gave a good signal (whilst keeping the 
concentration of DIG equal) was determined by experimental ISRs. This technique was 
performed each time new probes were generated because the /ET/DIG-labelling 
reactions will have varying efficiencies across batches.
The positive controls for the dot blot were; DIG-labelled control RNA (Roche 
Diagnostics) and commercially purchased DIG-labelled p(dT) (GeneDetect.com). 
Controls were diluted to concentrations of 0-10 ng/pL in RNA dilution buffer consisting 
of 50% H2O, 30% SSC and 20% formaldehyde (v/v). Control dilutions, antisense 
(undiluted) and sense (undiluted) probes were blotted (1 pL) onto nitrocellulose 
membrane and air dried prior to UV cross-linking for 1 min (both sides o f membrane). 
Membranes were washed in PBS for 1 min prior to blocking in 1% (w/v) BSA/PBS for 
30 min and incubation with sheep anti-DIG antibody conjugated to AP (1:5,000 in PBS) 
(Roche Diagnostics) for 30 min. Unbound antibody was removed by washing twice in 
PBS prior to incubation in SIGMA FAST BCIP/NBT substrate until a precipitate was 
visible. The reaction was stopped by incubation with Buffer 2. Dots were visualised in a
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BioChemi system prior to densitometry with Lab Works software to assess DIG- 
labelling efficiency.
2.11.3.6 In Situ  Hybridisation Protocol with Riboprobes
The ISR  protocol (pre-hybridisation, hybridisation, detection and visualisation) with 
riboprobes was identical to that adopted for the oligonucleotide probes (see Section 
2.10.2.2) with the exception that the pre-hybridisation buffer incubation and 
hybridisation of the riboprobes was performed at 60°C. Furthermore, the unbound 
riboprobes were washed utilising a different protocol as described below.
The following washing steps were followed at 60°C for ADAMTS-9 (antisense and 
sense probes) and 39°C for p(dT) unless otherwise stated:
1. lx SSC for 10 min.
2. 1.5x SSC for 10 min.
3. Twice in 2x SSC at 37°C.
4. 2x SSC 0.2 pg/mL RNAse A (Qiagen) at 37°C. RNAse treatment prevents 
background binding of excess probe.
5. 2x SSC at ambient temperature for 10 min.
6. Twice in 0.2x SSC for 30 min each.
2.12 Haematoxylin and Eosin Staining
The haematoxylin and eosin (H&E) stain is routinely performed in histological 
diagnosis. It is a method of detecting (and differentiating between) basophilic (stained 
blue/purple by haematoxylin) and eosinophilic (stained pink by eosin) structures within 
a tissue section. Basophilic structures include nucleic acids, therefore cell nuclei and 
ribosomes are stained. Eosinophilic structures are generally proteins which can be 
extracellular or intracellular. In this study H&E staining was performed on tMCAo 
tissue sections and compared with ADAMTS-9 ISR  to aid in determining which cells 
were Adamts9-positive.
H&E staining was performed in Coplin jars. Tissue sections (tMCAo) were taken out of 
the -80°C freezer and allowed to warm for 30 min prior to fixation in 4% PFA for 10
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min. Sections were rinsed in PBS for 1 min prior to treatment with filtered Harris' 
haematoxylin (Sigma) for 1 min before being rinsed under a running tap of H2O until 
the solution was clear. Water was drained and sections were incubated in eosin stain 
(Sigma) for 2 min prior to rinsing in H2O (as above). Dehydration of the tissue sections 
was performed with 50, 70, 80, 95 and 100% (v/v) ethanol for 2 min each. Next, 
sections were rinsed in xylene (Sigma) for 4 min prior to mounting with DPX mountant 
(Fluka, Buchs, Switzerland) and visualisation under an Olympus BX60 microscope in 
bright-field mode prior to analysis with the LabWorks Image Acquisition and Analysis 
Software.
94
Chapter 3
Development, Optimisation and 
Validation of Methods to Study 
ADAMTS-9 Expression in the CNS
95
3.1 Background
This chapter describes the thorough development, optimisation and validation of 
methods to study ADAMTS-9 expression in CNS inflammation at the mRNA level 
(real-time RT-PCR and ZSH) and the protein level (western blotting and ICC). This was 
conducted in order to apply the methods to the cell culture and rat model in Chapter 4 
and Chapter 5 respectively.
3.2 Real-Time RT-PCR Optimisation
3.2.1 Overview of Optimisation Steps
For this study, rat ADAMTS-9 primers were designed for use with the tMCAo model. 
Although primers were designed using Primer Express, it was critical to optimise and 
validate them prior to analysing rat tMCAo samples. Three putative primer pairs were 
generated for rat ADAMTS-9 and the pair which gave a clean melt curve with no 
primer-dimer was optimised further by conducting primer concentration and efficiency 
tests. It was essential to validate that the rat ADAMTS-9 primers were amplifying the 
correct target gene. Analysis of the real-time RT-PCR product was performed with 
AGE to confirm the correct size. Next, the product was sequenced prior to running a 
BLASTn search to ascertain that the sequence was unique and that of rat ADAMTS-9.
As is the case with most mathematical models, the 2'AACtmethod of real-time RT-PCR 
data analysis relies on assumptions in order for it to be valid. As well as requiring stable 
housekeeping gene expression, the target gene and housekeeping gene primer 
efficiencies must be approximately equal (Livak & Schmittegen, 2001). Therefore, a 
primer efficiency comparison test was conducted to validate the use of the 2 'AACrmethod 
in this study. Also, geNorm analysis was conducted to determine the most stable 
housekeeping genes for the B327-01 and SHSY-5Y cells.
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3.2.2 Results
3.2.2.1 Rat ADAMTS-9 Primer Concentration Test
Figure 3.1 shows the rat ADAMTS-9 primer combinations of 10F/3.3R, 10F/0.5R, 
3.3F/3.3R and 0.5F/3.3R displayed no non-specific signal in negative samples (lacking 
cDNA). The same combinations also displayed low Ct values indicating high 
amplification efficiency i.e. fluorescent signal rose above the background noise at an 
earlier cycle number. The primer pair combination which was chosen and utilised 
throughout the tMCAo study was 10F/3.3R because it yielded the cleanest melt-curve, 
with no primer-dimer and the highest ARn (fluorescence intensity) (not shown). 
Throughout the tMCAo rat model study, the ADAMTS-9 primers used at this 
concentration did not display primer dimer i.e. negative samples were not resolved.
3.2.2.2 Rat ADAMTS-9 and GAPDH Primer Efficiency Test
Figure 3.2 demonstrates that the slope of the line when Ct was plotted against 
logio(cDNA concentration) with ADAMTS-9 rat primers was -3.29 whereas the slope 
with GAPDH was -3.04. Based on these gradients, the calculated efficiencies o f the 
primers were 101.4% for ADAMTS-9 and 113.2% for GAPDH thus validating their use 
in this study (within 85-115% range).
3.2.2.3 Confirmation of Real-Time RT-PCR Product Size
The real-time RT-PCR amplicon obtained from a reaction with the ADAMTS-9 rat 
primers was the same size as the expected product (101 bp, see Table 2.3) as 
demonstrated in Figure 3.3. The real-time RT-PCR product was confirmed as being 
specific to rat ADAMTS-9 by sequencing at a central DNA sequencing service (not 
shown).
3.2.2.4 Validation of 2_AACt Method
The results of the primer efficiency comparison tests for human and rat GAPDH and 
ADAMTS-9 primers are shown in Figure 3.4. The slope generated by plotting ACt 
values against logio(cDNA concentration) for the human primers (Fig. 3.4A) was -0.05
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Figure 3.2 Rat ADAMTS-9 and GAPDH Primer Efficiency Tests
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Real-time PCR analysis of serially diluted cDNA with rat ADAMTS-9 (A) and GAPDH 
(B) primers to assess primer efficiencies. RNA was extracted from rat EAE tissue prior 
to cDNA synthesis. Serial dilutions of the cDNA were prepared (1:2, 1:3, 1:4, 1:5, 1:10, 
1:100, 1:1,000 and 1:10,000) and used as templates for real-time RT-PCR with 
ADAMTS-9 and GAPDH primers. Real-time RT-PCR was performed in duplicate and 
the experiment was repeated 3 times (independently). Note: Some cDNA dilutions were 
not amplified (template concentration was too low) and were omitted from the graphs.
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Figure 3.3 Analysis o f Real-Time RT-PCR Product Obtained with Rat ADAMTS-9 
Primers
i ii
Real-time RT-PCR product —> <-100 bp
The real-time RT-PCR product obtained with the rat ADAMTS-9 primers was analysed 
by 4% AGE to confirm the correct size. Real-time RT-PCR was performed (as 
described in Section 2.8.2) on cDNA, which was synthesised from RNA extracted from 
rat EAE tissue. The real-time RT-PCR product from 6  x 10 pL reactions was pooled 
and PCR clean-up performed with the QIAquick kit (Qiagen) prior to loading 10 pL 
DNA in an agarose gel. i = product, ii = 100 bp marker.
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Figure 3.4 Primer Efficiency Comparison Tests to Validate use of 2"AACt Method
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Real-time RT-PCR analysis of serially diluted cDNA with ADAMTS-9 and GAPDH 
human (A) and rat (B) primers to ascertain whether efficiencies of target gene and 
housekeeping gene primers are ~ equal (slope ~ zero) thus validating the use of 2 'AACt 
method. RNA extracted from (A) human U373-MG astrocytoma cells (untreated) and 
(B) rat tMCAo tissue (24 h) was reverse transcribed to cDNA, which was serially 
diluted (1:2, 1:3, 1:4, 1:5, 1:10, 1:100, 1:1,000, 1:10,000) prior to real-time RT-PCR 
(performed in duplicate) with ADAMTS-9 and GAPDH. Note: Some cDNA dilutions 
were not amplified (template concentration was too low) and were omitted from the 
graphs.
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whereas the slope with the rat (Fig. 3.4B) primers was 0.03. Therefore, the 2'AACt 
method was valid for this study because the slopes were 0±0.1. Comparable slopes were 
obtained with YWHAZ/ADAMTS-9 to validate the use of the 2'AACt method in the 
B327-01 and SHSY-5Y cells (not shown).
3.2.2.5 B327-01 and SHSY-5Y Housekeeping Gene Validation
It was demonstrated that both YWHAZ and SDHA were the most stable housekeeping 
genes for use with both the B327-01 and SHSY-5Y cells under the experimental 
conditions studied as calculated by geNorm and illustrated in Figure 3.5. YWHAZ 
primers produced cleaner melt-curves and were more efficient than the SDHA primers 
(not shown). Therefore, YWHAZ was the housekeeping gene utilised with the B327-01 
and SHSY-5Y cells to normalise expression levels of ADAMTS-9 following treatment 
with factors (e.g. cytokines). YWHAZ primers were optimised and validated similarly 
to the rat ADAMTS-9 primers as described in this study (not shown).
3.2.3 Real-Time RT-PCR Optimisation Discussion
For this study, real-time RT-PCR primers were designed to detect ADAMTS-9 mRNA 
in tMCAo rat tissue. AGE and sequencing analysis of the real-time RT-PCR product 
obtained with the primers confirmed they were specific to ADAMTS-9. However, it 
was important to ascertain that the primers had a high amplification efficiency 
percentage, which was comparable to that of the housekeeping gene primers. Primer 
efficiency and primer efficiency comparison tests were conducted on serially diluted 
cDNA to assess these primer parameters. A problem encountered whilst conducting 
these tests was that highly diluted cDNA (e.g. 1:1,000 and 1:10,000) was not amplified 
(or had very high Cts of >40). Having extensively repeated the tests it was decided that 
there simply was not enough starting template in these samples for amplification to be 
initiated efficiently. This was substantiated by the fact that template doubled with each 
cycle for the lesser diluted cDNA samples. Therefore, these data for the highly diluted 
samples were not plotted in the graphs for these tests.
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3.3 In Situ Hybridisation - Oligonucleotide Probe Approach
3.3.1 Overview of Optimisation Steps
Oligonucleotide probes were initially adopted to detect ADAMTS-9 mRNA in tMCAo 
tissue sections by ZSH. Unfortunately, non-specific binding of the probes was a common 
problem throughout the study. This was demonstrated by the strong signal obtained with 
the negative control sense probe. Therefore, the general ISR  protocol was adapted in a 
number of ways in an attempt to reduce the non-specific binding as described below:
1. Included a pre-hybridisation acetylation step (treatment with 0.1 M 
Triethanolamine-acetic anhydride) to block reactive amine groups (have positive 
charges that associate with nucleic acids), which bind to probes non-specifically.
2. Increased the probe hybridisation temperature (39-60°C) (to increase the 
stringency) and decreased the hybridisation incubation time (1-18 h).
3. Decreased the probe concentration (1:50-1:500) (keeping antisense and sense 
concentrations equal) because excess DIG may have led to false-positives.
4. Increased post-hybridisation washing temperature (up to 60-80°C) and intensity 
(vigorous shaking of slides in the wash buffers) to remove non-specifically 
bound probe.
5. Increased NSS blocking concentration (1-20%) and incubation time (1-5 h) 
because non-specific binding of the anti-DIG antibody was a potential source of 
the problem.
6 . Incubated SigmaFast BCIP/NBT in the presence of 1 mM levamisole to block 
endogenous AP, which the substrate may have been binding to.
7. Decreased incubation time with SIGMA FAST BCIP/NBT (10 min-18 h) 
because non-specific binding of the substrate to the tissue may have been a 
reason for the signal on the negative control sections.
8 . Attempted fluorescent detection (FZSH) as opposed to colourmetric 
AP/BCIP/NBT method to ascertain whether specificity was improved.
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3.3.2 Results
3.3.2.1 Oligonucleotide Probe Specificity
None of the optimisation attempts noticeably decreased non-specific binding with the 
oligonucleotide probes. A representative series of images obtained with these probes are 
shown in Figure 3.6. The signal displayed with the sense probe (Figs 3.6D, 3.6E, 3.6F) 
was not considerably different from that obtained with the antisense probe (Figs 3.6A, 
3.6B and 3.6C). Evidence that the antisense and sense probes were binding non- 
specifically came from using a 'no probe' control (Fig. 3.6G), which did not generate a 
signal. A p(dT) positive control confirmed tissue integrity because total mRNA 
expression was detected (Figs 3.6H, 3.61). Therefore, it was impossible to say with any 
certainty with oligonucleotide probes, which cells were expressing ADAMTS-9.
3.4 In Situ Hybridisation - Riboprobe Approach
3.4.1 Overview of Development and Optimisation Steps
A great deal o f time and work in this study was directed at optimising the ISR  method 
using oligonucleotide probes. Unfortunately, it was decided that the oligonucleotide 
probes were not appropriate for specifically detecting ADAMTS-9 in tMCAo CNS 
sections. A different ISR  approach was to utilise riboprobes. As opposed to the 
oligonucleotide probes purchased from GeneDetect.com, the ADAMTS-9 riboprobe has 
been characterised and utilised previously for ISR  (Jungers et al, 2005). Generation of 
the ADAMTS-9 antisense and sense probes from the DNA plasmid involved a number 
of molecular biological steps. The subsequent data in this section demonstrate the 
results of the various stages of riboprobe generation, validation and optimisation.
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Figure 3.6 In Situ Hybridisation o f tMCAo Tissue Sections with Oligonucleotide 
Probes showing Non-Specific Binding
Hybridisation with; oligonucleotide ADAMTS-9 antisense probe (A, B, C), sense probe 
(D, E, F), no-probe (G), p(dT) probe (H, I). Images o f A, D and H are from same region, 
images of B and E are from the same region, images o f C, F, G and I are from the same 
region. Images taken on a fluorescent microscope in bright-field mode (xlOO).
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3.4 .2  R esu lts
3.4.2.1 Riboprobe Generation
Diagnostic restriction digest of pBluescript KS+ plasmid to verify ADAMTS-9 
cDNA insert identity
Two bands were visualised by AGE following a restriction digest of pBluescript KS+ 
(containing an ADAMTS-9 insert) with PstI and Xbal as shown in Figure 3.7A. The 
larger of the bands was the size of the vector (-2958 bp), whereas the smaller band was 
the size of the ADAMTS-9 insert (-960 bp). This data confirmed that the insert within 
the pBluescript KS+ vector was that of the correct ADAMTS-9 cDNA clone.
Linearisation of plasmid DNA in preparation for /FT/DIG-labelling
Figure 3.7Bii shows that Xbal cut at one site within the plasmid because one band of the 
size of the plasmid and insert (-3918 bp) was observed. Figure 3.7Biii demonstrates 
that EcoRI cut at two locations close together within the plasmid (see Fig. 2.4) thus 
generating two pieces of linear plasmid DNA (one large, one small). The size of the 
EcoRI-EcoRI fragment was -130 bp which was the approximate difference between the 
size of the larger band in Figure 3.7Biii and the only band in Figure 3.7Bii. This 
confirmed that the antisense probe is slightly shorter than the sense probe following 
/FT/DIG-labelling.
Assessment of ISH  Riboprobe Purity following In Vitro Transcription/D IG - 
Labelling and DNAse I T reatm ent
For both the antisense and sense riboprobes, only one band was observed by AGE, 
suggesting the probes were pure (no template DNA), as demonstrated by the 
representative image in Figure 3.7C. The antisense probe was -450 bases (Fig. 3.7Cii), 
whereas the sense probe was -580 bases (3.7Ciii). The smaller size of the antisense 
probe was expected because of the presence of the EcoRI-EcoRI fragment seen in 
Figure 3.7B.
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A: Diagnostic Restriction Digest of pB luescript KS+ Plasmid to Verify ADAMTS-9 
cDNA Insert Identity. A miniprep was performed to obtain plasmid DNA from XL-1 
blue E. coli colonies, which were picked following ampicillin resistance selection. 
Plasmid DNA was cut with diagnostic restriction enzymes PstI and Xbal (see Figure 2.3 
for schematic of pBluescript KS+ plasmid) to release the ADAMTS-9 fragment prior to 
2% AGE analysis (Aii).
B: Linearisation of Plasmid DNA in Preparation for /PT/DIG-Labelling. Plasmid 
DNA was linearised with Xbal (Bii) and EcoRI (Biii) prior to 2% AGE. The single 
band observed following digestion with Xbal demonstrates the plasmid DNA was cut at 
one site. The two bands observed following digestion with EcoRI suggests the plasmid 
DNA was cut at two sites (close together given the small size of EcoRI-EcoRI fragment) 
(see Figure 2.4 schematic).
C: Assessment of I S H Riboprobe Purity following In  Vitro Transcription/DIG- 
Labelling and DNAse I T reatm ent. Riboprobes were subjected to 2% AGE following 
/FT/DIG-labelling and treatment with DNase I. Cii = linearisation with EcoRI and 
subsequent transcription with T7 polymerase (antisense probe). Ciii = Linearisation 
with Xbal and subsequent polymerisation with T3 polymerase (sense probe). Note: 
representative image of one batch of probes, these procedures were performed each time 
a new batch of probes were produced.
Ai and Bi = 500 bp DNA ladder, Ci = 100 bp DNA ladder.
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Figure 3.7 ADAMTS-9 Riboprobe Generation
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ADAMTS-9 insert (960 bp)
B
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♦ ♦ •  ♦ ♦1 11 111
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3.4.2.2 Verification of Riboprobe DIG-Labelling/Dilution Calculation
The serial dilutions of the commercial p(dT) and DIG-labelled RNA controls 
demonstrated that the dot blotting technique was sensitive enough to differentiate 
between different concentrations of DIG as demonstrated in Figure 3.8 A. The strong 
signal observed with the p(dT) dot blot (Fig. 3.8 A) confirmed that this probe could be 
utilised as the positive control in ISR  experiments.
The representative blot in Figure 3.8B shows that both the antisense and sense probes 
were labelled with DIG. The IOD of the batch of antisense probe represented in Figure 
3.8B was -100 whereas the sense probe was -5 7  (note IOD varied with each batch due 
to variations in /FT/DIG-labelling reaction). Therefore the ratio of DIG-labelling of 
antisense to sense with this batch of probes was - 2 : 1  thus using the antisense probe at a 
dilution of 1:50 and the sense probe at 1:25 would give approximately the same 
concentration of DIG in ISR  experiments. The concentrations at which the probes were 
utilised throughout the study were between 500-1500 ng/mL (depending on the batch).
3.4.2.3 ADAMTS-9 Riboprobe Specificity
The representative ISRs in Figure 3.9 demonstrate that the ADAMTS-9 riboprobe was 
specific. The intense cellular signal shown in 3.9A and B was not replicated with the 
sense probe (Figs 3.9C and D), which gave only background staining. Furthermore, 
with the antisense probe, the difference in signal between the positive cells and the 
background signal was clear. Negligible signal was obtained with the no-probe negative 
control (Fig. 3.9E). The high-affinity hybridisation of the riboprobe demonstrates that it 
is suitable for detecting ADAMTS-9 in rat tissue despite its generation from a mouse 
cDNA clone and previous use in mouse tissue (Jungers et al, 2005).
3.4.3 In Situ Hybridisation Optimisation Discussion
The fact that the ADAMTS-9 oligonucleotide probes were only 48 bases in length is 
proposed to be the main reason for the ISR  non-specific binding. The ADAMTS-9 
riboprobe was far longer (-450 bases), making the binding to the complementary 
sequence much tighter, thus allowing stringent washes to be performed. In support of 
these findings, a study by Komminoth et al (1992) demonstrated that DIG-labelled
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Figure 3.9 In Situ Hybridisation o f 5 Day tMCAo Tissue Sections Showing Specific 
Binding of ADAMTS-9 Riboprobe
Representative ZSHs of tMCAo tissue sections with; ADAMTS-9 antisense riboprobe 
(A and B), sense riboprobe (C and D) and no-probe (E). Images of A and C are from 
same region, images o f B, D and E are from the same region. Images taken on an 
Olympus BX60 microscope in bright-field mode (xlOO).
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riboprobes were more sensitive and displayed less background reactivity than DIG- 
labelled oligonucleotide probes. The original method would perhaps have been more 
specific and sensitive if a cocktail o f oligonucleotide probes had been used as opposed 
to the one 48-mer probe. The antisense cocktail would comprise of a number of 
oligonucleotides with specificity to bases in different regions of the target sequence, 
thus a positive signal would be more intense because of the increased concentration of 
DIG being present.
Following digestion of the plasmid DNA with EcoRI in preparation for 7FT/DIG- 
labelling, two bands were observed by AGE, which was not surprising given that there 
is a restriction site within the insert as well as in the MCS as shown in Figure 2.4. 
Having the EcoRI site within the insert offered the advantage that the 3' end of the 
antisense probe was more specific to ADAMTS-9 as opposed to being the transcript of 
the cDNA sequence, which was engineered into the insert to ligate the cDNA into the 
vector.
3.5 Optimisation of Anti-ADAMTS-9 Antibodies
3.5.1 Overview of Antibody Optimisation Steps
In order to study the expression of ADAMTS-9 at the protein level, specific and 
sensitive antibodies needed optimising and validating. A number of commercially 
purchased antibodies as well as the ADAMTS-9L2 antibody were tested for their ability 
to detect ADAMTS-9. Western blotting is the preferred technique to assess an 
antibody's specificity because it allows the visualisation of different processed forms of 
protein(s) which are being detected. Prior to testing antibodies by western blotting, it is 
impossible to say an ICC or IHC is specifically detecting the target antigen i.e. staining 
may be a result of the antibody binding non-specifically.
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3.5.2 Results
3.5.2.1 Analysis of Anti-ADAMTS-9 Antibody Specificity and Efficacy
The Cedarlane (anti-catalytic domain) and BioReagents (anti-propeptide) anti- 
ADAMTS-9 antibodies displayed negligible reactivity to ADAMTS-9 protein as shown 
by the representative western blot in Figure 3.10A and 3 .IOC. The representative 
western blot shown in Figure 3.1 OB, demonstrates that the RP4 antibody (anti­
propeptide) was not specific to ADAMTS-9 because the same reactive band was 
observed with (3.1 OBii) and without (3.1 OBi) peptide blocking. These outcomes were 
replicated in numerous repeat experiments with different samples i.e. both CNS-cell and 
tMCAo brain protein extracts under different western blotting conditions (not shown). 
Consequently, the Cedarlane, RP4 and Affinity BioReagents antibodies were not further 
utilised further to study ADAMTS-9.
Figure 3 .IOD indicates that the ADAMTS-9L2 antibody (anti-linker 2 domain) was 
specific to ADAMTS-9. In the representative blot shown, reactive bands were observed 
at -188 and (to a lesser extent) -100 kDa and -50  kDa (Fig. 3.10Di). These bands were 
absent following blocking of the antibody with the 'immunising' peptide (Fig. 3.1 ODii). 
Other bands were observed at -38, -62-64, -80  and -140 kDa when other tMCAo 
protein extracts were blotted (not shown). These bands were absent following blocking 
of the antibody with the immunising peptide. Therefore, this antibody was used to study 
ADAMTS-9 in CNS inflammatory disorders in further work.
3.5.3 Antibody Optimisation Discussion
Prior to analysing ADAMTS-9 at the protein level, it was essential to validate 
antibodies raised against the peptidase. There are problems when analysing protein 
levels of ADAMTS-9. Firstly, the fact that the ADAMTS-9 zymogen is -216 kDa 
(Somerville et al, 2003) means it is the largest of the ADAMTSs, making it difficult to 
resolve on SDS-PAGE, as described by Koo et al, 2007. Secondly, experiments are 
limited by the availability and quality of commercial antibodies as highlighted in a 
recent study analysing proteolytic cleavage of versican in the heart, in which the author 
states, 'the lack of adequate antibodies to murine ADAMTS-9 precluded us from 
investigating its expression' (Kern et al, 2007).
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Figure 3.10 Analysis of Anti-ADAMTS-9 Antibody Specificity and Efficacy
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It was demonstrated in this study that none of the commercial antibodies were suitable 
for generating meaningful data because they were either a) non-specific or b) lacking 
efficacy. Unsuccessful attempts were made to block out the non-specific binding of the 
RP4 antibody by incubating membranes in a higher concentration (up to 20%) of milk 
prior to application of the primary antibody. Also, the immunising RP4 peptide was 
used at a high concentration (100 pg). The antibodies which displayed low binding 
affinities (Cedarlane and BioReagents) were used at increased concentrations (1:500) 
but efficacy was not improved. To support these findings, no papers have been 
published with either the Cedarlane or Affinity BioReagents anti-ADAMTS-9 
antibodies. However, data have been published with the RP4 antibody previously (Koo 
et al, 2006; Koo et al, 2007); although, the authors do not report the use of peptide 
blocking or the performing of any experiments to determine the specificity of the 
antibody. The same western blotting protocol adopted by Koo et al, was applied to this 
study but non-specific binding was not eradicated.
In contrast to the commercially purchased antibodies, the ADAMTS-9L2 antibody was 
shown to label ADAMTS-9 with high efficacy. All commercial antibodies were raised 
against peptides with amino acid sequence homology to the human form of ADAMTS-9, 
which is a potential reason for their poor reactivity with rat protein extracted from 
tMCAo brains. However, this problem was not replicated with the ADAMTS-9L2 
antibody, which displayed high affinity to rat ADAMTS-9 protein in tMCAo extracts 
despite targeting the human form.
The bands detected in this study with the ADAMTS-9L2 antibody appear to be specific 
to ADAMTS-9 because they were absent on blots following incubation with peptide- 
blocked antibody. However, it is difficult to conclude whether the antibody is detecting 
numerous species of ADAMTS-9 protein present in the extracts or whether some of the 
smaller bands are a result of the extraction protocol (degradation). Dissolving of the 
protein pellet following extraction with TRI Reagent involved increasing the 
temperature to ~70°C and vigorous vortexing and mixing by pippetting. This may have 
disrupted the structure o f the proteins, which were present in the original sample thus 
generating fragments (still containing the 2nd linker domain) that are not 
pathophysiologically relevant e.g. the smaller bands at -35-39 and ~62-64. The larger 
proteins detected (e.g. -140 and -188 kDa) are more likely to be ADAMTS-9 species, 
which were present in the cell and tMCAo extracts. Data obtained with the ADAMTS-
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9L2 antibody were published previously (Demircan et al, 2005), showing a reactive 
band of similar size to the one detected in this study (-180-200 kDa). The authors 
detected bands at 75 and 100 kDa, which were described as being a result of 'cross­
reactivity with non-ADAMTS-9 proteins'. No mention of testing the specificity of the 
antibody by peptide-blocking was reported.
Unfortunately, the Apte laboratory only produced a finite amount of the antibody, 
therefore it was only utilised extensively in the tMCAo model to analyse whether 
differences in ADAMTS-9 mRNA expression correlated with protein levels (Chapter 5). 
The antibody was also used to assess the cellular localisation of ADAMTS-9 in the 
U373-MG cells (Chapter 4).
3.6 Summary
These data presented in this chapter, demonstrate the successful development, 
optimisation and validation of methods (real-time RT-PCR, ISR  and western 
blotting/ICC) to detect ADAMTS-9. This enabled the application of these methods to 
study expression levels and localisation of ADAMTS-9 mRNA and protein in CNS- 
derived cells (Chapter 4) and in the tMCAo rat model (Chapter 5).
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Chapter 4
ADAMTS-9 Expression and 
Modulation in CNS-Derived Cells
In Vitro
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4.1 Background
There is limited evidence as to the cellular source of ADAMTS-9 in the human brain. 
Furthermore, little is known about transcriptional regulation of Adamts9 in the CNS, 
though in other tissues it appears to be modulated by pro-inflammatory mediators 
(Bevitt et al, 2003; Demircan et al, 2005). In this study, the expression and modulation 
of Adamts9 was analysed in human astrocytes (U373-MG, U87-MG astrocytomas and 
B327-01), microglia (CHME3 human foetal cell line) and neuronal cells (SHSY-5Y 
human neuroblastoma cell line) by real-time RT-PCR. To understand further the 
transcriptional initiators of ADAMTS-9 expression in the brain, cells were treated with 
factors implicated in the pathogenesis of CNS inflammatory disorders including pro- 
inflammatory cytokines IL-1 p, IFN-y and TNF and the anti-inflammatory cytokine 
TGF-p. In addition, SHSY-5Y cells were treated with NGF and RetA, which are both 
important in triggering neuronal differentiation and growth, to assess whether 
ADAMTS-9 is modulated by such factors. An analysis of the cellular localisation of 
ADAMTS-9 protein in U373-MG was also conducted by ICC.
4.2 ADAMTS-9 in Astrocytic Cells
4.2.1 Overview of Approach
A wealth of evidence implicates astrocytes in CNS inflammatory disorders as well as in 
normal physiological processes. It has been documented that astrocytes secrete many 
mediators o f inflammation including cytokines as well as proteolytic enzymes (MMPs) 
(Yin et al, 2006). Therefore, cell culture methods were applied to analyse whether 
ADAMTS-9 is expressed by astrocytes in vitro and whether its expression can be 
modulated by inflammatory stimuli.
Despite using established cell-lines, it was important to characterise the U373-MG and 
B327-01 cells as astrocytic prior to using them in experiments (U87-MG cells were 
validated previously by Dr. Alison Cross). To do this western blotting and ICC were 
performed to detect GFAP, which is an intermediate filament protein found only in 
astrocytes. The My of GFAP as visualised by SDS-PAGE/western blotting varies 
between 47-55 kDa (Santos et al, 2005). Another marker which was detected was factor
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SlOOp (~20 kDa), which is localised in the cytoplasm and nuclei of astrocytes. 
Functions of SlOOp include cell growth regulation, calcium homeostasis and cell 
structure (Mbele et al, 2002). B327-01 cell characterisation was performed in 
collaboration with Helen Denney and Antoine Fouillet (both Sheffield Hallam 
University)
As well as secreting cytokines, astrocytes have long been reported to express cytokine 
receptors including IL-1RI, IL-1RII, p75, p55, TNFR and IFN-y-receptor (IFN-yR) 
(Tada et al, 1994; Carroll-Anzinger & Al-Harthi, 2006). Therefore, astrocytic cell 
cultures were treated with cytokines prior to real-time RT-PCR analysis to determine 
whether such mediators of CNS inflammation modulate the expression of Adamts9 
steady-state mRNA levels. Prior to treatment with cytokines an analysis of Adamts9 
expression levels for all the astrocytic cells under basal conditions was also conducted.
4.2.2 Results
4.2.2.1 Characterisation of Astrocytes
Figure 4.1 Aiii illustrates strong GFAP staining of U373-MG cells by ICC with anti- 
GFAP antibody. Incubation with PBS instead of the primary antibody displayed a lack 
of staining (Fig 4.1Aiv). Figure 4. IBiii demonstrates detection of a protein with Mj of 
-52  kDa by western blotting with anti-GFAP antibody. No bands were detected when 
anti-GFAP antibody was omitted (replaced by TBST) from the western blotting 
protocol as shown in Figure 4.1Biv.
ICC of the B327-01 cells with the anti-GFAP antibody produced unusual, diffuse 
(grainy) staining of the intermediate filaments (not shown). However, GFAP was shown 
by western blotting to be abundantly expressed by these cells as illustrated in Figure 
4.1Bi. A protein with Mj of -52  kDa was detected in B327-01 cells with the anti-GFAP 
antibody. No bands were detected when anti-GFAP antibody was omitted (replaced by 
TBS) from the western blotting protocol as shown in Figure 4.1Bii. To further confirm 
that the B327-01 cells were astrocytic, ICC was performed on these cells with an anti- 
S100P antibody. Figure 4.1Ai demonstrates strong ICC S100p staining o f the B327-01 
cells. No staining was observed when anti-S100p antibody was omitted (replaced with
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Astrocytes were characterised by ICC staining (A) and western blotting (B). Ai = B327- 
01 ICC staining (green) with anti-SlOOp antibody. Aiii = U373-MG ICC staining (green) 
with anti-GFAP antibody. ICC was performed on B327-01 (Aii) and U373-MG (Aiv) 
with the omission of primary antibodies from the protocol (replaced by PBS), serving as 
a negative controls for non-specific binding of the secondary antibodies. Nuclear 
staining was with DAPI (blue) in all ICC images. Images were captured and analysed 
on a confocal microscope (x400). Western blotting was performed on B327-01 (Bi) and 
U373-MG (Biii) with anti-GFAP antibody. Primary antibodies were omitted (replaced 
by TBST) from western blots of B327-01 (Bii) and U373-MG (Biv), serving as negative 
controls for non-specific binding of the secondary antibodies. B327-01 characterisation 
was performed in collaboration with Helen Denney and Antoine Fouillet (both Sheffield 
Hallam University).
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Figure 4.1 Characterisation of Human Astrocytic Cells
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PBS) from the protocol (Fig. 4.1 Aii). Therefore, both B327-01 and U373-MG were 
considered viable astrocytic cell populations.
4.2.2.2 Comparison of Adamts9  Expression between different Astrocytic Cells 
under Basal Conditions
Figure 4.2 shows that all astrocytic cells analysed in the study expressed ADAMTS-9 
mRNA. B327-01 astrocytes (2"aCt = 0.02) expressed -40  times more Adamts9 than 
U373-MG astrocytoma (0.0005) and ~70 times more than U87-MG astrocytoma 
(0.0003) as detected by real-time RT-PCR.
4.2.2.3 M odulation of Astrocytic Adamts9  Expression by Pro-Inflam m atory 
Cytokines 
U373-MG
Figure 4.3 demonstrates that treatment of U373-MG astrocytoma cells with 0.4-100 
ng/mL IL-lp significantly (p<0.01) modulated expression of ADAMTS-9 mRNA. The 
average relative fold increase in Adamts9 expression over control (0 ng/mL) when 
treated with IL-lp were ~5 (0.2 ng/mL), 14 (0.4 ng/mL), 19 (0.8 ng/mL), 25 (1 ng/mL), 
27 (10 ng/mL) and 26 (100 ng/mL). From 0-1 ng/mL of IL-ip treatment, modulation of 
Adamts9 expression was concentration-dependent. From 1-100 ng/mL expression of 
Adamts9 was not dependent on increasing IL-ip concentration and a 'plateau' phase was 
reached.
Figure 4.3 also illustrates that ADAMTS-9 mRNA expression was modulated by 
treatment with TNF in U373-MG. The average relative fold increase in Adamts9 
expression over control when treated with TNF were -2  (0.2 ng/mL), 5 (0.4 ng/mL), 4 
(0.8 ng/mL), 8 (1 ng/mL), 10 (10 ng/mL) and 8 (100 ng/mL). Adamts9 expression levels 
were statistically (p<0.05) greater than control levels at 1-100 ng/mL. Flowever, 
treatment of U373-MG with IFN-y displayed no statistically (p>0.05) significant 
modulation of ADAMTS-9 mRNA expression (Fig. 4.3).
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Figure 4.3 Effect of Pro-Inflammatory Cytokines on ADAMTS-9 mRNA Expression in U373-MG Astrocytoma Cell Line
______
U87-MG
Treatment of U87-MG astrocytoma cell line with IL-lp, IFN-y and TNF had no 
statistically (p>0.05) significant effect on ADAMTS-9 mRNA expression levels as 
detected by real-time RT-PCR. Cells were unresponsive to all concentrations tested (not 
shown). Culturing of cells, treatment of cells, RNA extraction, cDNA synthesis and 
real-time RT-PCR experimental procedures were identical to those adopted for the 
U373-MG cells.
B327-01 Astrocytes
Treatment of B327-01 astrocytes with IL-ip initiated a statistically (p<0.05) significant 
increase of ADAMTS-9 mRNA expression at 100 ng/mL as shown in Figure 4.4. The 
average relative fold increases of Adamts9 expression over control when treated with 
IL-ip were -5  (1 ng/mL), 5 (10 ng/mL) and 6 (100 ng/mL). In addition, Figure 4.4 
demonstrates that IFN-y caused a statistically (p<0.01) significant decrease in Adamts9 
expression. The average relative fold decrease in Adamts9 expression over control when 
treated with IFN-y were ~0.3 (1 ng/mL), 0.4 (10 ng/mL) and 0.3 (100 ng/mL). No 
statistically (p>0.05) significant effects on Adamts9 expression levels were observed 
with TNF treatment in B327-01 astrocytes.
4.2.2.4 Cellular Localisation of ADAMTS-9 Protein
Intense nuclear staining of U373-MG cells with the ADAMTS-9L2 antibody is shown 
in Figure 4.5A. Figure 4.5B further confirmed nuclear staining by co-staining with 
DAPI. Figure 4.5D depicts intense-staining of ADAMTS-9 contained within the 
nucleus in small spherical organelles. Furthermore punctate, intense ADAMTS-9 
expression was detected in the cytoplasm (potentially in the secretory pathway) (Fig. 
4.5D). ADAMTS-9 was not detected in the ECM. ICC without the incubation of the 
primary antibody displayed no staining (Fig. 4.5C). Therefore, these data indicate that 
ADAMTS-9 is expressed in the nucleus and cytoplasm of U373-MG cells.
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Figure 4.4 Effect of Pro-Inflammatory Cytokines on ADAMTS-9 mRNA Expression in B327-01 Human Astrocytic Cell Line
130
ICC staining of U373-MG astrocytoma cells with the ADAMTS-9L2 antibody 
visualised by (A and B) fluorescent microscopy (x200) and (D) confocal microscopy 
(x400). U373-MG cells were seeded in chamber slides at a density of 5 x 104 cells/500 
pL media/well and left for 24 h to adhere. Medium was discarded and cells were fixed 
in 4% PFA prior to blocking, ADAMTS-9L2 antibody incubation (18 h at 4°C) and 
detection with the Alexa Fluor 488-conjugated goat anti-rabbit IgG (H+L) secondary 
antibody. Cells were not treated with any stimulus. Image B shows ADAMTS-9 and 
DAPI colocalisation. Image C is ICC with no primary antibody incubation (replaced by 
PBS) overlaid on image obtained with DAPI staining (serves as a control for non­
specific binding of the secondary antibody) (fluorescent microscope x200). Arrows 
highlight intense nuclear organelle expression of ADAMTS-9. Arrowheads depict 
detection of punctate ADAMTS-9 expression in the cytoplasm. Due to having a finite 
quantity of ADAMTS-9L2 antibody, the repetition of this experiment was not possible.
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Figure 4.5 Localisation of ADAMTS-9 in U373-MG Astrocytoma Cell Line
1 w ScG ^Sii
132
4.3 ADAMTS-9 in the CHME3 Microglial Cell Line
4.3.1 Overview of Approach
Activation of microglia is a key event in many CNS inflammatory disorders resulting in 
the release of pro-inflammatory mediators. Such activation is likely to be triggered in 
some capacity by pro-inflammatory cytokines because microglial cells express IL-1RI, 
IL-1RII (Lee et al, 2002), TNFRI, TNFRII and IFN-yR (Kim & de Vellis, 2005). 
Therefore, the effect of cytokines on Adamts9 expression was analysed in a human 
foetal microglial cell line (CFIME3) by real-time RT-PCR.
4.3.2 Results
4.3.2.1 Effect of Pro-Inflam m atory Cytokines on Adamts9 Expression Levels in 
CHME3 Microglial Cell Line
Figure 4.6 shows a statistically significant (p<0.05) modulation of ADAMTS-9 mRNA 
expression in the CHME3 microglial cell line with 10-100 ng/mL IFN-y. The average 
relative fold increases of Adamts9 expression over control when treated with IFN-y 
were ~1 (1 ng/mL), 2 (10 ng/mL) and 3 (100 ng/mL). From 1-100 ng/mL of IFN-y 
treatment, modulation of Adamts9 expression was concentration-dependent. Treatment 
of CHME3 with IL-ip and TNF had no statistically (p>0.05) significant effect on 
ADAMTS-9 mRNA expression levels (Fig. 4.6).
4.4 ADAMTS-9 in the SHSY-5Y Neuroblastoma Cell Line
4.4.1 Overview of Approach
Neurones contribute to proteolysis in the brain by expressing MMPs (Liu et al, 2007). 
There is evidence that neurones require remodelling of glial scars to promote axonal 
outgrowth, a process which ADAMTSs have the potential to mediate by breakdown of 
CSPGs. ADAMTS-1 has been reported to be expressed in N1E-115; a mouse 
neuroblastoma cell line (Sasaki et al, 2001). Flowever, a comprehensive investigation 
into whether human neurones express ADAMTSs with proteoglycanase activity has not
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Figure 4.6 Effect of Treatment with Pro-Inflammatory Cytokines on ADAMTS-9 mRNA Expression in CHME3 Microglial Cell Line
135
been reported. Our laboratory has previously shown that U373-MG, U87-MG, B327-01 
and CHME3 microglial cells express ADAMTS-1, -4 and -5 (Cross et al, 2006; 
Haddock et al, 2003), however it is unknown whether SHSY-5Y neuroblastoma cells 
express these proteoglycanases. ADAMTS-9 has also not been studied in neuronal cells, 
therefore, an analysis of ADAMTS-1, -4, -5 and -9 mRNA expression levels in SHSY- 
5Y cells was conducted by real-time RT-PCR.
Generally, the intracellular signalling that occurs in neurones results in transcription of 
genes encoding for protective factors promoting growth and regeneration. The NTFs 
have been extensively implicated in triggering such signalling by binding to NTF- 
receptors on neurones (Allen & Dawbam, 2006). Many of the genes up-regulated by 
RetA during differentiation of neurones are those that encode for NTF receptors 
(Clagett-Dame et al, 2005). NGF is an NTF, heavily implicated in promoting axonal 
outgrowth o f neurones by binding to NTF receptors (Connor & Dragunow, 1998; 
Williams et al, 2006; Allen & Dawbam, 2006). Therefore, the effects of NGF on 
Adamts9, expression in SHSY-5Y cells (differentiated or undifferentiated with RetA) 
was analysed. Also, the direct effect of RetA treatment on ADAMTS-9 mRNA 
expression levels was investigated under basal conditions by comparison with 
undifferentiated SHSY-5Y cells using real-time RT-PCR.
The effect of cytokines on neurones has not been as extensively studied as NTFs, 
largely due to the fact that glial cells have been shown to be the main responders to such 
mediators. However, neurones do express cytokine receptors, e.g. TGF-pRII is 
expressed predominantly in neuronal cells and decreased levels o f the receptor 
correlated with increased neurodegeneration in AD (Tesseur et al, 2006). Neurones are 
the target o f many destructive inflammatory pathways initiated in acute and chronic 
brain disorders. However, they also have the potential to contribute to such processes 
by intercellular interactions with other cell-types. To further characterise the expression 
of ADAMTS-9 in the brain, an analysis of mRNA expression by real-time RT-PCR was 
conducted in SHSY-5Y following treatment with a cohort o f pro- and anti-inflammatory 
cytokines.
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4 .4 .2  R esu lts
4.4.2.1 Comparison of Aggrecanase ADAMTS mRNA Expression in SHSY-5Y 
Cells under Basal Conditions
Real-time RT-PCR analysis demonstrated that the SHSY-5Y cell line expressed 
ADAMTS-4, -5 and -9 but not ADAMTS-1 under basal conditions. Average relative 
expression of Adamts9 (2'ACt = 0.05) was ~28-times greater than Adamts4 (0.002) and 
150 times greater than Adamts5 (0.0003) (Fig. 4.7).
4.4.2.2 Effect of RetA Differentiation of SHSY-5Y Cells on Morphology and 
ADAMTS-9 mRNA Expression Levels
Culturing of SHSY-5Y in the presence of 10° M RetA impacted on the morphology of 
the cells. Microscopic analysis of RetA-treated cells (Fig 4.8ii) appeared to have 
differentiated when compared to untreated (Fig. 4.8Ai). RetA-treated cells had branched 
neurite outgrowths and had an elongated morphology when compared to untreated cells, 
indicating that they were more differentiated (Clagett-Dame et al, 2005). Furthermore, 
there was a marked decrease in proliferation of the differentiated cells, which remained 
at the same confluency without the requirement for passaging following seven days of 
RetA treatment (as described previously by Encinas et al, 2000). In contrast, 
undifferentiated cells displayed a high rate of proliferation and required passaging 
regularly.
Figure 4.8B demonstrates that culturing SHSY-5Y cells in the presence of RetA 
triggered a statistically (p<0.05) significant increase in Adamts9 expression when 
compared to omitting RetA from the culture medium as detected by real-time RT-PCR. 
Expression of Adamts9 in RetA-treated cells (2'ACt= -0.7) was ~2-fold higher than in 
untreated cells (2'ACt= ~0.4).
4.4.2.3 Effects of T reatm ent of SHSY-5Y Cells with Cytokines and G row th Factors 
on Adamts9 Expression
No statistically (p>0.05) significant effects on ADAMTS-9 mRNA expression were 
observed in SHSY-5Y cells (cultured +RetA and -RetA) following 0-100 ng/mL of
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Figure 4.8 Effect o f RetA-Treatment on SHSY-5Y Neuroblastoma Cell Morphology 
and ADAMTS-9 mRNA Expression Levels
A
0.8 
0.6
2 ACt
0.4 
0.2 
0
A: Equal numbers of SHSY-5Y cells were cultured in a T-75 flask with (Aii) or without 
(Ai) 10'5 M RetA for 7 days prior to capturing of images (note treated cells have 
decreased proliferation compared to untreated). Arrows indicate neurite outgrowth 
processes. Images captured on a light microscope (Leica) (x200). B: Real-time RT-PCR 
analysis o f the effect of RetA on relative steady-state Adamts9 expression levels (2'ACt) 
in SHSY-5Y cells. Cells were cultured for 7 days with or without 10'5 M RetA prior to 
seeding cells at a density o f lx l0 5 cells/well into chamber slides (with or without 10'5 M 
RetA) where they were left for 48 h (1st 24 h with serum-rich medium, 2nd 24 h in 
serum-free medium) prior to extraction of RNA with TRI Reagent and cDNA synthesis. 
Real-time RT-PCR was performed in duplicate normalised to YWHAZ housekeeping 
gene expression. Results expressed as ± SEM from 21 independent experiments. 
Statistically significant difference o f Adamts9 expression between -RetA and +RetA 
cells expressed as * = p<0.05 (unpaired, 2-tailed T-test).
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- RetA + RetA
treatment with IL-1 p, IFN-y, TNF, TGF-01 and NGF (not shown). Also, the treatment 
of SHSY-5Y cells (cultured +RetA and -RetA) with both TNF and IL-1 p combined did 
not display a synergistic effect to increase or decrease Adamts9 expression to a 
statistically (p>0.05) significant level (not shown). Cells were cultured for seven days 
with or without 10'5 M RetA prior to seeding cells at a density of lx l0 5 cells/well into 
chamber slides (+10'5 M RetA or -RetA) where they were left to adhere for 24 h in 
serum-rich medium prior to treatment of factors for 24 h in serum-free medium. RNA 
was extracted with TRI Reagent and cDNA synthesised prior to performing real-time 
RT-PCR in duplicate normalised to YWHAZ housekeeping gene expression. 
Experiments were repeated independently three times.
4.5 Discussion
The study presented in this chapter is the first reported comprehensive analysis of 
ADAMTS-9 expression and modulation in brain-derived cells in vitro. ADAMTS-9 
mRNA was expressed by all the cells that were cultured in the study by detection with 
specific real-time RT-PCR primers. Furthermore, the treatment of cell cultures with 
various factors showed differential modulation of Adamts9 expression as summarised in 
Table 4.1.
4.5.1 Astrocyte Characterisation Discussion
The characterisation of the B327-01 and U373-MG cells demonstrated they were of 
astrocytic origin. The B327-01 astrocytes were not derived from a glioma and were 
extracted and isolated from an epilepsy patient without further modifications. However, 
the cells have been frozen and passaged (upto passage 6) and therefore are classified as 
a ‘cell line’. The problems encountered in attempting to achieve characteristic GFAP 
ICC staining of these astrocytes was likely due to the fact that the cells have become 
more differentiated since the extraction process. However, the strong S 100p staining 
and GFAP western blot confirms the B327-01 cells are a viable astrocytic cell 
population. The conclusions of the astrocytic characterisation would perhaps have been 
strengthened by performing an IgG negative control ICC, to confirm that staining was 
not a result of non-specific primary antibody binding. IgG controls were not conducted 
because of the highly characteristic astrocytic intermediate fllamental staining observed 
with the GFAP and SlOOp primary antibodies.
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4.5.2 Discussion of the Effects of Factors on ADAMTS-9 mRNA 
Expression in CNS-Derived Cells
The cloning of an isoform of ADAMTS-9 from an astrocyte cDNA library previously 
demonstrated that the peptidase was expressed by such cells in the rat (Clark et al, 
2000). These data in this study demonstrate that ADAMTS-9 was also expressed by 
human astrocytes because the mRNA was detected in three different astrocytic cultures 
with higher levels present in B327-01 cells. Real-time RT-PCR also confirmed that 
ADAMTS-9 mRNA was expressed by CHME3 microglia and SHSY-5Y neuroblastoma 
cells under basal conditions. Overall, these data suggest that glial cells and neurones in 
the human CNS have the potential to constitutively express ADAMTS-9 in vivo. Under 
basal conditions, ADAMTS-9 is the dominant ADAMTS proteoglycanase mRNA 
expressed by SHSY-5Y neuroblastoma cells, whereas it was demonstrated that SHSY- 
5Y cells do not express Adamtsl. This finding is in contrast to that obtained in another 
neuroblastoma cell line (N IE-115), in which ADAMTS-1 expression was detected by 
Sasaki et al (2001). The difference in ADAMTS-1 expression profile between the two 
neuroblastoma cell lines is likely attributed to the fact that SHSY-5Y cells are of human 
origin, whereas the N1E-115 cells are derived from mice.
In glial cells the effect of each pro-inflammatory cytokine on Adamts9 expression levels 
was variable. This was highlighted by IFN-y, which had no impact on Adamts9 
expression levels in U373-MG but significantly down-regulated expression in B327-01 
astrocytes as well as being the only cytokine to modulate an increase in the CHME3 
microglia cell line. In U373-MG, IL-1 p and TNF significantly increased Adamts9 
expression over control. IL-1 p also significantly up-regulated Adamts9 in B327-01 
astrocytes but TNF had no significant effect on these cells. In support o f these findings, 
modulation of Adamts9 expression by IL-1 p and TNF has been reported previously by 
Demircan et al (2005) in chondrocytes and by TNF in an RPE-derived cell line by 
Bevitt et al, 2003. Adamtsl has also been shown to be up-regulated by IL-1 p in rat 
chondrocytes (Gouze et al, 2006) and in a mouse colon adenocarcinoma cell line (Kuno 
et al, 1997).
Data generated by our group previously in the same glial cell cultures suggests to a 
certain extent that ADAMYS-9 modulation is comparable to that of other ADAMTS 
aggrecanases in the CNS. IL-1 p had a similar effect on Adamtsl in U373-MG and
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B327-01 as it did on Adamts9 by triggering an up-regulation of expression. In CHME3, 
IL-1 p had the same effect on ADAMTS-1, -4 or -5 mRNA expression as it did on 
ADAMTS-9 in that no modulation was detected. Furthermore, TNF modulated an 
increase in ADAMTS-1, -4 and -5 mRNA in U373-MG in a similar fashion to 
ADAMTS-9. In contrast to data obtained with ADAMTS-9, TNF also modulated 
transcription of Adamtsl and Adamts4 in CHME3 and B327-01 astrocytes (Cross et al, 
2006).
Expression of Adamts9 was not altered by treatment with any cytokines in the U87-MG 
cell line. This result adds to previous data from our laboratory with IL-1 p and TNF, in 
that neither cytokines influenced ADAMTS-1, -4 or -5 mRNA expression levels in this 
cell line (Haddock et al, 2003). In contrast, TGF-pi was shown in the same study to 
significantly down-regulate Adamtsl expression levels in U87-MG. U87-MG cells have 
responded previously to treatment with IL-1 p (Lai et al, 2005), IFN-y (Hotfilder et al, 
2007) and TNF (Sawada et al, 2004) by up-regulating expression of other factors 
suggesting that the necessary cytokine receptors are expressed.
The concentrations o f cytokines required to induce a statistically significant modulation 
of Adamts9 expression in glial cells were: 1 ng/mL (both IL-1 P and TNF) in U373-MG 
cells, 100 ng/mL (IL-ip) and 1 ng/mL (IFN-y) in B327-01 cells and 10 ng/mL (IFN-y) 
in CHME3 cells. These concentrations are likely to exceed physiological concentrations 
(Gouze et al, 2006) that are present in the normal brain but exposure to a full repertoire 
of cytokines during CNS inflammation potentially has a combined effect on the 
regulation of ADAMTS-9 in vivo. Cells were only tested following treatment with 
cytokines for 24 h in this study, whereas in vivo, cytokine exposure is a more persistent 
phenomenon thus regulation of ADAMTS-9 is potentially more marked. A reason for 
not seeing modulation of ADAMTS-9 mRNA expression by factors in certain cell lines 
was perhaps because the incorrect time-point was studied. Unfortunately, due to time 
constraints, the effect of treating cells with cytokines/GFs at different time-points could 
not be analysed. It would be important to ascertain whether the regulation of ADAMTS- 
9 expression is a transient or long-term effect. Therefore, a future direction of the study 
would be to treat cells for a shorter (6, 12 h) and longer (48 h to a week) period of time.
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4.5.3 Potential Implications for Cancer
A potential contributing factor for the varying results between the two astrocytoma cell 
lines is how advanced the tumours were from which the cells were derived. U373-MG 
cells were obtained from a grade 3 tumour (poorly differentiated) whereas the U87-MG 
cells were from a more advanced grade 3/4 tumour (poorly 
differentiated/undifferentiated). Hence, the U87-MG cells are likely to be less astrocytic 
than the U373-MG cells, which may explain the lower basal Adamts9 levels and lack of 
cytokine-induced modulation of expression in U87-MG. A more detailed study of 
ADAMTS-9 with such cell lines could perhaps be undertaken from a cancer perspective. 
Nakada et al (2005), showed that U87-MG cells transfected with ADAMTS-5 were 
more invasive through a gel containing brevican than cells transfected with a control 
vector. It would be useful to ascertain whether ADAMTS-9-transfected cells displayed 
similar migratory properties by degrading aggrecan, versican or other ECM components.
Alternatively, there is evidence from studies in oesophageal cancer to suggest that 
Adamts9 is potentially a tumour suppressor gene, despite the mechanism for this 
property being unknown. ADAMTS-9 was shown to be down-regulated in carcinoma 
cell lines and primary tumours. In addition, Adamts9 was identified in a tumour 
suppressive critical region of chromosome 3 (Lo et al, 2006). The finding that 
ADAMTS-9 protein was expressed in the nucleus in this study is perhaps linked to a 
role in tumour suppression by influencing cell fate such as transcriptional regulation and 
cellular proliferation/differentiation via breakdown of DNA-binding proteins. However, 
nuclear expression of ADAMTS-9 protein was surprising because it is has previously 
been shown to be localised at the cell surface (Koo et al, 2007). In support of the ICC 
data in this study, the shorter (118 kDa) ADAMTS-9 isoform (cloned by Clark et al, 
2000) was detected in the nucleus of mammary ECs during an extensive proteomics 
screen (Desrivieres et al, 2007). In the study, nuclear extraction was performed on a) 
cells maintained in a proliferative stage, b) competent cells or those differentiated for c) 
one or d) four days. Following electrophoresis-separation of the extracts, mass 
spectrometry was performed prior to a BLAST search. ADAMTS-9 was only detected 
in the nucleus following four days of differentiation of the cultured ECs. A future 
direction would be to assess how the localisation of ADAMTS-9 protein is influenced 
by treating cells with factors such as pro-inflammatory cytokines.
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ADAMTS-9 protein was also detected in the cytoplasm in this study where punctate 
staining suggested its location in vesicles, such as those in the secretory pathway. 
However, the ICC study of ADAMTS-9 in U373-MG cells is subject to conjecture 
because a) the species of ADAMTS-9 being detected is unknown because a number of 
bands were observed with the ADAMTS-9L2 antibody as shown by western blotting in 
Section 3.5 (a future direction would be to ascertain the identity of these bands by 
sequencing or mass spectrometry), b) a rabbit IgG negative control was not conducted 
to ascertain that the antibody is specific and c) the experiment was not repeated due to a 
having a finite quantity of the antibody. Therefore, the conclusion that ADAMTS-9 is 
expressed in the nucleus and cytoplasm of U373-MG cells cannot be made with 100% 
certainty.
4.5.4 Discussion of the Effects of Factors on ADAMTS-9 mRNA 
Expression in SHSY-5Y Cells
In contrast to the results using glial cells, no modulation of Adamts9 expression was 
observed in the SHSY-5Y neuroblastoma cell line with any of the pro- or anti­
inflammatory cytokines or TGF-pi and NGF. TGF-pi had a different effect on SHSY- 
5Y than had previously been shown with ECs, where the GF up-regulated ADAMTS-9 
mRNA expression (Keating et al, 2006). A future direction would be to assess a 
positive control gene that at least one of these stimuli would have induced to confirm 
that the cells possess the necessary receptors and intracellular signalling pathways. 
Detection of IL-8 modulation would be suitable because the mRNA of this chemokine 
has been shown to be up-regulated in SHSY-5Y cells following treatment with IL-1 P 
(Tixier et al, 2005). It was surprising to note that the effects of pro-inflammatory 
cytokines on Adamts9 expression were not increased following differentiation with 
RetA because many pro-inflammatory pathways in the CNS are triggered by the 
retinoid (Mey, 2005). The lack of a synergistic effect o f a combined treatment with IL- 
1 p and TNF was in contrast to the modulation of Adamts9 expression by both cytokines 
in chondrosarcoma cells (Demircan et al, 2005).
ADAMTS-9 mRNA levels were significantly raised in SHSY-5Y cells treated with 
RetA when compared to untreated cells. In cartilage explants, East et al (2007) detected 
an increase in ADAMTS-5 mRNA but not ADAMTS-9 in response to RetA treatment. 
However, explants were only exposed to RetA for a maximum of three days whereas
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differentiated SHSY-5Y cells were cultured permanently in the presence of RetA in this 
study. The implication of ADAMTS-9 mRNA expression being up-regulated by RetA 
in SHSY-5Y is that it points to a potential role for the proteinase in response to RetA 
signalling cascades in both the normal brain and pathology. RetA signalling is a key 
response to nerve injury resulting in regeneration, inflammation modulation and glial 
cell responses, processes in which ADAMTS-9 could be involved (Mey et al, 2005).
The role of RetA in the developing and adult CNS is critical, especially in neurogenesis 
by promoting neurite outgrowth from which axons and dendrites are formed (Clagett- 
Dame et al, 2005). ADAMTS-9 has been shown to be expressed in foetal brain tissue 
(Clark et al, 2000; Somerville et al, 2003; Jungers et al, 2005) and reports have 
implicated the peptidase in having a role in development and embryogenesis 
(Llamazares et al, 2003; Hesselson et al, 2004). Consequently, these data suggests that 
ADAMTS-9 is potentially a gene which is triggered in response to RetA during 
differentiation and growth of neurones during embryogenesis (as well as in adult tissue).
4.5.5 Limitations of In Vitro Cell Culture Study
The study presented in this chapter has a number of limitations including the fact that 
cells in vivo respond to many extracellular factors, which are difficult to recreate in vitro 
such as matrix components, interactions with other cell-types and fluctuations in 
environment (e.g. blood composition) and the presence of innate and humoral immune 
factors.
Due to problems with commercial antibody quality and only having finite amounts of 
the effective ADAMTS-9L2 antibody, analysis of ADAMTS-9 at the protein level was 
limited to ICC analysis of the cellular localisation in U373-MG. Future work with an 
effective antibody would involve repeating this work (with an IgG control) as well as 
analysing ADAMTS-9 protein levels within cell extracts as well as in the culture media 
(to assess secreted levels) by western blotting. This would prove useful to ascertain 
whether protein levels correlated with the real-time RT-PCR data presented here. 
Furthermore, comparative real-time RT-PCR data are only a relative value which allows 
one to compare expression levels between the samples studied. It is not a reflection of 
actual copy number (which would require known amounts of RNA standards to 
calculate) within the cell.
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4.5.6 Summary
In summary, these data presented in this chapter provide evidence that a) ADAMTS-9 is 
expressed at the mRNA level by CNS-derived cells in vitro under basal conditions, b) 
ADAMTS-9 mRNA expression is modulated in glial cells by pro-inflammatory 
cytokines in vitro, c) ADAMTS-9 mRNA expression is up-regulated by RetA in the 
SHSY-5Y cell line in vitro and d) ADAMTS-9 protein potentially has a role within the 
cell nucleus. Consequently, this work provides preliminary evidence that ADAMTS-9 is 
involved in normal physiological processes and CNS inflammatory disorders.
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Chapter 5
ADAMTS-9 Expression and 
Modulation in Cerebral Ischaemia
148
5.1 Background
These data in Chapter 4 indicate that IL-ip was a potent inducer o f Adamts9 expression 
(especially in astrocytes). IL-1 p has been heavily implicated as a mediator of 
inflammation following cerebral ischaemia to the point that IL-lra has been 
successfully tested therapeutically in human stroke clinical trials (Emsley et al, 2005). 
Furthermore, a previous study by our laboratory showed that proteoglycanases 
ADAMTS-1 and ADAMTS-4 were up-regulated following tMCAo, in the rat (Cross et 
al, 2006). Therefore, a study of ADAMTS-9 in stroke was conducted by utilising the 
tMCAo rat model of cerebral ischaemia. In addition, a bioinformatical screen of the 
human ADAMTS-9 potential promoter region was conducted to assess whether it 
contained the binding site for HIF-1, a transcription factor heavily implicated in stroke.
5.2 ADAMTS-9 Expression in tMCAo Rat Model of Focal 
Cerebral Ischaemia
5.2.1 Overview of Approach
Many of the characteristics of human stroke i.e. necrosis, infarction, time-delayed 
responses, reperfusion and recovery can be modelled in animals. MCAo (transient or 
permanent) in rodents is the most widely used model of stroke with the technique 
offering many advantages including: a) it does not require craniotomy, b) focal 
occlusion in the large cerebral artery mimics the most common cause of stroke in 
humans and c) the technique is well established and routinely performed (Garcia et al, 
1995). The main limitation of the model is that rodents can have difficulty eating 
because the technique involves cutting the external carotid artery (ECA) in order to 
access the MCA with the thread. Following MCAo, cell death has been shown to follow 
a time-course highly similar to that in humans with infarction occurring early in the 
striatum prior to delayed infarction in the dorsolateral cortex involving BBB opening 
(Garcia et al, 1995). The early stages are characterised by expression of hypoxia- 
induced genes whereas in the progressive phase neutrophils are present and many 
inflammatory mediators can be detected such as TNF and IL-1 p (Carmichael, 2005).
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Analysing ADAMTS-9 protein (by western blotting) and mRNA (by real-time RT-PCR) 
levels at 6, 24 and 120 h following reperfusion allows the assessment of whether the 
peptidase is up-regulated in the early necrotic phase or in the latter inflammatory stage 
of stroke. It also gives a clue as to whether ADAMTS-9 expression correlates with 
recovery of neuronal function i.e. when symptoms lessen after a number of days. The 
ADAMTS-9L2 antibody was utilised for western blotting, unfortunately, due to limited 
quantities (and a lack of a suitable commercial antibodies), IHC on tMCAo tissue 
sections could not be performed to analyse protein localisation in this study.
JSH. was performed to determine the cellular origin of ADAMTS-9 by comparison with 
IHC of known cellular markers (e.g. GFAP, NeuN, EDI, vWF) utilising serial sections. 
Furthermore, ISR  enabled the assessment of the morphology of the cells expressing 
Adamts9, providing additional evidence as to cell-type. Unfortunately, this technique 
could not be used to compare changes in the localisation of Adamts9 expression 
between tMCAo and sham brains due to variations in tissue quality between samples 
(i.e. some samples had degraded over time). Also, the technique was not used to 
quantify expression levels (e.g. by a grading system) because the comprehensive real­
time RT-PCR study was a more sensitive and quantitative method.
5.2.2 Results
5.2.2.1 Analysis of ADAMTS-9 mRNA Expression Levels in tMCAo Tissue 
6 Hours
At 6 h, ADAMTS-9 mRNA was up-regulated in the ipsilateral hemispheres (IHs) o f all 
five animals subjected to tMCAo when compared to the contralateral hemispheres (CHs) 
of the same brain (front and back regions combined for each hemisphere) (Fig. 5.1). The 
relative increases in expression were statistically significant. The means o f the relative 
levels (2'ACt) of ADAMTS-9 mRNA expression for the IHs (front and back combined) 
of the tMCAo brains were 0.004, 0.049, 0.026, 0.024 and 0.017 compared to the 
respective CH means of the same brains; 0.002, 0.024, 0.005, 0.010 and 0.008. No 
statistically significant differences between the IHs and CHs were detected in the brains 
of the two sham operated animals at 6 h post-procedure as shown in Figure 5.1.
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Figure 5.1 Relative Levels of ADAMTS-9 mRNA Expression in Rat Brains 6 H Post-tMCAo or Sham-Operation
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24 Hours
Figure 5.2 shows that in all four rat brains analysed at 24 h post-tMCAo, ADAMTS-9 
mRNA expression was up-regulated in the IHs when compared to the CHs of the same 
brain. The increases were statistically significant. The means of the 2'ACt values of 
ADAMTS-9 mRNA expression for the IHs of the tMCAo brains were 0.037, 0.034, 
0.028 and 0.009 compared to the respective CH means of the same brains; 0.008, 0.007, 
0.003 and 0.002. In contrast, no statistically significant differences between the IHs and 
CHs were detected in any of the brains of the four sham-operated animals at 24 h post­
procedure (Fig. 5.2).
120 Hours
At 120 h post-tMCAo, all three brains analysed displayed a statistically significant up- 
regulation of ADAMTS-9 expression in the IHs when compared to the CHs of the same 
brain as shown in Figure 5.3. The means of 2 'ACt values of ADAMTS-9 mRNA 
expression for the IHs of the tMCAo brains were 0.013, 0.003 and 0.003 compared to 
the respective CH means of the same brains; 0.004, 0.001 and 0.001. Similarly to the 
results at 6 and 24 h post-procedure, no statistically significant differences between the 
IHs and CHs were observed in sham-operated animals after 120 h (Fig. 5.3).
All Time-Points (Pooled Data)
The pooled data from all the time-points studied (as shown in Figure 5.4) demonstrates 
that ADAMTS-9 mRNA was up-regulated significantly at 6, 24 and 120 h post-tMCAo. 
At 6 h, ADAMTS-9 mRNA levels were significantly increased ~3-fold (p<0.001) in the 
IHs (2’ACt = 0.024) of tMCAo brains when compared to the CHs (2'ACt = 0.008) of 
tMCAo brains. In addition, Adamts9 expression was significantly (p<0.001) up- 
regulated ~ 9-fold in the IHs of tMCAo brains at 6 h post-operation when compared to 
the sham-operated (2"ACt = 0.003) animals (all regions pooled) at the same time-point. 
Also, the CHs of tMCAo brains expressed ~3-fold higher levels (statistical significance 
= p<0.01) of ADAMTS-9 mRNA when compared to sham-operated tissue (IHs and 
CHs combined) (Fig. 5.4).
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Figure 5.2 Relative Levels of ADAMTS-9 mRNA Expression in Rat Brains 24 H Post-tMCAo or Sham-Operation
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Figure 5.3 Relative Levels of ADAMTS-9 mRNA Expression in Rat Brains 120 H Post-tMCAo or Sham-Operation
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Figure 5.4 Relative Levels of ADAMTS-9 mRNA Expression in Rat Brains at all Time-Points following tMCAo or Sham-Operation
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At 24 h, the pooled data shown in Figure 5.4 demonstrates that ADAMTS-9 mRNA 
expression was significantly raised in the IHs (2‘ACt = 0.027) of tMCAo brains 
whencompared to the CHs (2'ACt = 0.005) from tMCAo and sham-operated hemispheres 
(2'act = 0.002). The statistically significant (pO.OOl) difference in expression between 
both tMCAo hemispheres was ~6-fold whereas a 13-fold increase was observed 
between IHs of tMCAo brains compared to sham (pO.OOl). In addition, the CHs of 
tMCAo brains expressed ~2-fold higher levels (statistical significance = p<0.01) of 
ADAMTS-9 mRNA when compared to sham-operated tissue (IHs and CHs combined) 
at 24 h (Fig. 5.4).
Although mean relative expression levels were lower than those detected after 6 and 24 
h, statistically significant increases in ADAMTS-9 mRNA were observed in the IHs of 
tMCAo when compared to CHs of tMCAo brains and sham-operated brains (both 
pO .O l) at 120 h as demonstrated in Figure 5.4. The tMCAo IHs (0.007) displayed ~3- 
times higher ADAMTS-9 mRNA expression than the tMCAo CHs (0.002) and 4-times 
more than sham brain hemispheres (0.002). In contrast to data at 6 and 24 h, the CHs of 
tMCAo brains expressed no statistically significant (p>0.05) differences in ADAMTS-9 
mRNA levels when compared to sham-operated tissue (IHs and CHs combined) at 120 
h (Fig. 5.4).
5.2.2.2 Analysis of ADAMTS-9 Protein Expression Levels in tMCAo Tissue
The representative image in Figure 5.5 of western blotting with anti-P-actin antibody 
demonstrates that equal protein levels (6 pg) were loaded between samples in the 
tMCAo study. At 6 h post-tMCAo/sham-operation, five main bands were detected with 
the ADAMTS-9L2 antibody at -98, 62, 49, 39 and 35 kDa as shown in Figure 5.6i. 
Densitometrical analysis demonstrated that the sum of the IODs of all the ADAMTS-9 
protein bands detected were lower in CHs of sham brains when compared to IHs of 
sham brains and tMCAo brains (Fig 5.6ii).
At 24 h post-procedure, a -188 kDa band was observed in tMCAo samples but not in 
sham-operated brains as shown by the western blot in the Figure 5.7i. Densitometrical 
analysis indicated that higher levels o f the -188 kDa protein were present in the CHs of 
tMCAo brains when compared to the IHs (Fig 5.7ii). Bands at -80  (faint) and 50 kDa 
were also observed with slightly higher levels of the former in tMCAo IH samples when
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Fig. 5.5 Legend: Western blotting analysis of tMCAo and sham-operated rat brains 
with anti-P-actin antibody as a protein loading control. Protein was extracted from tissue 
with TRI Reagent prior to determination of protein concentration by BCA assay. SDS- 
PAGE (10%) was performed with 6 pg protein/well before transferring separated 
proteins to nitrocellulose membrane and western blotting. Neg. = western blotting 
whereby the primary antibody was omitted from the protocol (replaced by TBS), which 
served as a control for assessment of non-specific binding of the secondary antibody. 
Image is representative of all western blotting in this study. Note: protein levels were 
comparable across the samples.
Fig. 5.6 Legend: Western blotting analysis of tMCAo and sham-operated rat brains at 6 
h post-procedure with ADAMTS-9L2 antibody (5.6i). Protein was extracted from tissue 
with TRI Reagent prior to determination of protein concentration by BCA assay. SDS- 
PAGE (10%) was performed with 6 pg protein/well before transferring separated 
proteins to nitrocellulose membrane and western blotting. Peptide blocking was 
performed with the ADAMTS-9L2 'immunising peptide' to assess non-specific binding 
of the primary antibody (PB). NC (negative control) = western blotting whereby the 
primary antibody was omitted from the protocol (replaced by TBS), which served as a 
control for assessment of non-specific binding of the secondary antibody. Densitometry 
was performed on detected bands using the Lab Works Image Acquisition and Analysis 
Software to semi-quantify expression levels by measuring the IODs. The sum of the 
IODs of the three bands (-98, 62, 49, 39 and 35 kDa) detected in each hemisphere for 
sham and tMCAo brains are presented in graphical form (front and back regions 
combined) (5.6ii).
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Figure 5.5 Protein Loading Control for tMCAo Western Blotting Study
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Western blotting analysis of tMCAo and sham-operated rat brains at 24 h post­
procedure with ADAMTS-9L2 antibody (5.7i). Protein was extracted from tissue with 
TRI Reagent prior to determination of protein concentration by BCA assay. SDS-PAGE 
(10%) was performed with 6 pg protein/well before transferring separated proteins to 
nitrocellulose membrane and western blotting. Peptide blocking was performed with the 
ADAMTS-9L2 'immunising peptide' to assess non-specific binding of the primary 
antibody (PB). NC (negative control) = western blotting whereby the primary antibody 
was omitted from the protocol (replaced by TBS), which served as a control for 
assessment of non-specific binding of the secondary antibody. Densitometry was 
performed on detected bands using the LabWorks Image Acquisition and Analysis 
Software to semi-quantify expression levels by measuring the IODs. The sum of the 
IODs of the three bands (-188, 80 and 50 kDa) detected in each hemisphere for sham 
and tMCAo brains are presented in graphical form (front and back regions combined) as 
well as the IODs for the individual -188 and 80 kDa bands (5.7ii).
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Figure 5.7 Expression of ADAMTS-9 Protein in Rat Brains at 24 H Post-tMCAo or
Sham-Operation
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compared to sham as detected by densitometry (Fig. 5.7ii). The sum of the IODs of all 
the bands detected with the ADAMTS-9L2 antibody were higher for tMCAo brains 
when compared to sham as shown by the densitometry graph in Figure 5.7ii.
Five days (120 h) post-procedure, bands were observed at -140, 64 and 38 kDa in both 
tMCAo and sham-operated samples (Fig 5.8i). The densitometry shown in Figure 5.8ii 
indicates that the sum of the IODs of all the bands observed with the ADAMTS-9L2 
antibody were higher in IHs of sham brains compared to IH and CHs of tMCAo tissue. 
Whereas, the CHs of sham-operated brains had less ADAMTS-9 protein than the IH 
and CHs of tMCAo tissue (Fig. 5.8ii).
5.2.2.3 Cellular Origin of ADAMTS-9 mRNA in tMCAo Tissue
Identification and characterisation of ADAMTS-9-positive cells was performed with the 
kind assistance of neuropathologist Dr. Stephen Wharton (The University of 
Sheffield/Royal Hallamshire Hospital, Sheffield, UK).
Intense ADAMTS-9 mRNA expression in large cells of the cerebral cortex, thalamus 
and the dentate gyrus/Comu Ammonis (CA3) of the hippocampus of tMCAo tissue 
sections is demonstrated in Figures 5.9A, C and E). The localisation of NeuN 
expression in large cells (neurones) was comparable to that of ADAMTS-9 mRNA 
expression described above as shown by IHC (Fig. 5.9B, D and F). Furthermore, 
ADAMTS-9 mRNA was detected in smaller cells of the same regions as shown in 
Figures 5.9A, C and E. The H&E stains in Figures 5.9M and N confirmed which 
regions of the brain were being studied.
ADAMTS-9 mRNA expression was not detected in cells which were positive for vWF 
(detected by IHC and shown in Fig. 5.9J) i.e. blood vessels. Figure 5.9H shows 
representative GFAP staining localised around the blood vessels of the leptomeninges 
whereas Figure 5.91 demonstrates that expression of this protein was localised globally 
in the hippocampus. GFAP protein and ADAMTS-9 mRNA did not appear to be 
localised in exclusively the same regions. The smaller cells, possibly glial cells, 
expressing Adamts9 potentially also express GFAP.
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Western blotting analysis of tMCAo and sham-operated rat brains at 120 h post­
procedure with ADAMTS-9L2 antibody (5.8i). Protein was extracted from tissue with 
TRI Reagent prior to determination of protein concentration by BCA assay. SDS-PAGE 
(10%) was performed with 6 pg protein/well before transferring separated proteins to 
nitrocellulose membrane and western blotting. Peptide blocking was performed with the 
ADAMTS-9L2 'immunising peptide' to assess non-specific binding of the primary 
antibody (PB). NC (negative control) = western blotting whereby the primary antibody 
was omitted from the protocol (replaced by TBS), which served as a control for 
assessment of non-specific binding of the secondary antibody. Densitometry was 
performed on detected bands using the LabWorks Image Acquisition and Analysis 
Software to semi-quantify expression levels by measuring the IODs. The sum of the 
IODs of the three bands (-140, 64 and 38 kDa) detected in each hemisphere for sham 
and tMCAo brains are presented in graphical form (front and back regions combined) 
(5.8ii).
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Figure 5.8 Expression of ADAMTS-9 Protein in Rat Brains at 120 H Post-tMCAo or
Sham-Operation
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75H detection of Adamts9 (antisense probe) (A, C, E) and IHC detection of 
NeuN (B, D, F), GFAP (H, I) and vWF (J) in tMCAo (24 h) tissue sections. 
Images M and N are H&E stains. ZSH with the sense probe served as a 
control of ADAMTS-9 riboprobe specificity (G). IHC negative controls 
(omission of primary antibody from protocol as control for non-specific 
binding of the secondary antibodies) for GFAP (K) and vWF (L) are 
included. A, B, H, J, L and M are serial sections of the same region 
(leptomeninges [LM]/cerebral cortex [CC]/thalamus [T]). C, D and G are 
taken from the same region as A, B, H, J, L and M but showing more 
cerebral cortex (view shifted up). E, F, I, K and N are serial sections from 
the same region (hippocampus). Black Arrows represent Adamts9-positive 
large cells (neurones). Red arrows represent Adamts9-positive small cells 
(potentially glia). BV = blood vessel, DG = dentate gyrus, Cornu Ammonis 
field 3 = CA3. Images were taken on an Olympus BX60 microscope in 
fluorescent mode (IHC) or bright-field mode (ISR  and H&E) (xlOO).
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Figure 5.9 Cellular Expression of ADAMTS-9 mRNA Expression in tMCAo Tissue
Sections
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ISH detection of Adamts9 (antisense probe) (A, C, E) and IHC detection of 
NeuN (B, D, F), GFAP (H, I) and vWF (J) in tMCAo (24 h) tissue sections. 
Images M and N are H&E stains. 75H with the sense probe served as a 
control of ADAMTS-9 riboprobe specificity (G). IHC negative controls 
(omission of primary antibody from protocol as control for non-specific 
binding of the secondary antibodies) for GFAP (K) and vWF (L) are 
included. A, B, H, J, L and M are serial sections of the same region 
(leptomeninges [LM]/cerebral cortex [CC]/thalamus [T]). C, D and G are 
taken from the same region as A, B, H, J, L and M but showing more 
cerebral cortex (view shifted up). E, F, I, K and N are serial sections from 
the same region (hippocampus). Black Arrows represent Adamts9-positive 
large cells (neurones). Red arrows represent Adamts9-posi\ivQ small cells 
(potentially glia). BV = blood vessel, DG = dentate gyrus, Cornu Ammonis 
field 3 = CA3. Images were taken on an Olympus BX60 microscope in 
fluorescent mode (IHC) or bright-field mode (ZSH and H&E) (xlOO).
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Figure 5.9 cont. Cellular Expression of ADAMTS-9 mRNA Expression in tMCAo 
Tissue Sections
100 um i
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Identification of specific brain regions was achieved by analysis of H&E staining, IHC 
(of cellular markers) and ISR  signal. Sections incubated with the sense strand (Fig. 5.9G) 
and no probe displayed only background ISR  signals. IHCs performed without the 
incubation of the primary antibodies (replaced by PBS) showed no 
fluorescent signal (Fig. 5.9K and L). Therefore, these data suggest that neurones and 
potentially glial cells express ADAMTS-9 mRNA in tMCAo tissue.
5.2.2.4 Morphological Analysis of Adamts9-Positive Cells in tMCAo Tissue
Expression of ADAMTS-9 mRNA was detected in pyramidal neurones of the cerebral 
cortex (Fig. 5.10A), dentate gyrus of the hippocampus (Fig. 5.1 OB) and CA3 of the 
hippocampus (Fig. 5 .IOC). The cells were large and triangular/conical in morphology, 
characteristic of pyramidal neurones (Lopez-Gallardo & Prada, 2001). Adamts9 was 
also detected in the densely arranged granular neuronal cells of the dentate gyrus (Fig.
5.1 OB). Smaller cells also expressed Adamts9 as shown in Figure 5.10A, B and C. Such 
cells were not as morphologically distinct as the neuronal cells but they are likely to be 
glia based on the size. Sections incubated with the sense strand (Fig. 5.10D) displayed 
only faint background signals. Consequently, these data strongly suggest that different 
neuronal cell-types express ADAMTS-9 mRNA and indicates that glial cells are 
potentially also expressing the peptidase.
5.4 Discussion
These data presented in this chapter represents the first study of ADAMTS-9 in a CNS 
inflammatory disorder. It demonstrates that ADAMTS-9 is up-regulated at the mRNA 
level following tMCAo and that the mature-form (-188 kDa) is present 24 h post­
occlusion, although the absence of this species at 6 and 120 h may be due to the protein 
extraction method (see Section 3.5.3). Furthermore, these data shows that Adamts9 is 
expressed by neurones and potentially glia in vivo as shown by ZSH analysis of tMCAo 
tissue sections.
The real-time RT-PCR data provide strong evidence that the transcription of Adamts9 is 
modulated by pathological conditions mimicking those that occur in response to 
cerebral ischaemia in humans. Statistically significant increases in ADAMTS-9 mRNA 
expression were detected in all tMCAo IHs when compared to tMCAo CHs and sham-
172
Figure 5.10 Neuronal expression o f ADAMTS-9 mRNA
ISR  detection of Adamts9 (antisense probe) in A) cerebral cortex, B) dentate gyrus of 
the hippocampus and C) CA3 of the hippocampus of tMCAo (24 h) tissue sections. Full 
black arrows represent Adamts9-positive pyramidal neurones. Arrowheads represent 
Adamts9-positive granular neurones. Red arrows represent smaller Adamts9-yos\\\vQ 
cells (potentially glia). Z5H with the sense probe served as a control o f ADAMTS-9 
riboprobe specificity (D). Images A and D are from the same brain region. Images were 
taken on an Olympus BX60 microscope in bright-field mode (x 400).
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operated animals at all time-points post-procedure (twelve tMCAo brains versus nine 
sham brains). These data are in contrast to ADAMTS-5 mRNA expression levels, which 
were generally not altered in the tMCAo model as shown previously by our laboratory 
(Cross et al, 2006).
5.4.1 Implications of ADAMTS-9 mRNA and Protein Data at 6 Hours 
Post-tMCAo
A rapid increase in ADAMTS-9 mRNA expression at 6 h post-tMCAo was detected. 
The initial hypoxic stages of stroke involve the up-regulation of transcription factors 
such as HIF-1 and NF-kB (Dimagl et al, 1999), a process which involves IL-ip (Yao et 
al, 2006; Jung et al, 2003). There is evidence that IL-lp is important in the early stages 
following stroke because IL-lra was only effective when administered 3 h post-MCAo 
as opposed to 8-12 h (Toulmond & Rothwell, 1995). As shown in Chapter 4, IL-ip up- 
regulated ADAMTS-9 expression in CNS-derived cells in vitro. Therefore, such IL-ip- 
mediated modulation is potentially responsible for the increased levels of Adamts9 
expression shown in brains at 6 h post-tMCAo in vivo.
However, the increase in ADAMTS-9 mRNA expression did not correlate with an 
increase in protein expression in tMCAo brains at 6 h. Western blotting with 
ADAMTS-9L2 antibody detected no variation in the intensity o f bands between tMCAo 
and sham-operated protein extracts. The detected bands at ~98, 62, 49, 39 and 35 kDa 
were not present following western blotting with the peptide-blocked antibody or 
negative control (no primary antibody) suggesting that they represent ADAMTS-9 
fragments as opposed to being a result of non-specific binding. However, given that 
Demircan et al (2005) reported non-specific binding of the antibody (albeit with no 
evidence for this i.e. peptide blocking experiments were not performed), it cannot be 
said with 100% confidence that the antibody is entirely specific. Given the fact that the 
proteins are considerably smaller than the -188 kDa mature form (Somerville et a\, 
2003) of the enzyme, the bands are likely to be a result of ADAMTS-9 processing (see 
Fig. 1.5). The band at -98 kDa could potentially correspond to the 100 kDa band 
described previously as representing ADAMTS-9 following cleavage of the prodomain, 
GON domain and TSP-ls 9-15 (Koo et al, 2007). However, Demircan et al (2005) 
previously detected a band at 100 kDa with the ADAMTS-9L2 antibody but dismissed 
it as being a result of non-specific binding to proteins other than ADAMTS-9. The small
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size of the proteins at -62 , 49, 39 and 35 kDa detected at 6 h are likely to represent 
ADAMTS-9 fragments containing the 2nd linker domain (to which the antibody is raised) 
but lacking most domains N- and C-terminus to it (including the metalloproteinase 
domain) i.e. in-active forms.
The fact that ADAMTS-9 expression is raised at the mRNA level but not the protein 
level after 6 h is probably a result of insufficient time elapsing for protein translation to 
have occurred to a detectable level. However, another potential explanation is 
translational (post-transcriptional) control of gene expression, which has been compared 
to (pre-) transcriptional control (e.g. cytokine modulation) in terms of importance (Mata 
et al, 2005). Post-transcriptional control involves the suppression of protein synthesis by 
a number o f mechanisms including mRNA turnover (decay) and repression of 
translation (Wouters et al, 2005).
Pertinent to the 6 h ADAMTS-9 data is the widely reported finding that hypoxia can 
cause a rapid inhibition of the initiation step of mRNA translation. Hypoxia suppresses 
translation by triggering phosphorylation (and inhibition) of eukaryotic initiation factors 
(eIF2a and eIF4F), which are critical for facilitating the recruitment of the ribosomal 
subunit prior to loading onto the mRNA (Wouters et al, 2005; van den Beucken et al, 
2006). Therefore, the rapid depletion of oxygen following tMCAo may have led to the 
increase in ADAMTS-9 mRNA levels via pro-inflammatory mediators, whereas 
ADAMTS-9 protein synthesis was potentially inhibited by hypoxia-induced inhibition 
of translation.
5.4.2 Implications of ADAMTS-9 mRNA and Protein Data at 24 Hours 
Post-tMCAo
At 24 h post-tMCAo, ADAMTS-9 mRNA expression was comparable to those detected 
at 6 h. This was in contract to ADAMTS-1 (~4-fold) and ADAMTS-4 (2-fold), mRNA 
levels of which were higher at 24 h than at 6 h post-tMCAo as detected by our 
laboratory previously (Cross et al, 2006). Importantly, the mature-form of ADAMTS-9 
protein was only detected by western blotting (-188 kDa band) in tMCAo brains and 
not in sham-operated tissue at 24 h. The deduced Mj o f the mature form of ADAMTS-9, 
lacking the prodomain is 184 kDa but this is likely to be higher (>185 kDa) given that 
there are nine consensus sites for AMinked glycosylation (Somerville et al, 2003). The
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-188 kDa band observed in this study was the same size as that detected by western 
blotting previously with the ADAMTS-9L2 antibody (Demircan et al, 2005). The 
finding that the CHs of tMCAo brains contained higher levels of mature ADAMTS-9 
protein than the IHs was surprising given that ADAMTS-9 mRNA levels were higher in 
the IHs when compared to CHs (discussed further in Section 5.4.4).
Bands at -80  and 50 kDa were detected by western blotting in tMCAo and sham- 
operated brains at 24 h, which suggests they represent ADAMTS-9 fragments 
containing the 2nd linker domain as they were absent following blocking of the antibody 
with the immunising peptide. However, it cannot be ruled out that the presence of the 
detected bands may be due to non-specific binding of the antibody to proteins other than 
ADAMTS-9 (Demircan et al, 2005). The -8 0  kDa band was slightly more intense in the 
IHs of tMCAo brains than sham-operated brains perhaps a result o f there being more 
overall ADAMTS-9 protein in the tissue prior to processing. The band at -5 0  kDa is 
likely to represent the same fragment detected at 6 h (-49 kDa).
5.4.3 Implications of ADAMTS-9 mRNA and Protein Data at 120 
Hours Post-tMCAo
ADAMTS-9 mRNA levels were decreased by 120 h post-stroke when compared to 
earlier time-points. However, despite levels being lower than at 6 and 24 h, Adamts9 
levels remained significantly higher in tMCAo IHs when compared to tMCAo CHs and 
sham-operated brains at 120 h. This is in contrast to ADAMTS-1 and ADAMTS-4 
levels in tMCAo IHs, which were not significantly higher than sham-operated or 
tMCAo CHs at 120 h (Cross et al, 2006).
No difference in ADAMTS-9 protein levels were detected between tMCAo and sham- 
operated brains at 120 h by western blotting with ADAMTS-9L2 antibody. The three 
bands detected by western blotting of brain protein extracts at 120 h were at -140, 64 
(both faint) and 38 kDa. The bands were not present following peptide blocking or 
western blotting with the omission of the primary antibody. However, the bands may 
still have been a result of the antibody binding to non-ADAMTS-9 proteins (Demircan 
et al, 2005). The -64  kDa band is likely to represent the same ADAMTS-9 fragment 
observed at -62  kDa in the 6 h brains whereas the -38  kDa band potentially represents 
an ADAMTS-9 species following further processing. Neither the -64  kDa nor -38  kDa
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forms of ADAMTS-9 will have retained their metalloproteinase domain because the 
fragments are too small (see Fig. 1.5), thus they are likely to be proteolytically inactive. 
However, the very faint band observed at -140 kDa is potentially important because it 
is likely to still contain the metalloproteinase. The -140 kDa protein is -48  kDa less 
than the reported mature-form, which was detected in tMCAo brains at 24 h suggesting 
that further C-terminal processing has occurred. The finding that the -188 kDa form of 
ADAMTS-9 was not detected at 120 h, but processed forms were, suggests that the 
half-life of the protein is quite short and it has been broken down.
5.4.4 Overall Discussion of tMCAo Real-Time RT-PCR and Western 
Blotting Data
The early stages post-stroke are the most crucial with many clinical trials failing 
because administration occurred outside the 'temporal window of efficacy' (Dimagl et al, 
1999). Therefore the findings in this study that ADAMTS-9 mRNA is up-regulated 
rapidly following tMCAo (6 h and 24h) and the mature enzyme (protein) is expressed at 
24 h in tMCAo brains is important. Many of the mediators o f stroke have well-defined 
time courses of increasing, peaking and decreasing expression levels following 
ischaemia, which may or may not correlate with the pattern of ADAMTS-9 expression 
(by modulating expression) observed in this study. Experiments in the rat have shown 
that TNF (which up-regulated Adamts9 in U373-MG) expression started to increase at 2 
h post-ischaemia prior to peaking at 12 h and remaining high for 24 h before returning 
to normal levels at 120 h. Whereas IL-ip levels started to rise at 4 h, peaked at 24 h 
before returning to normal at 120 h (Perera et al, 2006). Furthermore, our laboratory has 
shown previously that IL-ip and TNF mRNA were increased in tMCAo IHs when 
compared to tMCAo CHs and sham brains at 24 h. However, the impact of IL-ip may 
be nullified by IL-lra levels, which were also higher in tMCAo at the mRNA level at a 
statistically significant level (Cross et al, 2006).
The finding that ADAMTS-9 mRNA expression was raised in the CHs of tMCAo 
brains when compared to both hemispheres of sham-operated tissue (at 6 and 24 h) was 
important because it suggests that the ischaemia had a systemic effect. This was 
potentially a result of decreased blood-flow to the CHs caused by tMCAo or a 
consequence of activated cells (and therefore pro-inflammatory mediators) migrating 
from the IHs to the CHs. Such responses may explain to a certain extent why higher
177
levels o f the mature-form of ADAMTS-9 protein were detected in the CHs when 
compared to the IHs in tMCAo brains at 24 h. Furthermore, ADAMTS-9 protein 
potentially had a shorter half-life in the IHs because of its breakdown by up-regulated 
proteinases e.g. MMPs, whereas the ~188 kDa was still readily detectable in the CHs. 
To confirm this theory, intervening time-points would need to be studied such as 12, 16 
and 20 h post-operation.
It is likely that TIMP-3 is the natural inhibitor of ADAMTS-9 in vivo (Hashimoto et al, 
2001). Previous studies in our laboratory showed that TIMP-3 levels remained constant 
between tMCAo IHs, tMCAo CHs and sham-operated brains at all time-points post­
procedure (Cross et al, 2006). Therefore, the increase in mature-ADAMTS-9 detected at 
24 h was potentially not counteracted by an increase in TIMP-3, thus the enzyme could 
be contributing to the pathological consequences of a stroke or aiding in recovery.
5.4.5 Cellular Origin of ADAMTS-9 Discussion
The ISR  study provided strong evidence that neurones are the predominant cell-type 
expressing ADAMTS-9 in tMCAo rat brains because the distribution of ADAMTS-9 
mRNA expression was comparable with NeuN expression (shown by IHC). High- 
magnification morphological analysis of ISR  and the fact that specific neuronal , 
populations are characteristically present in distinct brain regions confirmed that , 
pyramidal neurones and granular neurones were Adamts9-positive. The finding that 
Adamts9 is expressed in the cerebral cortex is supported by Jungers et al (2005), who 
also detected (with a radiolabeled version of the riboprobe used in this study) the 
mRNA in the cerebral cortex of embryonic mouse brains, however, no cell-types were 
identified.
In addition to neurones, there were smaller cells which were positive for Adamts9 but 
NeuN-negative and therefore are likely to be glia. Although GFAP was expressed in the 
regions of Adamts9-positive small cells it was difficult to determine whether the ISR  
signal was from astrocytes. This is because whereas NeuN is particularly useful for 
deducing co-localisation with mRNA because it is a marker for neuronal nuclei, 
whereas GFAP is an intermediate filament protein that is present in processes which are 
distant from the cell nucleus. Therefore, it cannot be confirmed that these Adamts9-
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positive cells were astrocytes but it cannot be ruled out especially given that such cells 
express Adamts9 in vitro as shown in Chapter 4.
As well as astrocytes, the small cells could potentially be microglia/macrophages or 
infiltrating inflammatory cells. It was demonstrated that a microglia cell line (CHME3) 
expressed ADAMTS-9 in vitro (Chapter 4), therefore an antibody against EDI 
(microglia/macrophage marker) was used for IHC of tMCAo tissue sections in an 
attempt to confirm this finding in vivo. Unfortunately, despite using varying dilutions of 
primary and three separate secondary antibodies and attempting both AP-BCIP/NBT 
and fluorescent detection (see Table 2.6), non-specific binding (high-background 
staining) was a major problem (not shown). Therefore, a comparison of ADAMTS-9 
ISR  and EDI IHC could not be performed. Future work would involve performing 
GFAP ISR  and EDI ISR  to determine whether the mRNA was co-localised with 
Adamts9 in glial cell nuclei.
The comparison of Adamts9 ISR  and vWF IHC successfully ruled out ECs as a 
predominant source of ADAMTS-9 expression in tMCAo. Areas of vWF expression 
(blood vessels) displayed negligible expression of Adamts9. This data is in contrast to 
other work, which showed that ADAMTS-9 mRNA is expressed by both human 
umbilical vein ECs (HUVECs) and dermal micro vascular ECs (HUDMECs) (D. J. 
Buttle, pers commun). RT-PCR and western blotting on samples extracted from CNS- 
derived ECs, would confirm whether such cells express ADAMTS-9 mRNA and 
protein respectively. Previous studies (albeit in non-CNS-derived cultures) have shown 
that other ADAMTSs are expressed by ECs including ADAMTS-1 (Norata et al, 2004) 
and ADAMTS-13 (Turner et al, 2006). IgG negative control IHCs were not conducted 
in the tMCAo study because highly characteristic NeuN, GFAP and vWF staining were 
observed.
5.4.6 Limitations and Future Directions of tMCAo Study
It would be important to repeat the western blotting of tMCAo proteins following 
separation with SDS-PAGE gels containing a lower percentage of acrylamide (4%). 
This would enable better resolution of the higher Mj species and perhaps enable the 
detection of the zymogen, which is potentially more active than the mature form (Koo et 
al, 2007). To further interprete the western blotting data in this study, future work
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would involve identifying proteins detected by blotting on PVDF membranes prior to 
excising the detected bands and performing protein sequencing. Alternatively, tMCAo 
protein extracts could be subjected to 2-D SDS-PAGE, which separates proteins on the 
basis o f isoelectrical point (pH at which a protein carries no net charge) and Mj. 
Following 2-D SDS-PAGE, bands of interest would be excised and subjected to mass 
spectrometry to identity the protein (Lahm, & Langen, 2000). In this study, 6 pg of total 
protein was loaded/SDS-PAGE well prior to western blotting, which was perhaps too 
low a concentration to detect some sparingly expressed ADAMTS-9 species. Future 
work would involve loading higher levels of protein to further strength the conclusions 
drawn in this thesis.
The ADAMTS-9 conclusions drawn from the real-time RT-PCR and western blotting 
tMCAo data would have been made with increased confidence if the analysis of 
ADAMTS-1, -4 or -5 expression was performed as an internal positive control. The 
detection of comparable expression levels to those published previously (Cross et al, 
2006) would have further validated the methods applied in this study. This approach 
would not have been available to validate the ISR  because this technique has not been 
performed previously in our laboratory on ADAMTSs in tMCAo tissue. Despite, these 
controls not being performed, these data in this study was considered to be highly valid 
because of the inclusion of stringent negative controls e.g. omission of primary 
antibodies for western blotting, no RT samples for real-time RT-PCR and sense probes 
for/SH.
A limitation with the tMCAo study was the small number (twenty-one) of animals 
analysed. Two additional animals were subjected to tMCAo but no symptoms were 
observed and were therefore not included in the study. Tissue was obtained from The 
University of Manchester and unfortunately due to time and cost restraints, only twenty- 
three animals could be utilised for this study. Limitations of studying a small sample 
size were emphasised by the fact that data obtained from animals subjected to tMCAo at 
identical time-points were variable. In contrast, data obtained from across the sham- 
operated animals were highly comparable, suggesting that tMCAo initiated different 
responses between animals. Variation in post-ischaemic responses is a phenomenon that 
occurs in humans, no one stroke is identical and symptom severity varies between 
patients (Dimagl et al, 1999). Therefore, the rat model would likely be unrepresentative 
o f human stroke if  all these data were identical following tMCAo. The fact that
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statistically significant modulation of Adamts9 expression was detected in all animals 
subjected to tMCAo, whilst no modulation was detected in all sham brains enabled 
conclusions to be drawn with confidence despite the small sample size.
5.4.7 Summary
To summarise this chapter, these data indicate that a) ADAMTS-9 mRNA is up- 
regulated in response to tMCAo at 6, 24 and 120 h post-procedure, b) the mature form 
of ADAMTS-9 protein is expressed at 24 h post-tMCAo and c) pyramidal and granular 
neurones are the predominant cells expressing ADAMTS-9 mRNA in tMCAo tissue 
Thus, ADAMTS-9 is potentially implicated in the brain's response to cerebral ischaemia 
and possibly other CNS inflammatory disorders.
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Chapter 6
Analysis of Putative ADAMTS-9 
Promoter Region for Transcription 
Factor Binding Sites
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6.1 Background
This thesis has demonstrated that human ADAMTS-9 mRNA expression is modulated 
by pro-inflammatory cytokines in glial cells in vitro. Furthermore, expression of the rat 
species of ADAMTS-9 was shown to be modulated at the mRNA level in response to 
tMCAo in vivo. One potential mechanism for up-regulation of ADAMTS-9 mRNA 
expression is through the activation of transcription factors, which are proteins that bind 
to specific DNA sequences (transcription factor response elements) through DNA- 
binding domains. Transcription factors bound to upstream promoter regions are required 
for RNA polymerase II activation of transcription of eukaryotic genes (Turner et al, 
2001). Many transcription factors are activated by factors pertinent to CNS 
inflammation e.g. as a result of intra-cellular signalling cascades activated by binding of 
cytokines to cell-surface receptors.
To provide evidence as to which transcription factors potentially activate the expression 
of ADAMTS-9 in human and rat, a bioinformatical screening of the putative promoter 
regions for these species was conducted. The software adopted for this analysis was 
Matlnspector (http://www.genomatix.de/cgibin/matinspector_prof/mat_fam.), which 
locates transcription factor binding sites in DNA sequences. The tool utilises an 
extensive library of matrix descriptions for the transcription factor binding sites and 
assigns a ‘quality rating’ for each match as described by Quandt et al (1995) and 
Cartharius et al (2005). The software gives a ‘matrix similarity’ value, which expresses 
how close the input sequence is to the matrix of a particular transcription factor. It takes 
into account how highly conserved nucleotides are within a particular position of the 
matrix sequence e.g. mismatches in highly conserved positions decrease the matrix 
similarity score. A perfect match = 1.00, whereas a good match is considered to be 
>0.80 (Quandt et al, 1995).
6.2 Bioinformatical Approach
The human (NM_182920) and rat (NM_001107877) ADAMTS-9 sequences were 
obtained from the Entrez nucleotide database (http://www.ncbi.nlm.nih.gov/sites/entrez? 
db=Nucleotide&itool=toolbar) and were subjected to nucleotide BLAST searches. As 
expected ADAMTS-9 sequences were 100% matched. From the ‘query result screen’,
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the NCBI Map Viewer (http://www.ncbi.nlm.nih.gov/mapview) option was chosen for 
the ADAMTS-9 sequence, which enabled the location of the gene on the corresponding 
chromosome to be visualised. In Map Viewer, the ADAMTS-9 gene was selected on the 
chromosome and the ‘sequence viewer’ option was chosen from the drop-down menu. 
The ADAMTS-9 plus strand sequence and the sequence upstream of the gene were 
visualised in NCBI Sequence Viewer v2.0 (http://www.ncbi.nlm.nih.gov/entrez/viewer. 
fcgi?view=graph&val=NT_022517.17&_gene=ADAMTS9) in ‘graph’ mode. The 
putative ADAMTS-9 promoter sequence (4 kb) immediately upstream (to the 5’-end) of 
the ADAMTS-9 gene was exported from the Sequence Viewer in FASTA format and 
imported into the Matlnspector input form. From the Library Selection menu, 
‘Transcription factor binding sites’ was chosen. Next, Matrix Library 7.0 was selected 
and only ‘vertebrate’ matrix groups were searched for in the query. Identified 
transcription factor binding sites of relevance to this study were highlighted in the 
putative ADAMTS-9 promoter regions in Microsoft Word.
6.3 Results
6.3.1 Analysis of Putative Human ADAMTS-9 Promoter Region for 
Transcription Factor Binding Sites
The BLASTn search of the human ADAMTS-9 gene confirmed it was located on 
chromosome 3. Matlnspector identified 824 sequences in the putative human 
ADAMTS-9 promoter region (4 kb), which matched consensus transcription factor 
binding sites in the software matrix library. Figure 6.1 illustrates the locations o f the 
consensus sequences for transcription factors pertinent to CNS inflammation e.g. those 
that are regulated by cytokines. Three NFkB binding sites were located at bp: 1324- 
1336, 3336-3348 and 3565-3577 upstream of the human ADAMTS-9 gene in the 
putative promoter region. The matrix similarity scores for the three sites were 0.84, 0.90 
and 0.92 respectively. In addition, one consensus binding site for transcription factor 
activator protein 1 (AP-1) was identified in the putative promoter sequence by 
Matlnspector (Fig. 6.1), 3703-3713 bp from the start o f the ADAMTS-9 gene. The 
matrix similarity score for the site was 0.95. Also, an IRF-1 consensus site was shown 
to be present in the putative promoter region, located 3221-3241 bp 5’ to the start o f the 
ADAMTS-9 gene sequence (Fig 6.1), with a matrix similarity o f 0.88.
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Figure 6.1 Map of Putative Human ADAMTS-9 Promoter Region Showing Consensus
Binding Sites o f Transcription Factors Pertinent to CNS Inflammation
CCCCCCTCCCTCCTGCCCTCCTTGGCTGCGGCGGCGACGCGAGGCAGCGGCCGTGGAGAGCGCGCGGAGCCCGGCGCCCGCCG 
CCAACTTTTGACTTTAGGAGTCGCTGAGGTCTCGCTGCGAGGGTCCCGTCTGCGCTCGGCTGAGCAACGCCGCCGCCTGCCGA 
GAGCTGAGCCGCTCGGGCCGCAGGAGGAGCCGGAGGAGCAGGAGGAGGAGGAGGACTGGGGCTCGGCTGCTTGGCCGCATAAT 
GCCCAGCGAGCGGGCAGGAGAAGGCGAGGAACTTGCGCTCCGAGGCGCGCCGGGCGCCCTGTGCTGGCCGGGATAGCTGAGCG 
GCTTCTTGAATGGGGGGCTGGGGGGGCGGAGGCGGGGGGGCCGCGGGTCCACAGCCTCTCAAATGCCCCCGGTGCACGCCTCT 
AAGAGGAGGAGAGGGGAGGAGAAAGCGAGACGAACGGGGACCGCCTCCTTCCAGACCATGTCCCCTCCTCGGCCGGCCCGTGC 
GGGACTCGCAGCCGGAGGCCCTGCCGGCTGCAAGAGGCGGAGGCCAGAGGCGTCACCAGCGCCGGGGCAGCTGTTCCTGGTCC 
CCGCCACCTCGCTGAAGTGGGGTTTTCTGAGATTCCCTGCCCCGGGGAGGGAAAGCAGGGAAAGTTCTCTCCCTTTCCTGGCG 
CGCGTGCAGCCACTTCCCCTCTCGTCTTTTTCCTCTCCTCTCCTCTCTCTCCTCCCTTCCGAGTCTCTTTTTCCTCCTCCCCC  
TTGTCTCTCTGCTGCTGTGCCTCTCGGACTCTGTCCCTTCTCCCCATTTTCCCCTGTGATGTCTGTCTTCTCCCCGCCCCACC  
GTGTCCCTGTCTGTTTCTCACATTTCTCCTTTTCCTTTCCTTTCTCTTCCGTCCCCATCTCTTGCCACCAGTCCCCATCTTTT  
GGTTTCTTACAAGTGAAAGTGGCCCAGCGCCGGAGCGCCTTCCCTTCCTACACTTTTTCATTCGGGAAGAGATTTGGCACCTG 
AGCTCCGCTCTCGATTTAATCACCCCAAGTCAAGAGTTTTAGAAATGGGGTTCTTAATCCTGCAGGTCGGAGTGTGTTTCTAA 
TACGTGGTCTCTTGAAAATTTCGCAAAATATTTAAGCTGTGCTTTCCACCAACCTCTGTCACCATTCATGGAGGGTCCATAGC 
AT TCT GTAGGT CC CC T GCCCCAAAAAAGGT TAAGAACAAAT T T T GGCAGCAAGAAGGGGCGGGGAC T C T GGCGCCCC T CAC TA 
CCAGGGGGTTTAGAGATGGGAGGGGAAGGGGGGATGGAGTGTAAAGTTGTAGATCCCTGTGGGAGGCACCAGTCCCTGGAGGG 
AT T T C T CA ft T CAC TTCCGCTTGCTTT CAGCC T GAGAGAT GC T T GGAAAGAC T GGGAAAGAC T GAAAGCAGGC GC T T CAAGC TA 
CACCTTCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAATTGTTCAATCTTGGGTGGTTCAGTGGCGCCTTTTC 
T T T AACCAGCCCT CAGGAAGATAGAAT T T CAAGATAAT T TCAAGAGGAAAGACAT GACAAT AT CGT TAAAAAT ATAT AAAT AT 
ATGAC TAAT AAAT ATAT AT T T GCCCAAGT AT CC TAGAACGGGGGT T GAGGT T C T GT T GCGT GGTAGGT T AGCAC T CAGGAC TA  
GAAATACCAAAGATTGCCAACACCAGGAACCAAATCGCAATATGCTAGCAATGTCAACTATTCTTGAGATACTAATACATATA 
TTTCTTCTGGTGAAGGGTAAAAATGACTTGGCAAGACGAATTTGCTAAATAATTGTTAACCCAAATTGATAATGTTACCATCG 
TCT TAT T AC T GGAAT T T CAT AAT GGATAT GT AAAAT G T AAGGAT GGAAAAAT AACAT C T GT AT T G T GCACAAT T AGAGAT T T T 
TAGAGAATGGCATTTAAACCTTGAACCTCCAAATTAATTCACTAAAATACGTTTCTTCTAATACACAATCTTTCTTTTTATTA  
TAACAACATTCCCCACAATCACAGTGTCTGGGAGTTGCTGAAAATTTAGTAAGGAACAGAAAAATATCAAGAAATCAATCTAT 
TGGCTGATTCCTGTGGAAAATATTCCAGTACTTCCATTGTAAAATTACTCAAAAATATAGCACTTTCCAGTATTTCCCATTAA  
ATCTTTTTTTCTCTTTCAGTTCAAATCCTTCCTGACAAAGAGAAGTTAACTAATGGTATAGAAATTACGATATGTAGGGACAG  
AAGCCTCCTTTGTGTACTCTCTCTCCTTTGCTTTCTTTCTAGGACTTTGCTTGAAGAATGAACTTTGTCTACAGTTTTAAAAA  
ATTGATCCACAAGAGCTGATAGGCCAGAAAGATACAAAATATCTCTTGGTGAACTCCTGAGGTGACCAAGAACCTAGGTTTAT 
GAATTTCTCATCCTTAGTGAGTCTACCCATCTTTTCTTCAGTGTATTAGCTGGCTTCTGCATTTACATCTGTAAAAAAGTCTT 
AAAGAAT C T TAGGAAAATGT C T T T T AAAT CGTGAGACAT GAAAAAGACAGT TGAGC T AACT AAGCAAGT CAGGCAAAAAT C T T 
T T GT C T GAAT AAT T AC T CT T T GT C T AAAT AAGT AC TC T TAT T CAGTAC T TACCAT GGGGTAACAT ATAGCAT T TAAT T TAAT T 
CTCAAAACAGCTCTTTCAGGAAGTCAGTGTCAGTAATCTCATTTTACCAATAAGGATACCGAGATCTGAATAAGTGAAATAAT 
TTGACCCCCCTCAATCCAGTAAGTGAGAGACACGAT T CAAACTCCGT T TCAGT CGT T CAAT CCAAGT TCATAACTAT TATCAT 
AT GT CAT GAAT AAC T GAT TAAT CAGAAGC AC T GC T AGAT T T T T GGAGGGT T GC T T T G T GGGAAAAT GGC T AAAAT CAT T CAGA 
GAATTGCCTCAAGCTTTTATTGCATGTATAACTTTTCTTTAGCTCTCTCTTATTCTTCTCATGCAAAGTATTTAATGAAAATC  
ATGTCAGCGATTTCATTGATATTTCACAGCTTTTCCCTCAGCAGTTAGAAGAGATCTGGCACATAGTAGGTAGTCAATAAGTA 
TTTATTAAGACTAGGCATGGTGGCTCACACCTGTAATCCTAGCACTTTGGAAGGTTGAGGTGGGAGGATTGCATGAGGTCAGT 
T CAGCGGT T CAAGACCAGCC T T GGCAACATAGCAACC CCT T GTCT CTACAAAAAAAGAGAAAAGAA
AATTGGCCCCTCATAAAAATT TGCTCTGAAAGAAGCAAACCTTT TCAAGGTCACCTGGAGTTAAAGGAGGGACAGTT TT 
TAGCCCGTTTTCTTCGTGGGACTTTACTGGAATTGAATGGTATTGTAGGTTAAGTGGAAGTATTCATTGGCTGATTCGTCATG 
AAAAT TAGAT CCC AGAGGAGT GAT GAAT GAT AT TAGT CAC T AGGGAGAGATAATCCGGCCAAT GGAAAT GACAGT GAT GACAT 
CACAAAT GAC T CT GT T T GCC TAAT GCCAC T GGAAACAGCAGGAAGGAGACT T GAAGCAAAGCCAT CAAT T TCCACAGAAAGGG 
GAAACCCAC ACCCAAAT GGTAGGGAGGGC CCAGGAGC CAGAAT T CAAGT GAAT AGT T T CCT GAGT GGT CAGCAGCGT CAGGT G 
ATTTGGGGAACAGATAAGCCCCTGGTACTTGGTAGCACTGCATTCTGGTCAGTGAATCACCAAGCTGGGACCTGGTGCTGGCT 
GAGCTCTGTGACCTTGGGCCTAAAGAATCTTAGGGAGATGTGTTTTACATGACAAGAAATGAAAAGGACAATTGTGCTAACTA 
AATAATTTGGGTTCCAATCTTTTGTCTGAATAATAATAATGAGAATCTTTTCTTGAGTACTTACTATGTACCAGACCATGTGT 
ACTATGTCCTCTCTGATCCGGTTTCCTATTTGCAGACTGCAGCAGGTAGAAACTGTGTTGTCTTTGTTTGCCCTGTGAGTGAA 
TGACCTTAGTGTATTT
The putative promoter sequence (4 kb) immediately upstream o f human ADAMTS-9 
was obtained using Sequence Viewer v2.0. Transcription factor binding sites within the 
putative promoter sequence on chromosome 3 were identified using Matlnspector 
software. Consensus binding sites o f transcription factors pertinent to CNS 
inflammation are highlight in colur and underlined as follows: Blue = NFkB, Brown = 
AP-1 and Trance = IRF-1.
185
6.3.2 Analysis of Putative Rat ADAMTS-9 Promoter Region for
Transcription Factor Binding Sites
Chromosome 4 was identified as the location of the rat ADAMTS-9 gene within the rat 
genome as confirmed by a BLASTn search of the peptidase DNA sequence. 
Matlnspector matched 507 sequences within the ADAMTS-9 putative promoter region 
with the matrices of transcription factors. Within the putative rat ADAMTS-9 promoter 
region, two NFkB consensus binding sites were identified by Matlnspector as illustrated 
in Figure 6.2. The sites were located at 2231-2243 (matrix similarity = 0.86) and 3336- 
3348 (0.90) bp from the start o f the ADAMTS-9 gene. An AP-1 site was also identified 
in the putative promoter sequence, 208-218 bp upstream of the ADAMTS-9 gene (Fig 
6.3), with a matrix similarity score of 0.88. Furthermore, the putative rat promoter 
sequence o f ADAMTS-9 contained two sequences where IRF-1 could bind 343-363 and 
2626-2646 bp from the ADAMTS-9 gene. The matrix similarity ratings were 0.87 and 
0.89 respectively. In contrast to the putative human ADAMTS-9 promoter, the rat 
sequence contained a consensus HIF-1 binding motif (matrix similarity = 0.96) at 3314- 
3330 bp 5’to the gene (Fig 6.2).
6.4 Discussion
6.4.1 Implications for In Vitro ADAMTS-9 Glial Cell Study
The bioinformatical analysis presented in this chapter provides preliminary evidence 
that ADAMTS-9 gene expression is potentially a target of transcription factor activation 
in human and rat. The findings that three NFkB and one AP-1 consensus binding sites 
are present in the putative human promoter region suggest that pro-inflammatory 
cytokines could up-regulate ADAMTS-9 expression by activating these transcription 
factors. It is well established that binding of both IL-ip and TNF to cell-surface 
receptors trigger intracellular signalling cascades, resulting in the activation of NFkB 
and AP-1 transcription factors. A study by Kordula et al (2000) demonstrated that such 
mechanisms occur in astrocytes to trigger gene expression. Therefore, the up-regulation 
of ADAMTS-9 mRNA expression in glial cells by IL-ip and TNF as demonstrated in 
Chapter 4 was potentially a result o f transcription factor NFkB and/or AP-1 activation.
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Figure 6.2 Map of Putative Rat ADAMTS-9 Promoter Region Showing Consensus
Binding Sites of Transcription Factors Pertinent to CNS Inflammation
TAGCAT TAT CAT CAT CAAT AT GAT T C T CCAAAC T C T T T T TAAT GGGGC CAAT T T AC T T CCAAGT C T GT AAGCAAGGC ACAGAT
CCCTTGTCTTCTGTTCAGCAGCCATTAGACATCAGTAAGGCAGAGTCAAGCCCTTTCAGCTCTAAATCTGATCTTGAGCTTTT
CCAACAGTTACTT TATCCACCCGGCAAACCCCCCATTAAACTC T GAT T V . C GGCAAAGC T T CAAT TGC T T C CAT GACACAT
GTTGCTCATAGCGCTTCTTTTCATGAGCGGAGTTTTCAAAGCGATTCCCAGAGACGTTGCTTATACAAATGGTTCCAGCACAC
C TAGATAAAA T T GT GGATAAGAGCAT GGAGCAGT GC C T GGGT T GGAAACCCCAGCAT CCACA
TAAGCTAAAATTGGATGTGCGCGCCTGTTACTCTGGCAGTGTGCCCCGACTTGCCAGCCTAGCACAAAGATGAGCTTCCATTG
ATTTTAGGGATCTTGTTACAAGCAGAGAGCAACAGGGAAGACACTGGATGTGCTGCCCCTCTGGCCTCTGCATGACATTCACA
GAAGGACACACCNNNACACNCANNCACATATACACAAACACACACACNNCACACCACACACNNNNNNNNNCACACNCNNNNNA
NNNCACNNNNNNNNlWOTNNNNNNNNNNNNNNbmNNNNNNNNNM^
Nl'MTNNNNNNNNNNNCNNNCANNNNNNNNNNNNNNNACNNNNNNNNN^r^^ MNCCCNNNTANNN^MNN]^ [NNN^WNN^ N^NNN^MNNNNNNNNN^^
IWNNNNNNNJSnsnsnrNNlNrNNNNNNNNNNNNNNNNNNNfWNNNNTnrNNNNNN
NNMWNNNNNNNNNNNNNNNNNNlNn^NNl^NlNnNINN^^
NM^nSINNDWnTNNNNN^NNNNfMSnSINlSnTNNNNNNNKNNNNNNN^^
NNNNNTIMTNNNbWNNNNNNNNNNNNNNNNNNNNNNNN^
NNNNNNl^NNNNlSnSINNNNNNNNNNNNNNNNNNNTmNNNNNNNNNNMTNNNNNNNNNNNNNNNNNNNNNNNNNNKNNNNNNNN
JSnTMNTNNlSnSINlSnSINTSnTNNNNNNNISnsnsnTNNNNNNNNNNKNNlSnTNlSnSllSnSI]^ ^
NNMTNNTnWNNmNNNNMTNNNTMTNNNNNNNNNNNNNNNNISnsnWNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN^NN^MNNN^MNNNNNNNNNNNNNNNNNMWNNNNNN]^ INNNNNNN^MM^ T^NNNNNN^MNr^ T^NN^MNNNNNNNNNNNN]WNNNNNNNNNN^JNlSE^^
NNMSMTNNNNNNNNNNNNTMNNNNNNNNNINnNINNNNl^
NNNNNNNNNNNNNNNNNNNMTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNT^^
NNNNNNNNNNNNNMNNNNNNNNNMNnTNNNNT^^
NNNNNNNAGCCCAGAAACAGAC T T T TAGAGTACCAT C CAAT ACCT T AGAGT T C TAGAAGT CAAAAGT C T GGGCAGCC T CAGT A  
AGCTTCTCTACTTAGGGCTTTAGTGACTGAAACAAGGTTTCAGCCTGCCTGGGCATTCTGGACAAGTCTGCTTTGAGTCCACT 
CTGGTTGCTGACAAATTTCCGTTCTTGCAAGTCTGGAATGGAGCTTCCTTGTACTTGGTGGATTTTTTTCCGATATGTTTTTG  
ATGCCTTTCCTCACCAAGCCATCTTGTCTTCATCTATTTGTCCCTAGAAAAGATTGCTGCTTATGCGCGTCCCATGGGAGTCC. 
CTGCAATGTCATTTCAAAGCCAGCGATGGAGTGTCCGTCCCTTTGCACTGAACCGCTTTGTATTTTTGTGGTGTTGCAGGGGT 
CTGTCTCACTCTCCGGTTTGAGATTGGTCTCAATTGTAGCATCCTCCTGCTTCAGCCATGTAGGTGGGCCCACCAGCGTGCGG 
CCTCTACCTCACACTGTAGTCTCACGTATTTCCTCGTCCCGCACCACCTCCAGTGCCTGTGACTGAGCTGGGCCTCCAGATAG 
TCTGCCGTGAAGTCTACAAATCAGTGACCTTAATTTCACCTACACAGTCTGATATACCACAGATCCTTGGAAGTAACGCCGGA 
AGGCAAAGCCGAAGGGGCCATCTTCGAATTTGCTTCTTGTACCCTGCTCCTC TAAACAATCA
GCTGGCCTGAGCAGCTCCTCTGTTTGTAGAAGATGGGTGGATTTGAGAAGACGGGAGGGGCAGAGACAAGATTTAAGCCGGTG 
CGTGAGCAGTACTCTTTCCGTAGCCTTGTGCGCTTTCTTGGCGGGCAAGCCTGCAGACCACACATGGCATCATCTGTTACAGG 
AAGCC T T GCAGGC T TGACGGGTAT C CAGACAAAAT GGCAT C CAGAAGC C T AAC TGAAGAGGC T GT GT T GCAGAT TGAGAAGGG 
CCCGTTTCCTCTGTCCAACCATTCTCACGTCAACCTCAGTGTATTGTTTGCTGTCCTTTAAGAAGACTGCTGTTTGTCTGGAA 
AGATCGGCATAGTTCTGGCAGATTTGTTCCTCCTTTAACAAATCACTAAGTCCATAAACGTTTAGTAAGAGTCAGTTTTACTC 
CAGGCCCTGAATTAGGTATAAAACATCATATCTGTCCTCTGAGAGCCTCTAGCTGTAGATACTCCTGTCCTTTCACCAGATGA 
CT TAAAAGGAGGACCGAAAAT GAGGTGGGAATGACTAGCGGTGACAT T CAGAAACCT CAGT GGTAGCTGTGGCCAAAGGAGAG 
ACT T T CAT T CCCCAGGT GT T T CCAC TAGAAT GT T C TAT GAGGACAT GT GTAAAT CCACAC T GT CC AAT C GAGAAGC
ATTGAATGGGACTGACCAGTGGGAGGCAGATTGGATTACATTTTACTTAATTTTAATTTTAAATATTAACTGC  
TACGTGCAACCCCTGTATTATACAGCTCAGAAAATACATACTCTGGAACCATTCATTCATTTTTTTCAATGTGTGTGTATGTG  
TTCCTGCATGTGTGTTTACATGTGCATGGGAATGGGGGGGGCAGGTCCATGTCAATTACATGCATCATTCATTCTCCATCTTG 
GTTTTTGATTGCTGAGCCTTGAGCTCACCAGTTTGGCTGATCTGGCTGTCAGAAGACTCCAGTGTCTCTGCCATCTCCCCAGG 
AAAGGGGTTATAGAGAGGCACTGCCCTACCTGGCTTATTTAAGTAGGTTCTGGGGATTGAATTCAGATCTGAAAGTTTGCATA 
GCAGGCTCTCAGCTGACTGGGCCATCCACCCCCCTCCAGCCTTCCCATTGTTCATTCTGTTGGTTACTTTTAATTCCTCCATG  
ATCTTCTGTTCTTCAGCTTCGAAAGGTGTTTAAATCTAACATCTGAATCACCTTCTCATGTAACTTAATTCTCTCTGATTAAT 
T T C TAGCAT CAACAT T AAGAT AAT GCAAGCCAAAGAGT T T T T AGAGGT AGAT GCAAAAAGCAAAAC TAC ATAAAAT T TAT TAT 
T GT AT AGAAAT AC AAG
The putative promoter sequence (4 kb) immediately upstream of rat ADAMTS-9 was 
obtained using Sequence Viewer v2.0. Transcription factor binding sites within the 
putative promoter sequence on chromosome 4 were identified using Matlnspector 
software. Consensus binding sites o f transcription factors pertinent to CNS 
inflammation are highlight in colur and underlined as follows: Blue = NFkB, cji = 
HIF-1, Brown = AP-1 and = IRF-1. Note: the full chromosome 4 sequence
downstream of the ADAMTS-9 gene was not fully available hence the undetermined 
bases (N).
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6.4.2. Implications for ADAMTS-9 in Response to Cerebral Ischaemia
Consensus binding sites for NFkB (two sites) and AP-1 (one site) were also identified in 
the putative rat ADAMTS-9 promoter region. Consequently, pro-inflammatory 
cytokine-mediated activation of these transcription factors in the rat in vivo may have 
been important contributing factors in the up-regulation of ADAMTS-9 mRNA 
expression detected following tMCAo, as shown in Chapter 5. Further evidence that 
transcriptional activation of ADAMTS-9 is a feature of cerebral ischaemia comes from 
the finding that IRF-1 consensus binding sites were present in the human (one site) and 
rat (two sites) putative promoter regions. IRF-1 is a transcription factor, which has been 
implicated in inflammation and apoptosis (Vaughan et al, 1997). A study by Iadecola et 
al (1999) provided evidence that IRF-1 is important in cerebral ischaemia. IRF-1 gene 
expression was up-regulated within 12 h of MCAo in mice, with levels peaking at 4 
days. Furthermore, the volume of ischaemic injury was decreased by 23 ± 3% in IRF-1' 
/+ and by 46 ± 9% in IRF'7' mice with less severe neurological defects than WT. 
Therefore, in both humans and rats, IRF-1 activation potentially up-regulates 
ADAMTS-9 expression following cerebral ischaemia.
The role of HIF-1 as a 'master transcription factor' (Hirato, 2002) in response to hypoxia 
following cerebral ischaemia has been well documented. To date it has been shown that 
HIF-1 regulates the expression of over 100 target genes (Ke & Costa, 2006) including 
-5%  of all genes in arterial ECs in hypoxic conditions (Manalo et al, 2005). Therefore, 
the presence of a HIF-1 binding site in the putative rat ADAMTS-9 promoter sequence 
is a potential explanation for the up-regulation of Adamts9 expression detected at 6 and 
24 h following tMCAo in the rat. This is substantiated by the decreased levels of 
Adamts9 expression 120 h post-tMCAo, when the brain would have returned to 
normoxic conditions.
6.4.3. Limitations of Bioinformatical Approach
The bioinformatical study presented in this chapter is limited because it is not known a) 
exactly where the promoter sequence of ADAMTS-9 on chromosome 3 (in human) or 
chromosome 4 (in rat) is located and b) what size the promoter region is. Therefore, the 
identified consensus sequences may be located outside the promoter region thus binding 
of the transcription factor would not trigger expression of ADAMTS-9. There are a
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number of approaches which can be applied to confirm and identify the promoter region 
of a particular gene. The most widely used experimental procedure is to clone a segment 
of DNA, upstream of the gene, in a vector carrying a reporter gene. The expression of 
the reporter gene can be determined in appropriate host cells. To further analyse the 
location of the promoter region, deletion mutants can be constructed to assess the 
importance of the different regions of the identified promoter in terms of initiating 
transcription. Deletion mutants can be generated using exonuclease III, which 
progressively cleaves dsDNA generating multiple sequences from within the potential 
gene regulatory region (Strachan & Read, 1999). The mutants can be cloned into a 
vector, which has a reporter gene downstream of the MCS prior to transfection into 
human cells, pertinent to the study of interest i.e. glial or neuronal cells. The reporter 
gene must a) code for a protein which is not endogenous to the transfected cells and b) 
be easily detected. A commonly used reporter gene is luciferase, which encodes for a 
protein that emits light. Consequently, constructs which contain the promoter region of 
ADAMTS-9 will trigger the expression of the reporter gene in the cells following 
transfection. Following this 'mapping' approach, one can deduce whether the 
transcription factor binding sites are within the ADAMTS-9 promoter region.
6.4.4 Summary
This chapter demonstrated using a bioinformatics-based approach that NFkB, AP-1 and 
IRF-1 transcription factor matrices matched sequences in both the human and rat 
putative ADAMTS-9 promoter regions. In addition, a HIF-1 binding domain was 
identified in the rat ADAMTS-9 ‘promoter’. Therefore, ADAMTS-9 gene expression 
has the potential to be activated by transcription factors, which are implicated in CNS 
inflammatory disorders. Such mechanisms may have contributed to the modulation of 
ADAMTS-9 expression detected in the CNS inflammatory models studied in this thesis, 
in vivo (tMCAo) and in vitro (glial cells treated with cytokines).
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Chapter 7 
General Discussion
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7.1 Implications of the Study
ADAMTS-9 is a recently discovered peptidase which has been studied mainly in 
embryogenesis because it has a highly similar structure to C. elegans gonadal 
morphogenesis proteinase GON-1 (Somerville et al, 2003; Llamazares et al, 2003) and 
cartilage because it cleaves the major structural component; aggrecan (Somerville et al, 
2003). Despite ADAMTS-9 being expressed in the developing and adult CNS and 
having the ability to cleave CSPGs present in brain ECM, it has not been studied in this 
tissue.
The findings in Chapter 4 that ADAMTS-9 mRNA is expressed under basal conditions 
by human astrocytic, neuronal and microglial cell lines in vitro suggests that the 
peptidase is constitutively expressed in the brain. Therefore, ADAMTS-9 could 
potentially play a part in normal ECM remodelling following expression by endogenous 
CNS cells via cleavage o f lecticans particularly versican and aggrecan (Somerville et al, 
2003) and potentially brevican. In support of this hypothesis that ADAMTS-mediated 
proteoglycanolysis is occurring in vivo in the brain, our laboratory has shown previously 
that brevican and phosphacan were colocalised with ADAMTS-4 on astrocytes (by IHC) 
in tMCAo tissue (Haddock et al, 2007). Similar experiments with ADAMTS-9 would 
be important to confirm activity.
As well as being constitutively expressed by cells in vitro, there is evidence stemming 
from this study showing that ADAMTS-9 expression is regulated by external factors as 
summarised in Figure 7.1. Each of the factors had differential effects on ADAMTS-9 
mRNA expression across the cell-types suggesting that in vivo modulation of the 
peptidase is complex. Three of the factors that modulated Adamts9 expression were pro- 
inflammatory cytokines, heavily implicated in CNS inflammation (reviewed by Viviani 
et al, 2004; Owens et al, 2004). As well as being a key event in acute disorders such as 
trauma or stroke, inflammation is also a feature of chronic diseases such as MS and PD 
(reviewed by Lucas et al, 2006), thus ADAMTS-9 has the potential to be modulated in 
response to a host of CNS pathologies. Support for this hypothesis was demonstrated in 
Chapter 5, in an animal model of cerebral ischaemia, an acute inflammatory insult, 
highly prevalent in humans. Adamts9 mRNA expression was shown to be significantly 
raised in rat brains subjected to tMCAo (compared to sham-operated tissue). Such 
modulation in vitro and in vivo was potentially a result of activation of ADAMTS-9
191
da
TOd
cd
XJO3h
oo
tO-C 3
tO44
cd
tO40
do• i-H
C/3
C/30)VicuX
tO<
ONIcn 
H
<
Q<<4-io
d
. 2lid
3TOoa
TOd
TO
tO
edsh<DSO<DGO
dC/30)5-i
<U004-»
SOO
TO0)
C/3
cdCQ
T O
tO
0)o
to00
TOSOoO
3
C/3
Cd-d
5-1toTOSOos
TO<0
C/3
C/3tol-lSOuX
to
bX)
. a'to40
soo•4->• r-HTOTO
cd
(O+-»•
C/3O
SOUso,o
to5-1dt>D
dO
to
3
00
TO0)HHSO<0
C/3<0ShCO
<05-1
C/3
cd
00o
.a so
Sho4—<O.<0U—I
cd
.2•ao
J 3o
TOSO
cd
TO(Oj >
3>so• r-H
<0-d
dOo
<0
C/3<0 TO 
'*—• CO (O CO
to43
cd00H->
tooSOtoTO>(O
cdd
to5hCO
b£).a
■>o5-1CO
C/3OS
3
soo• r*H
oda
cd
SO• r-H
m
£
U
§
t :oCO
<000
3(Jh
CO
C O .
.-3
<0• Ha
to  c0 00 o
ctjVhOD(O
5-h(Oo
<0onSOO
CO
C/3(O
3o
3"otosou
<0
COoSO<0osc rto
C/3
SOcdad03
TOSOctj
CO0 3
SOto
C/3<0
5-hCO
CO
5-h
CO
£
000
1
C4—Io
C/3
<0
Oh<
SO_ o
SOU• »-H
5-hO
C/3S5-hH—>
to
C/3
tO03
3
C/3
(O
d
C/3SOto
C/3SOoCO
to
C/3dCdOto-d
[Oht—(
TO
l
od
5-h
TOSOCtj
SOcdad43so
£►—1
-d
TO
(OH—>cd > 
%—> O 
cd
to-O
2 ^3%->
SO
tO4—*ocu
TO3oo
SOo•4—>0 ,
'Co00SOcd
§oTO
5-h0
1COd
toH—>
cd_ o
3.a
C/3
£o
10
cd
TO<0
C2
C/3
(O0sotodc rto
5-h<0
oa0
5-hjOu
ON100
H
<
Q<
to-so
SO(O
C/3toS-H
CU
(O
Cd
tO-XO
S-HH->C/3
TO
(O3o
3,a
>
cd<040
(O- d
o- d
o.cdU—1
C/3
cd
4 3od
COcuX-*->
3do
5-hdtod
Shto43
d4 0
xbDJO
340
&oa
3TO
cd
S-H
CU
C+Ho
C/3
tO
5-hdbD
to40
0>doVhdtod
to40
toH->o
£
soo
to
5-hCUX<0
o\I0 0
H
ONICZ5
H
<
Q<
t+Ho
d.2
cd3bD
to
f040
C /3
C/3
O n100
H
<
Q<inm(O
Sh
CUX<0
o
C/33
C/3(Odo
Shdtod
dd
cd
ShbD
192
Figure 7.1 Modulation of ADAMTS-9 Expression in the CNS
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gene expression by transcription factors through binding to consensus sequences shown 
to be present in the putative promoter regions as demonstrated in Chapter 6.
Given the finding that the potentially active-form (~188 kDa) of ADAMTS-9 was 
expressed in tMCAo brains and not in sham-operated tissue, it is tempting to postulate 
that ADAMTS-9 has a destructive role in the CNS. However, from these initial studies 
it is not possible to ascertain whether ADAMTS-9 up-regulation is damaging or 
protective and could potentially be both in different pathologies. These data showing 
that RetA increased the expression of ADAMTS-9 mRNA in SHSY-5Y cells suggests 
the peptidase has a protective role in the CNS because RetA has been shown to promote 
neurite outgrowth and regeneration post-CNS damage (Mey et al, 2005). Further 
evidence that ADAMTS-9 is potentially implicated in the neuronal response to injury 
came from data demonstrating that granular and pyramidal neurones were the 
predominant cells expressing Adamts9 in tMCAo tissue sections.
To further understand the role of ADAMTS-9 within the CNS, it would be important to 
answer the question of where the protein is localised in vivo. Unfortunately, IHC 
analysis of ADAMTS-9 protein could not be performed in this study due to limited 
quantities of the ADAMTS-9L2 antibody. ICC of U373-MG cells demonstrated that 
ADAMTS-9 was localised within the nucleus and intracellular vesicles but not the ECM. 
However, this result may have been because ICC was performed on monolayer 24 h 
(post-seeding on chamber slides) cultures, which were unlikely to have synthesised 
ECM within the time frame of the experiment. Other studies have suggested that though 
ADAMTS-9 is secreted, it remains localised at or near the cell surface, potentially in the 
pericellular matrix (glycocalyx), which is a region of ECM closely associated with the 
plasma membrane (Somerville et al, 2003; Koo et al, 2006; Koo et al, 2007).
Following up-regulation, ADAMTS-9 could be contributing to neuronal regeneration by 
two potential mechanisms: 1) promotion of neuronal differentiation/proliferation by 
enzymatic activity in the nucleus or 2) operating as a peptidase on the cell-surface of 
migrating CNS cells and clearing a path through the ECM or glial scar by degradation 
of known substrates aggrecan and versican (Somerville et al, 2003), enabling neuronal 
outgrowth and/or migration of neuronal precursor cells. Alternatively, the breakdown of 
CSPGs by ADAMTS-9 could have a damaging effect on the CNS by allowing the 
migration of inflammatory cells and activated microglia to susceptible neurones.
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The efficiency by which ADAMTS-9 cleaves CSPGs does not appear to be as high as 
ADAMTS-1, -4 or -5, perhaps limiting the impact of the peptidase as a proteoglycanase 
in vivo (Somerville et al, 2003). Therefore, the up-regulation of ADAMTS-9 expression 
following stroke is not necessarily a bad thing because it is unlikely that the normal 
ECM structure will be significantly degraded by the peptidase.
7.2 Future Directions
To further elucidate the role of ADAMTS-9 in CNS inflammation, it would be 
important to focus on functional studies. An ADAMTS-9 knock-out animal would be a 
useful tool to assess the role of the enzyme not just in the CNS but also in general 
physiology. Pertinent to this study would be to subject ADAMTS-9'7' mice to tMCAo 
and compare symptom-severity with ADAMTS-9+/+ animals. This would give a clearer 
indication as to whether the higher levels of Adamts9 in tMCAo (shown in this study) 
correlate with destructive or protective responses. To date KO mice have increased our 
understanding of the functions of ADAMTS-1, -2, -4 and 5 (reviewed by Flannery, 
2006).
To augment the studies in this thesis a continuous source of efficacious/specific anti- 
ADAMTS-9 antibodies would be highly useful, particularly ones recognising different 
domains o f the peptidase e.g. the prodomain. This would enable the determination of 
whether the zymogen, potentially the most active species (Koo et al, 2007) or processed 
forms were present in protein extracts, as detected by western blotting (based on the size 
of the protein). This was not possible with the ADAMTS-9L2 antibody, which detected 
active and latent protein. Effective antibodies would enable semi-quantification of 
proteins in extracts by performing densitometry on western blot bands or by 
development of a quantitative enzyme-linked immunosorbent assay (ELISA). The 
antibodies would also be used to determine whether protein levels correlated with 
mRNA levels, as determined by real-time RT-PCR in the cell culture protein extracts. 
Furthermore, in disease models such as tMCAo, a better understanding of whether the 
protein was active or not could be gained. The antibody would also be utilised for IHC, 
analysing the cellular localisation of the ADAMTS-9 protein in tMCAo tissue. This 
would support the ISR  study which showed that neurones were the predominant cell- 
type expressing ADAMTS-9 mRNA. Performing IHC with cellular markers and
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conducting co-localisation analysis with ADAMTS-9 IHC would be a better approach 
to confirm glial cell association than comparing IHC with ISR. Also, ICC would be 
conducted with the antibody to ascertain whether the localisation of ADAMTS-9 
protein is intracellular in all cell-types used in this thesis, which appeared to be the case 
in U373-MG (although this experiment needs repeating).
Many of the inflammatory mechanisms seen following cerebral ischaemia are common 
to other CNS pathologies. Therefore, it would be illuminating to compare the responses 
o f ADAMTS-9 observed in the tMCAo model with other brain disorders/diseases. The 
techniques developed, optimised and validated in this study can be applied to other 
disorders such as MS by utilising MS post-mortem tissue or the EAE model (Cross et al, 
2005; Haddock et al, 2006).
It is likely that the substrate profile of ADAMTS-9 is not yet complete. The expression 
of the purified, full-length ADAMTS-9 protein would provide a useful tool to further 
investigate potential substrates for the enzyme. Also, a range of deletion mutant-forms 
of ADAMTS-9 would provide a better understanding as to which domains are important 
in proteolytic activity and activation. It was originally planned to express ADAMTS-9 
in High Five insect cells (Invitrogen) as part of this study as was achieved previously 
with ADAMTS-1, -4 and -5 (Vankemmelbeke et al, 2003) but due to time constraints 
this was not possible. Somerville et al (2003) stated that 'given its complex domain 
structure and cell surface localisation, a purified ADAMTS-9 is not yet available'. 
Therefore, it is likely that the generation of recombinant ADAMTS-9 will be difficult to 
achieve but the rewards would be to vastly improve our understanding of the peptidase.
7.3 Conclusion
The study documented in this thesis provides evidence that ADAMTS-9 has the 
potential to be implicated in normal physiology and pathology in the CNS. Functional 
studies are required to further elucidate the role of ADAMTS-9 within the brain before 
considering whether the peptidase is a candidate for therapeutic intervention to treat 
CNS inflammatory disorders.
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